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Abstract
The human endometrium is a highly specialised tissue, which provides an optimal
environment for the establishment and maintenance of a successful pregnancy. The
endometrium undergoes remarkable cycles of remodelling, involving proliferation,
differentiation, including decidualisation of the stroma, and in the absence of
pregnancy, breakdown and repair. The menstrual cycle is governed by the steroid
hormones oestrogen and progesterone acting via their nuclear receptors, but at a
paracrine level by a myriad of growth factors, cytokines and proteases.
Decidualisation of the endometrium is essential to create an environment conducive
to the implantation of a conceptus, and in the absence of fertilisation, is likely
mandatory for the onset of menstruation. Decidualisation is also associated with a
unique immune environment, characterised by the presence of large numbers of
uterine-specific natural killer cells (uNK). uNK cells increase in number in secretory
phase endometrial stroma, implying the control of progesterone on their expansion.
However, they lack the nuclear progesterone receptor and growth and differentiation
may depend on interactions with endometrial stromal cells (ESCs) and other
hormones such as luteinising hormone (LH) and human chorionic gonadotrophin
(hCG). Transforming growth factor (1 1 (TGF(31) is present in both epithelial and
stromal cells within the endometrium at stages of the menstrual cycle consistent with
rapidly proliferating or remodelling tissue and inflammatory events, and has been
demonstrated to transduce progesterone action. Whether TGF|H influences
decidualisation is unclear.
The aims of this research project have been to investigate the role of TGF(31 in
mediating factors involved in decidualisation, with particular regard to expression of
nuclear progesterone receptor (PR), the Wnt antagonist, Dickkopf-1 (DKK), and
markers of decidualisation in order to identify a potential role for TGF(31 in
decidualisation and menstruation, and to characterise further the uNK cell to
determine how uNK cells may interact with other uterine hormones and ESCs during
the secretory phase and early pregnancy.
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In primary human ESC cultures, both non-decidualised and decidualised in vitro, PR
mRNA and protein expression was initially augmented over 2 h then downregulated
in a TGFpi-specific and time-dependent manner. Furthermore, DKK expression
levels were downregulated after TGF|31 treatment in a biphasic manner in non-
decidualised cells and over a period of 24 h in decidualised cells. However, the
downregualtion of both PR and DKK, reported to be a progesterone-responsive gene,
could not be attributed to TGF(31 preventing gene transcription as TGF(31 was
without effect on progesterone or oestrogen binding to their respective response
elements. In addition, TGFpl treatment of in vitro decidualised ESCs and stromal
cells from 1st trimester decidua inhibited production of classical decidualisation
markers, IGFBP-1, tissue factor and prolactin at both mRNA and protein levels, and <
suppressed the transactivation potential of the prolactin promoter by acting at the
critical decidualisation region. SMAD4 knockdown employing siRNA techniques
was inconclusive. Therefore, no data was obtained to elucidate whether TGFfll was
acting via the SMAD signalling pathway or via alternative pathways e.g. Wnt, MAP
kinase and JNK signalling.
Primary cultures of human uNK cells were used for studying the possibility that LH
and hCG may be the hormones responsible for the influx and proliferation of uNK
cells. LH/hCG receptors were not expressed on the uNK cells, however, mannose
receptors, which have been proposed to bind hCG, were localised to uNK cells.
Furthermore, when uNK cells were treated with hCG, colocalisation of hCG and
mannose receptors was observed. Additionally, treatment with low doses of hCG
inhibited IFNy protein release from uNK cells derived from 1st trimester decidua,
providing a functional role for hCG acting via the mannose receptor.
Further investigation into the interactions between the mannose receptor and
LH/hCG would be important in clarifying the mechanisms controlling uNK influx
and proliferation. The interactions between ESCs and uNK cells need to be clarified
further to assess the roles of uNK cells in reproductive processes. This work has thus
revealed a potential novel mechanism for the influx and recruitment of uNK cells
mediated by the mannose receptor.
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Chapter One
1 Literature Review
1.1 The Human Uterine Endometrium and the Menstrual
Cycle
The human uterine endometrium is a unique, dynamic organ in its ability to undergo
extensive and rapid remodelling, with cycling proliferation, differentiation, and
degeneration. During every menstrual cycle, the endometrium regenerates and
proliferates after menses; progressively and sequentially differentiates to prepare for
successful implantation of a conceptus; and, if pregnancy fails to be established,
breaks down and is shed during menstruation (Wynn and Jollie 1989). The
endometrium is composed of two compartments, the basalis, which persists from
cycle to cycle, and the transient superficial functionalis. Morphological changes
during the menstrual cycle occur only in the functionalis and it is this layer which is
shed during menstruation. Regeneration of the endometrium, after menstrual
shedding, occurs from the underlying basalis. These well-documented changes occur
over a 24 to 35 day period and are primarily governed by sequential exposure to the
ovarian hormones, oestrogen and progesterone (Markee 1940; Noyes, Hertig et al.
1950; Buckley and Fox 1989).
The classic 28 day menstrual cycle is generally described in three phases, the
proliferative phase (days 5-14), the secretory phase (14-28) and in the absence of
implantation, menstruation (days 1-4) (Figure 1.1). The following descriptions of the
changes occurring in the endometrium have been adapted from studies by Markee et
al, Noyes et al, and Buckley et al (Markee 1940; Noyes, Hertig et al. 1950;
Johannisson, Landgren et al. 1982; Johannisson, Parker et al. 1982; Buckley and Fox
1989).
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1.1.1 The proliferative phase
The following description is based on the work of Markee et al, Li et al, Johannisson
et al and Wynn et al (Markee 1940; Wynn 1974; Johannisson 1985; Johannisson,
Landgren et al. 1987; Li, Rogers et al. 1988; Wynn and Jollie 1989).
The proliferative phase follows menstruation and is characterised by re-
epithelialisation and proliferation of endometrial glandular, stromal, and vascular
endothelial cells, producing a notable thickening of the endometrium from about 1
mm to 3-4 mm by the time of ovulation (Glasser 2002). Oestrogen, regulated by
follicle stimulating hormone (FSH), is the steroid hormone responsible for the
changes observed during the proliferative phase. Under the influence of FSH,
released from the adenohypophysis, a cohort of antral follicles begins to undergo
preovulatory maturation. One of the follicles will become dominant, the Graafian
follicle, and will eventually ovulate, secreting oestrogen. The increase in oestrogen
levels exerts an inhibitory effect on the adenohypophysis, resulting in a decrease in
FSH secretion below the minimum level that will support the growth of the other
follicles; hence, the Graffian follicle further develops, with oestrogen levels
continuing to rise. Once a threshold level is reached positive feedback on the
adenohypophysis occurs resulting in the LH surge which is responsible for ovulation,
usually observed approximately 16 h later (LH+0).
The proliferative phase is further categorised into early, mid, and late proliferative
phase. The early proliferative phase (days 5-7) is usually identified by the formation
of new glands which are typically straight, tubular in structure and somewhat
undifferentiated, and the stroma, which resemble undifferentiated fibroblasts (More,
Armstrong et al. 1974) contain spindly cells with large nuclei. The glands are lined
by columnar epithelial cells with basally located nuclei. Occasionally mitotic figures
are observed (Wynn and Jollie 1989). The mid proliferative phase (days 8-10) sees an
increase in length and tortuosity of the glands with pseudostratified cells and
prominent mitotic figures (Johannisson, Landgren et al. 1987). The stroma becomes
highly vascularised. During the late proliferative phase (days 11-14) the glands
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contain tall columnar cells and exhibit marked tortuosity and wider lumen
(Johannisson, Landgren et al. 1987). Increased mitotic activity and the formation of
pronounced nuclei are observed in the stroma in the 1 to 2 days preceding ovulation,
LH-1 and LH-2 (Wynn and Jollie 1989).
1.1.2 The Secretory Phase
The following description is based on the work of Markee et al, Li et al, Johannisson
et a\ and Wynn et al (Markee 1940; Wynn 1974; Johannisson 1985; Li, Rogers et al.
1988; Wynn and Jollie 1989).
Following ovulation, the secretory phase is associated with morphological and
functional changes evident in the luminal epithelium, glandular and stromal
compartments and the vasculature (Dockery and Rogers 1989). These changes are
primarily governed by circulating levels of progesterone, although oestrogen
continues to be produced by the corpus luteum (Dockery and Rogers 1989). Under
the control of LH the theca and granulosa cells of the follicle luteinise, forming the
corpus luteum. The corpus luteum is responsible for the high level of progesterone in
the secretory phase of the cycle. In the early secretory phase (Day 14-20), the level of
progesterone rises rapidly and structural changes are observed in accordance
(Dockery and Rogers 1989). The first sign that ovulation has occurred is the
appearance of subnuclear vacuoles of glycogen in the glandular epithelium (day 16).
These vacuoles displace the nuclei to the centre of the cells resulting in the alignment
of nuclei. The glands become convoluted, accompanied by increased tortuousity and
dilation. The stromal mitotic rate is still at a maximum. In the mid secretory phase
(day 19 to day 23), the secretory activity of the glands becomes apparent with
copious intraluminal secretions seen at around day 20. At this time the stromal
changes represent the earliest phase of the cascade of differentative events leading to
decidualisation. Focal stromal oedema peaks around day 22/23. In the late secretory
phase (day 24 to day 28), there is differentiation of spiral arterioles and areas of
oedematous stroma become more extensive. Perivascular stromal cells become more
apparent as their cytoplasm increases in volume and their nuclei enlarge. These are
predecidual cells and on day 25 the progressive spread of predecidual changes begins
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under the surface epithelium forming a solid sheet of tissue. The stromal cells
undergo a decidual reaction in preparation for implantation and progressively form
the decidua during pregnancy.
Pinopodes are expressed on days 19-21 on the apical surface of the luminal uterine
epithelium (Psychoyos 1992; Nikas, Drakakis et al. 1995). The timing of their
appearance is progesterone-dependant and they appear around the time of
implantation (Martel, Monier et al. 1991; Nikas, Drakakis et al. 1995; Nikas and
Psychoyos 1997). Infiltration of leukocytes begins to occur around day 26. Although
macrophages and lymphocytes accumulate, the major leukocyte cell type in the
secretory phase is the uterine Natural Killer cell (King, Wellings et al. 1989;
Trundley and Moffett 2004). These cells remain abundant in the first trimester of
pregnancy and will be discussed in more detail in section 1.4.2. If pregnancy does not
occur, glandular secretion becomes exhausted and the glands have a saw-toothed
appearance. Growth of the endometrium ceases and dehydration results in shrinkage.
Focal necrosis becomes apparent and menstruation begins (day 1).
1.1.3 Menstruation
In the absence of nidation, the superficial functional layer of the endometrium is
discarded by the process of menstruation in response to declining progesterone levels
because of corpus luteum demise (Henzl, Smith et al. 1972; Cornillie, Lauweryns et
al. 1985). The withdrawal of progesterone converts the refractory uterus into a
spontaneously steroid-responsive organ (Csapo and Resch 1979). Menstruation is the
process of remodelling which prepares the endometrium for implantation of a
blastocyst in the ensuing menstrual cycle. Endometrial breakdown and shedding is
initiated at focal points, with areas of breakdown evident coincident with
regeneration of neighbouring areas (Fraser 1990; Salamonsen and Woolley 1999).
Menstruation occurs only in humans, Old World monkeys, anthropoid apes and two
non-primate species, the elephant shrew (Elephantus myuras jamesoni) and some
bats (e.g. Glossophaga sorcinina). Due to the terminal differentiation of the stroma
during the menstrual cycle, in response to progesterone and independently of a
blastocyst, menstruation must occur in order to allow regeneration of the
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endometrium for the next cycle (Ferenczy 1976; Wynn and Jollie 1989). This may
provide a maternal protective mechanism that counteracts the aggressive implantation
occurring in menstruating species (Finn 1987; Finn 1996). Indeed, human trophoblast
implantation is unique, exhibiting the greatest degree of trophoblast invasion seen in
all species even amongst those with a hemochorial placenta, including the higher
apes (Ramsey, Houston et al. 1976; Pijnenborg, Robertson et al. 1981; Bell 1990).
Menstruation does not occur in mammals with less aggressive implantation (Bell
1990). For instance, in rodents, trophoblast cells adhere to the luminal epithelium but
do not invade the endometrium. Trophoblast cells phagocytose the epithelial cells
placing the blastocyst within the stroma compartment, after which the blastocyst
becomes invasive and stromal changes occur (Pijnenborg, Robertson et al. 1981; Bell
1990). It is therefore unnecessary for these mammals to menstruate as the stromal
reaction occurs only in the presence of pregnancy. This concept that menstruation is
dependent on invasive implantation is further supported from the hormone-primed
mouse model, in which no bleeding, nor decidualisation was observed with
progesterone withdrawal (Finn and Pope 1984). However, when the hormone primed
mouse uterus was stimulated with a drop of oil, mimicking the trophoblast and
initiating decidualisation of the endometrium, and the progesterone source
withdrawn, a menstruation-like response occurred (Finn and Pope 1984).
Knowledge of changes arising in the endometrium, both preceding and during
menstruation is largely based on the elegant study by Markee undertaken almost 70
years ago (Markee 1940). Markee described a period of regression occurring 2-6 days
before the onset of bleeding with the determination that progesterone and oestrogen
are major controlling factors over these structural changes (Markee 1940). It was
known that progesterone acts following oestrogen priming and then is withdrawn in
the lead up to menstruation. The effects of these hormonal changes were studied in
endometrial fragments transplanted into the eye of the rhesus monkey, where changes
in the vasculature could be observed (Markee 1940). Striking changes were noted in
the endometrial blood vessels. The arteries that supply the endometrium are straight
when in the basalis region but become coiled within the functionalis (Markee 1940).
As the secretory phase of the menstrual cycle progresses, the spiral arteries become
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increasingly coiled until circulation slows and stasis occurs due to the increased
resistance encountered in the vessels (Markee 1940). Approximately 4 to 24 hours
prior to menstruation, vasoconstriction of the spiral arteries commences. This induces
anoxia in the functionalis and results in bleeding. Leukocyte infiltration accompanies
menstruation (Bulmer, Lunny et al. 1988; King, Burrows et al. 1998). Changes
observed in the endometrium across the menstrual cycle are reviewed in Campbell et
al, Salamonsen et al and Critchley et al (Campbell and Cameron 1998; Salamonsen,
Kovacs et al. 1999; Critchley, Kelly et al. 2001) and summarised in Figure 1.1.










Figure 1.1: Diagrammatic representation of changes that take place in the human
endometrium across the menstrual cycle, including the cyclical nature of
degeneration and regeneration of the functional endometrial layer, based on the
"classic" 28 day model as described by Noyes et al 1950, derived from (Noyes,
Hertig et al. 1950). Men = Menstruation, Prolif = Proliferation, Sec = Secretory.
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1.1.4 Decidualisation and the maintenance of pregnancy
As detailed in section 1.1.2, the transformation of endometrium to decidua begins in
the secretory phase of the cycle under the influence of progesterone with
characteristic changes observed in all compartments of the endometrium (Loke, King
et al. 1995). First, secretion from the glandular epithelium is maximal during the
implantation window with production of various hormonally regulated proteins
including progesterone-associated endometrial protein (also known as glycodelin,
placental protein 14, lactoglobulin, a-2 microglobulin, pregnancy-associated a-2
globulin) and albumin (Psychoyos 1992; Dockery 2002). In decidua, the glands in the
upper two thirds of the tissue become atrophied and are non-secretory while those in
the lower third continue secretory activity (Dockery 2002). Second, as detailed in
section 1.1.2, the stroma also shows predecidual change that develops fully in the
event of implantation. This stromal differentiation begins around post-ovulatory day
9 in oestrogen-primed stromal cells surrounding the spiral arterioles.
Ultrastructurally, stromal decidualisation is characterised by progressive cell
enlargement, rounding of the nucleus with coordinate increase in complexity and
number of nucleoli, expansion of the secretory apparatus and dilation of the rough
endoplasmic reticulum and golgi apparatus, in addition to cytoplasmic accumulation
of glycogen (Wynn 1974; Cornillie, Lauweryns et al. 1985). This reaction then
spreads throughout the stroma completing the pre-decidual transformation of the
endometrium (Dunn, Kelly et al. 2003). In addition, extracellular matrix (ECM)
proteins are distributed around each stromal cell with the decidual ECM being
particularly rich in laminin and fibronectin. Decidualising stromal cells acquire the
ability to secrete a variety of phenotypic antigens, including, insulin-like growth
factor binding protein-1 (IGFBP-1) (also known as al pregnancy-associated
endometrial protein, placental protein 12) and prolactin (Dunn, Kelly et al. 2003).
Finally, increased coiling of the spiral arterioles begins in the secretory phase and
continues in decidua. If pregnancy is established, these decidual changes become
more widespread creating three layers: decidua compacta, decidua spongiosa and a
basal undifferentiated layer, allowing regeneration following birth. uNK cells are the
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main leukocyte population in first trimester decidua and these are further discussed in
section 1.4.2.
The process of decidualisation is unique to species that undergo haemochorial
placentation and is an essential pre-requisite for the establishment of a specialised
environment for embryo implantation and trophoblast invasion (Finn 1986; Finn
1987; Bell 1990). Furthermore, among the species with haemochorial placentation,
the degree of decidualisation appears to relate to the degree of trophoblast invasion
(Ramsey, Houston et al. 1976; Christensen, Verhage et al. 1995).
1.1.4.1 Decidualisation Markers
Documented markers of the decidualisation process include prolactin (Maslar and
Riddick 1979; Healy, Salamonsen et al. 1990; Tseng and Mazella 1999), IGFBP-1
(Bell, Jackson et al. 1991; Bryant-Greenwood, Rutanen et al. 1993; Lee, Giudice et
al. 1997) and tissue factor (Lockwood, Krikun et al. 1994; Krikun, Schatz et al. 1998;
Krikun, Schatz et al. 2000; Lockwood, Krikun et al. 2000), all of which have been
used to confirm decidualisation induced in vitro. Other markers of decidualisation are
reviewed in Tang et al (Tang, Guller et al. 1994). In vitro studies employing ESCs
are commonly used as a model to characterise the molecular events regulating
stromal decidualisation without the limitations of hormonal and cellular interactions
that are inherently involved in the decidualisation process in vivo. These studies have
elucidated many regulatory mechanisms involved in the decidualisation process, such
as, altered steroid receptor expression and steroid metabolism, remodelling of ECM
and cytoskeleton, altered expression of intracellular enzymes, growth factors and
cytokines and their receptors, and induction of decidua-specific transcription factors
(Oliver, Cowdrey et al. 1999; Popovici, Kao et al. 2000; Christian, Mak et al. 2002;
Dunn, Kelly et al. 2003; Gellersen and Brosens 2003). However, the cellular
interactions and target genes involved in decidualisation are complex and still poorly
understood.
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1.1.4.1.1 Prolactin
Prolactin (PRL) is synthesised within the anterior pituitary. Synthesis of PRL has
been described in decidualised endometrial cells (Riddick, Luciano et al. 1978) and
subsequently, it was confirmed that PRL production correlated with the extent of
stromal decidualisation in a study of human endometrial explants from different
stages of the menstrual cycle (Maslar and Riddick 1979). Furthermore, it has been
demonstrated that increasing cell size associated with stromal decidualisation
parallels the expression of PRL (Christian, Mak et al. 2002). PRL is considered to be
important in human implantation and early pregnancy, as discussed in review by
Jabbour and Critchley 2001 (Jabbour and Critchley 2001). Prolactin receptor knock¬
out female mice are sterile due to severely compromised preimplantation
development and implantation failure of the few embryos reaching the blastocyst
stage, strongly implicating PRL in control of reproductive functions, including
implantation (Binart, Helloco et al. 2000). Prolactin is widely expressed and has been
located in the pituitary lactotroph, dermal fibroblasts, epithelial cells of the prostate
and breast, Leydig cells of the testis and in cells of haematopoetic lineage (Walters,
Daly et al. 1983; DiMattia, Gellersen et al. 1988; Montgomery, Shen et al. 1992;
Pellegrini, Lebrun et al. 1992; Ben-Jonathan, Mershon et al. 1996; Richards and
Hartman 1996). In humans, PRL is a single copy gene consisting of five exons
separated by four introns (Truong, Duez et al. 1984) (Figure 1.2). The pituitary
transcription start site is located in exon 1 (Truong, Duez et al. 1984). Decidual PRL
(dPRL) gene transcription requires activation of a tissue-specific promoter located
approximately 5.7 kilobases (kb) upstream of the pituitary-specific promoter located
in exon la (Berwaer, Martial et al. 1994; Gellersen, Kempf et al. 1994). Transcription
from the decidual start site leads to an elongated 5'-untranslated region within the
decidual mRNA transcript, but the open reading frames of the decidual and pituitary
PRLmRNA results in identical proteins (Gellersen, DiMattia et al. 1989).
















Figure 1.2: Human prolactin gene (above) and transcripts (below). Coding regions
are depicted as chequered bars; non-coding regions are depicted as black bars.
Initiation of transcription at exon la leads to an elongated 5'- untranslated region in
the decidual transcript. Redrawn from Telgmann et al, 1998 (Telgmann and
Gellersen 1998).
In the non-pregnant endometrium, dPRL is detected between the mid secretory phase
and menstruation, coinciding with the first signs of decidualisation. dPRL protein is
expressed primarily in stromal cells in the late secretory phase but epithelial cells are
also immunoreactive for dPRL at this point in the cycle (Bryant-Greenwood, Rutanen
et al. 1993). Whilst the protein has also been detected in both stromal and epithelial
cells, mRNA has only been detected in the stromal cells (Dimitriadis, Salamonsen et
al. 2000). In pregnancy, dPRL secretion progressively increases until a peak at 20 -
25 weeks, and declines toward term (Wu, Brooks et al. 1995). dPRL expression in the
secretory endometrium is increased after in vivo administration of
Medroxyprogesterone acetate (MPA) (Reis, Maia et al. 1999) and in vivo
administration of the antiprogestin, mifepristone (RU486), significantly reduced
dPRL expression in decidualised stromal cells (Wang, Zhu et al. 1994; Tseng and
Mazella 1999). PRL mediates its effects via single pass transmembrane-spanning
receptors that belong to the class 1 family of cytokine receptors. Two isoforms of the
receptor have been described in humans (Kline, Roehrs et al. 1999). PRL receptor
expression in the endometrium is temporally regulated throughout the menstrual
cycle with minimal expression detected in glandular epithelial cells during the
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proliferative phase with maximal expression observed in the mid-late secretory phase
(Jabbour, Critchley et al. 1998; Jones, Critchley et al. 1998). In pregnancy, the
receptor is maintained and localised to the decidua and foetal membranes (Maaskant,
Bogie et al. 1996). A role for PRL in immune regulation is well documented (Yu-Lee
1997). PRL receptor expression has been reported in haematopoietic cells within the
endometrium, including a novel target cell of PRL, the uNK cell (Jabbour, Critchley
et al. 1998; Jones, Critchley et al. 1998; Gubbay, Critchley et al. 2002). PRL has also
been shown to regulate the expression of interferon-regulatory factor (IRF-1), which
is located in the glands and upregulated in the secretory phase (Jabbour, Critchley et
al. 1999).
1.1.4.1.2 IGFBP-1
The insulin-like growth factor system consists of peptide growth factors (IGFs) and
their receptors but also specific binding proteins (IGFBPs) that regulate the
availability of IGFs to their receptors (Lamson, Giudice et al. 1991). Six types of
soluble IGFBPs exist and each has a degree of tissue specificity (Shimasaki and Ling
1991). All six IGFBPs have been localised within the human endometrium and with
the exception of IGFBP-5, all are seen to increase in the secretory phase compared
with the proliferative stage (Zhou, Dsupin et al. 1994). The production of IGFBP-2
and -3 in cultures of ESCs treated with oestrogen and progesterone has been
demonstrated (Giudice, Milkowski et al. 1991). Immunohistochemical studies have
demonstrated an increase in IGFBP-1 levels in human endometrium in the secretory
phase and early decidua (Bell and Drife 1989; Bryant-Greenwood, Rutanen et al.
1993). IGFBP-1 is considered a marker of decidualisation and its biosynthesis is used
to assess this process in cultures of ESCs (Irwin, Kirk et al. 1989; Bell, Jackson et al.
1991; Giudice, Dsupin et al. 1992). The specific function of IGFBP-1 in the uterus in
unknown although it may be regulating bioavailability of IGF-1, a stimulator of cell
growth and PRL production in long term cultures (Rosenberg, Mazella et al. 1991). It
has also been proposed to have a role in implantation (Giudice and Irwin 1999).
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1.1.4.1.3 Tissue factor
Tissue factor (TF) is a membrane-bound glycoprotein, with an extracellular domain
that acts as a receptor for factor VII, which is involved in the thrombin pathway and
thought to maintain equilibrium between haemostatic and fibrinolytic pathways in the
human endometrium (Schatz, Krikun et al. 2001). Indeed, TF is reported to augment
VEGF production, further supporting TF's role in vascular haemostasis (Abe, Shoji
et al. 1999). In utero haemorrhage in tissue factor knockout mice, has provided
further evidence that TF is a major haemostatic agent, and implies a role for tissue
factor in regulation of bleeding and murine blood vessel development (Carmeliet,
Mackman et al. 1996). In vitro culture of ESCs has confirmed hormonal control of
TF expression. After obtaining optimal TF levels, induced with oestrogen and
progesterone treatment, a reduction of TF levels comparable to pre-treatment levels
was observed with steroid hormone withdrawal (Lockwood, Nemerson et al. 1993).
In decidualised ESCs, expression of TF parallels that of PRL (Lockwood, Nemerson
et al. 1993) and is reported to be controlled by the specificity protein (SP)-l
transcription factor (Krikun, Schatz et al. 2000). In vitro studies have elucidated that
progesterone stimulates SP-1 and antagonises SP-3, which in turn antagonises SP-1
production (Krikun, Schatz et al. 2000). Moreover, SP-1 is enhanced and SP-3 levels
abrogated in the perivascular cells of secretory phase endometrium when
progesterone levels are high (Krikun, Schatz et al. 2000). It has been proposed that
the chronic upregulation of tissue factor in the decidualised stroma contributes to
hemostasis during trophoblast invasion and remodelling of the vasculature
(Nemerson 1988; Lockwood, Krikun et al. 1994). In the absence of pregnancy, TF
levels are reported to fall prior to menstruation permitting menstrual-associated
haemorrhage (Lockwood, Nemerson et al. 1993). In women using Norplant, a long-
acting progestin-releasing contraceptive implant, the observed decline in endometrial
TF protein and mRNA levels may partially account for their irregular bleeding
patterns (Runic, Schatz et al. 1997; Runic, Schatz et al. 2000).
Other markers of decidualisation that have been reported in human and rat decidual
stroma include vimentin, desmin, laminin and fibronectin (Glasser and Julian 1986;
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Glasser, Lampelo et al. 1987; Van Muijen, Ruiter et al. 1987) consistent with
structural rearrangements within the cells.
1.1.4.2 Progesterone and cAMP in decidualisation
Studies on ESC decidualisation in vitro have demonstrated that progesterone
treatment alone is a weak inducer of the decidual transformation but can only
stimulate cellular changes after prolonged exposure (Huang, Tseng et al. 1987; Zhu,
Huang et al. 1990; Tseng, Gao et al. 1992; Mizuno, Tanaka et al. 1998). It has been
reported that women with low serum progesterone levels at four weeks gestation can
have successful pregnancies following assisted reproductive technologies (ART)
treatment (Azuma, Calderon et al. 1993) therefore; it is possible that, in addition to
progesterone, other local factors are important for decidualisation. A synthetic
progestin, such as MPA, is usually used in place of progesterone for in vitro studies,
as it is metabolically stable and thus more effective at inducing decidualisation and
subsequent prolactin expression (Zhu, Huang et al. 1990 752). However, addition of
cAMP in combination with MPA evokes decidualisation of ESCs in culture on a
greatly reduced time scale (Tang, Guller et al. 1993; Tang, Guller et al. 1993; Brar,
Frank et al. 1997) due to stimulation of the protein kinase A pathway (Brar, Frank et
al. 1997). Evidence for the involvement of cAMP and its analogues in the
decidualisation of human endometrium has been presented (Tang, Guller et al. 1993;
Tang, Guller et al. 1993; Brosens, Takeda et al. 1996; Brar, Frank et al. 1997;
Brosens, Hayashi et al. 1999) and experiments using cultures of ESCs have shown
that prolactin expression is dependent on activation of the PKA pathway (Brar, Frank
et al. 1997; Telgmann, Maronde et al. 1997) and treatment of ESCs with cAMP
evokes an increase in prolactin mRNA expression and protein release (Tang, Guller
et al. 1993; Brosens, Takeda et al. 1996; Brar, Frank et al. 1997; Brosens, Hayashi et
al. 1999) which is sustained (Telgmann and Gellersen 1998). These authors
demonstrated the ability of cAMP to synergise with a synthetic progestin to result in
stromal differentiation and an increase in prolactin levels. High intracellular cAMP
levels appear to act by sensitising the cells to progestins and thereby ensuring
maximal prolactin expression (Telgmann and Gellersen 1998). Deletion of a region
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of DNA in the dPRL promoter -332 bp to -270 bp relative to the transcription start
site suppressed the ability of cAMP to induce prolactin expression identifying this
particular region as an important target of cAMP induced signalling (Telgmann and
Gellersen 1998).
It is thought that ligands such as PGE2, corticotrophin-releasing factor, and relaxin
bind to their cognate receptors on the cell surface of ESCs and activate G-coupled
proteins (Tang, Guller et al. 1993; Moy, Kimzey et al. 1996; Brar, Frank et al. 1997;
Telgmann, Maronde et al. 1997; Christian, Marangos et al. 2001), which can be
stimulatory (Gs) or inhibitory (Gi). The Gs proteins activate enzymes such as
adenylate cyclase or phospholipase C, responsible for the generation of the second
messengers, cAMP, and diacyglygerol (Meyer and Habener 1993). Two cAMP
molecules can then bind to the latent PKA holoenzyme, comprised of two regulatory
units (R) bound to two catalytic units (C), in the cytosol and induce a conformational
change which dissociates C-subunits from the complex, activating PKA (Tasken,
Andersson et al. 1994). The cAMP pathway is further discussed in section 1.6.3. The
intracellular level of cAMP is not only regulated by the rate of synthesis but also its
degradation. Phosphodiesterases (PDE) convert cAMP to AMP which no longer
stimulates PKA activity, hence preventing augmentation of the progesterone-induced
decidualisation process (Mehats, Andersen et al. 2002). It has been speculated that
the increase in cAMP in decidualising cells may be attributable to inhibition of PDE
activity (Gellersen and Brosens 2003), perhaps by such agents as relaxin (Bartsch,
Bartlick et al. 2001; Ivell 2002). In cultures of human ESCs, interaction of relaxin
with LGR7 and LGR8, the relaxin receptors (Hsu, Nakabayashi et al. 2002; Sudo,
Kumagai et al. 2003), both acutely and permanently elevates intracellular cAMP
levels in concert with induction of prolactin secretion (Telgmann and Gellersen 1998)
and produces maximal stimulus on prolactin production when added in combination
with a synthetic progestin (Huang, Tseng et al. 1987; Zhu, Huang et al. 1990).
The mechanisms and factors involved in decidualisation are complex and it is likely
that other factors that are involved have not yet been identified.
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1.1.4.3 Implantation
Successful implantation requires the simultaneous development of the endometrium
to a receptive state and the embryo to blastocyst stage. The endometrium is receptive
to implantation only for a few days in each menstrual cycle (the implantation
window) (Navot, Anderson et al. 1989; Li, Warren et al. 1991; Tabibzadeh 1998).
The implantation window falls in the mid-late secretory phase, day 20 and 24 in a "28
day" cycle, in the human (Hertig, Rock et al. 1956; Bergh and Navot 1992; Harper
1992) (section 1.1.2).
The implantation process itself is quite unique in humans in comparison to other
species and is haemochorial (Pijnenborg, Robertson et al. 1981). After fertilisation of
the oocyte within the fallopian tube, the zygote undergoes successive cleavage events
forming a morula which enters the uterine lumen around 72-96 hours post
fertilisation (Bulletti, Polli et al. 1994; Edwards 1994). The blastocyst forms on day 5
and comprises an inner cell mass with an outer layer of trophectoderm (Edwards
1994). Subsequently, the peripheral cytotrophoblast differentiates into
syncytiotrophoblast. Human chorionic gonadotrophin begins to be produced by the
embryo preventing the demise of the corpus luteum and is further discussed in
section 1.1.4.4.
Implantation occurs in three stages: apposition, adhesion, and invasion (Bulletti, Polli
et al. 1994; Edwards 1994). The apposition stage occurs when the hatched blastocyst
is present in the uterine lumen and in close, but not direct, contact with the luminal
epithelium (Bulletti, Polli et al. 1994; Edwards 1994). Between days 6-7
postfertilisation, adhesion of the blastocyst to the uterine epithelium occurs involving
direct interaction of the trophectoderm with the epithelium (Bulletti, Polli et al. 1994;
Edwards 1994). After this attachment, the trophoblast invades the endometrium.
Placenta formation begins once the blastocyst has invaded and become embedded in
the decidua (Bulletti, Polli et al. 1994; Edwards 1994). Several cytotrophoblast cells
extend through the syncytiotrophoblast and invade the decidua where they fuse
forming the cytotrophoblast shell, which surrounds the inner surface of the
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implantation site, anchoring the developing trophoblast to the maternal decidua
(Bulletti, Polli et al. 1994; Edwards 1994). Villous trophoblast cells will eventually
form a layer over the placenta and have the function of nutrient and oxygen transport
from maternal blood to the foetus (Bulletti, Polli et al. 1994). The extravillous
trophoblasts also invade the decidual spiral arterioles and become incorporated into
the vascular wall, changing its plasticity and allowing the delivery of greater volumes
of blood (Pijnenborg, Robertson et al. 1981; Aplin 1991; Edwards 1995; Tabibzadeh
and Babaknia 1995). In cases of under-invasion of the trophoblast, pathologies such
as miscarriage, pre-eclampsia and foetal intrauterine growth restriction (IUGR) can
result (Loke and King 1995). Such foetal conditions can lead to the development of
problems in adult life (Barker 1997; Barker 1997; Barker 1997). Conversely, when
over-invasion occurs there is abnormal placentation and a "placenta percreta" can
develop (Bjercke 1999).
Implantation clearly involves a tightly orchestrated series of events which requires
the controlled expression of a variety of molecules (Psychoyos 1986; Simon,
Francees et al. 1995; Simon, Pellicer et al. 1995; Tabibzadeh and Babaknia 1995;
Giudice 1999; Giudice 1999; Aplin 2000). Therefore, it is important for this process
to be under stringent control and a synchrony between the developing blastocyst and
the endometrium is fundamental for successful implantation. This is likely to occur
via the actions of steroid hormones, oestradiol and progesterone, and soluble
mediators such as colony-stimulating-factor (CSF) (Kauma, Aukerman et al. 1991;
Pollard, Hunt et al. 1991; Daiter, Pampfer et al. 1992), leukaemia inhibitory factor
(LIF) (Chamock-Jones, Sharkey et al. 1994; Stewart 1994; King, Jokhi et al. 1995;
Sawai, Azuma et al. 1995; Nachtigall, Kliman et al. 1996), and integrins (Lessey,
Damjanovich et al. 1992; Tabibzadeh 1992; Lessey, Castelbaum et al. 1994), to name
but a few of the local factors involved in an extremely complex process.
Imbalances of the steroid hormones, oestrogen and progesterone, and/or their
receptors can result in an "out-of-phase" development that has the potential to be
significantly detrimental to a successful implantation (Psychoyos 1986; Bonhoff,
Johannisson et al. 1990). As both processes are steroid hormone-dependent,
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implantation and decidualisation are likely to be closely linked, especially as one
important feature of a receptive endometrium is pre-decidualisation of the stroma. In
humans, decidualisation is a blastocyst-independent event, but successful blastocyst
implantation is a decidualisation-dependent event (Rosenwaks 1987; Sarani,
Ghaffari-Novin et al. 1999). In contrast, implantation has been shown to be
dependent on embryonic age rather than endometrial maturation in another study
involving IVF treatment of women (Bergh and Navot 1992). The receptive
endometrium is thought to balance implantation with excessive trophoblast invasion
by providing appropriate signals (Tabibzadeh and Babaknia 1995) essential for the
implantation process and maternal acceptance (Edwards 1994).
For successful implantation, stringently regulated interactions between the maternal
decidua and the foetal trophoblast must occur (Aplin 2000; Aplin and Kimber 2004;
Staun-Ram and Shalev 2005). The decidua secretes products e.g. IGFBP-1, that have
been demonstrated, in an in vitro model, to bind to trophoblast-specific integrins in
order to modulate trophoblast migration, invasion or both (Irving and Lala 1995;
Hamilton, Lysiak et al. 1998; Giudice 2003). In turn, the invading trophoblast
secretes matrix metalloproteinases (MMPs) (discussed further in section 1.3.3) that
act to breakdown the decidual extracellular matrix, further facilitating remodelling of
the decidua to permit trophoblast invasion. To limit overinvasion of the maternal
decidua, the decidual stromal cells express high levels of the tissue inhibitors of
MMP (TIMPs) (discussed further in section 1.3.3), which have also been
demonstrated to modulate trophoblast invasiveness in vitro (Aplin and Kimber 2004).
Cytokines such as IL-1 and TGFJ3 (discussed further in section 1.5.1.2 and 1.5.1.12
respectively), present at the decidual - trophoblast interface, are reported to regulate
trophoblast invasion in vitro by stimulating MMP and TIMP production, respectively
(Staun-Ram and Shalev 2005). Trophoblast-derived cytokines, such as insulin-like
growth factor 2, inhibit IGFBP-1 expression in human decidualised stromal cells in
vitro (Hamilton, Lysiak et al. 1998), providing evidence to suggest that trophoblast
invasion and migration is self-controlled in addition to control by the maternal
microenvironment through molecular and cellular interaction (Aplin 2000; Aplin and
Kimber 2004; Staun-Ram and Shalev 2005).
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1.1.4.4 Human chorionic gonadotrophin (hCG)
The oncofoetal antigen, hCG, is a heterodimeric glycoprotein hormone secreted by
the syncytiotrophoblast cells in the chorionic villi (Rao 2001). hCG is composed of
244 amino acids with a molecular mass of 36.7 kDa (Rao 2001). hCG is composed of
noncovalently associated a and (1 subunits and multiple N-linked and O-linked
oligosaccharide side chains (Rao 2001). The a subunit is identical to that of
luteinising hormone (LH), follicle-stimulating hormone (FSH), and thyroid-
stimulating hormone (TSH) but the P subunit is unique to hCG (Rao 2001). hCG is
detectable in maternal serum as early as 1 day after the initiation of embryo
implantation and rapidly escalates to a peak value of more than 100,000 mlU/ml
around 60 - 90 d gestation before gradually declining to levels under 50,000 mlU/ml
within the second trimester (Jaffe, Lee et al. 1969). These values vary significantly
between individual patients. The primary role of hCG is to prevent demise of the
corpus luteum (CL) and maintain luteal progesterone production thereby ensuring
embryo survival (Yen, Jaffe et al. 1999). In addition, hCG is an established tumour-
associated antigen that is over expressed in a variety of cancers, including colon,
lung, pancreas, oesophagus, breast, bladder, cervix, stomach, and prostate (Triozzi
and Stevens 1999). The hormonal actions of hCG are propagated via the LH/hCG
receptor, which is the same g-protein coupled receptor that can be activated by both
proteins (Rao 2001). The LH/hCG receptor was originally reported to be expressed
on ovarian granulosa cells, theca interna cells and luteal cells but has subsequently
been located in the human endometrium (Reshef, Lei et al. 1990; Lei, Reshef et al.
1992) and myometrium (Kornyei, Lei et al. 1993). Owing to its receptor's
endometrial locus, hCG has been implicated in full decidualisation of ESC and in
support of this, human endometrial stromal cells, cultured in vitro, decidualise in
response to hCG treatment (Han, Lei et al. 1999; Su, Mi et al. 2002). In addition, the
mRNA for the LH/hCG receptor has also been detected in T lymphocytes derived
from the peripheral blood of pregnant women (Lin, Lojun et al. 1995).
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1.2 Oestrogen and Progesterone
The steroid hormones, including progestins, oestrogens, androgens, glucocorticoids
and mineralocorticoids, are small, potent, lipophilic molecules that regulate a wide
array of cellular biological and physiological functions, such as proliferation,
survival, differentiation, organ development, metabolism, and haemostasis. In the
female reproductive tract, the coordinated actions of the steroid hormones, oestrogen
and progesterone (Figure 1.3), are pivotal to succinct female reproductive functions.
They act throughout the reproductive tract, including the hypothalamus, pituitary,
uterus, and ovary. Oestrogens act on the uterus to increase cellular proliferation
across the proliferative phase and also stimulate expression of progesterone receptors
(PR) during this phase. The presence of a functioning PR is crucial to fertility in mice
with the PR null mouse being infertile displaying defective ovulation, implantation,
and stromal cell decidualisation (Conneely, Mulac-Jericevic et al. 2002). The actions
of oestrogen and progesterone are mediated via their cognate receptors both of which
are expressed in the human endometrium (section 1.2.2).
Progesterone Oestradiol
Figure 1.3: Diagram depicting the structure of; A, progesterone and B, oestradiol.
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1.2.1 Structure and function of steroid receptors
The actions of oestrogen and progesterone are mediated via their binding to specific
intracellular receptors, located primarily in the nuclear compartment. Both oestrogen
and progesterone receptors are members of the nuclear receptor superfamily of
transcription factors which encompasses the receptors for steroid hormones, thyroid
hormones, vitamin D and retinoic acid, as well as several "orphan" receptors
(Robinson-Rechavi, Escriva Garcia et al. 2003). The nuclear steroid receptors share
common structure and functional domains that can be exchanged between related
receptors without loss of function, as summarised in Figure 1.4. AF-1 and AF-2 are
two transcriptional activation functional domains that mediate the transactivational
activity of all steroid hormone receptors. AF-1 is located in the N-terminal region and
contributes to constitutive ligand-independent activation by the receptor. AF-2 is a
short amphipathic a-helix, ligand-dependent transcriptional activation functional
domain, located in the C terminal of the receptor and is highly conserved between
members of the nuclear receptor superfamily. Steroid receptors are comprised of five
regions, denoted A/B, C, D, E and F. The A/B region is located at the N-terminus and
contains the AF-1 domain. The C region contains a highly conserved DNA-binding
domain (DBD), spanning 60 -70 residues. This domain contains amino acids required
for the recognition of the specific hormone response elements and dimerisation.
Aberrations in DNA and mutations of the C region can result in receptor dysfunction.
Proximal to the C region is the hinge or D region, which acts as a bridge between the
DBD and the ligand-binding domain (LBD). This enables the receptor to adopt
different conformations by rotation. Region E or the LBD accommodates the
transactivation domain, AF-2. This region, as the name suggests, is responsible for
the ligand-dependent activation of the receptor. The LBD is also responsible for
determining whether or not the receptor is activated, interaction with heat shock
proteins, mediation of homo and heterodimerisation and transcriptional repression
function (Gronemeyer and Laudet 1995; Chambon 1996; Moras and Gronemeyer
1998). Region F is present in the C-terminal of the LBD in some steroid nuclear
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receptors. The region is not well conserved and to date, no function identified.
Functional regions A/BCD E F





Figure 1.4: Functional domains of nuclear/steroid receptors. The functional and
structural regions A/B, C, D, E and F are indicated in the schematic diagram. Also
shown are the two transcription activation function regions (AF-1 and AF-2).
Adapted from Brosens et al, 2004 (Brosens, Tullet et al. 2004).
In the absence of ligand, the receptors are inactive and are present in complexes
containing other proteins such as heat shock protein 90. Hormone-bound receptors
are recruited to target gene promoters via homodimer binding to specific DNA
sequences in target genes known as hormone response elements (Carson-Jurica,
Schrader et al. 1990). The PR and the glucocorticoid receptor (GR) bind to the same
consensus sequences (glucocorticoid/progesterone response element; GRE/PRE) and
it is thought that, in the uterus, progesterone has local immunosuppressive effects
similar to the systemic effects of the glucocorticoids (Brosens, Tullet et al. 2004).
Once tethered to the promoter regions in target genes the steroid receptors can
modulate gene transcription resulting in a function change. In addition, nonconsensus
sequences (nGRE) exist which allow binding of the PR or GR to suppress gene
transcription. Steroid hormone actions may also be mediated via membrane receptors,
in addition to nuclear receptors, and may interact with intracellular second
messengers or other signal transduction pathways in a non-genomic manner
(Boonyaratanakornkit and Edwards 2004). It should also be noted that, when present
in high concentrations, steroid hormones are able to mediate their actions act via non-
genomic mechanisms e.g. modulation of ion channel function (for review see Revelli
et al (Revelli, Massobrio et al. 1998)).
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1.2.2 Oestrogen and Progesterone receptors
The progesterone receptor was first identified in the chick oviduct and mammalian
uterus in the 1970s (Milgrom, Atger et al. 1970; Sherman, Corvol et al. 1970; Leavitt
and Blaha 1972). Two isoforms of the progesterone receptor (PR) exist, PR A and PR
B (Horwitz and Alexander 1983; Lessey, Alexander et al. 1983). PR A and PR B are
derived from different promoter usage of the same gene located on chromosome 11
and function as transcriptional regulators of progestin-responsive genes (Clarke,
Roman et al. 1990; Kastner, Krust et al. 1990). PR A differs from PR B in that it is
devoid of 164 amino acids at the N-terminus (B-upstream sequence, BUS) (Horwitz
and Alexander 1983). Both forms of PR are activated by progesterone but they are
thought to have differing functions. PR B is the more transcriptionally active isoform
(Wen, Xu et al. 1994) and in settings where both the A and B forms are present PR A
can act as a dominant repressor of PR B function (Tung, Mohamed et al. 1993;
Vegeto, Shahbaz et al. 1993). This suggests that in cells where there is an abundance
of PR A the responsiveness to progesterone may be reduced and that the ratio of PR
A: PR B may determine the cellular response to the hormone. PR A has also been
shown to inhibit the function of the glucocorticoid, mineralocorticoid, androgen and
oestrogen receptors (McDonnell, Clemm et al. 1994; McDonnell and Goldman 1994;
Wen, Xu et al. 1994). A third PR, PR-C, has been identified and has been speculated
to be capable of altering the transcriptional activity of PR A and PR B (Wei,
Gonzalez-Aller et al. 1990; Wei, Hawkins et al. 1996). Additionally, a novel
membrane protein unrelated to nuclear PR was recently identified (Losel and
Wehling 2003; Zhu, Bond et al. 2003). It is reported to have the properties of a G-
protein-coupled receptor for progesterone and has been shown to be involved in
mediating the extranuclear signalling actions of progesterone that promotes oocyte
maturation in fish. The role of this membrane PR (mPR) in mammalian cells is
unknown. One possible suggestion is the regulation of rapid non-transcriptional
signalling of progestins via the relationship between the membrane and classical
nuclear PR, although this has not yet been explored. The functional importance of
this receptor with context to the endometrium is currently under investigation
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(Fernandes, Pierron et al. 2005; Karteris, Zervou et al. 2006; Krietsch, Fernandes et
al. 2006).
There are two structurally related isoforms of oestrogen receptor (ER), namely, ERa
(Green, Kumar et al. 1986) and ERp (Kuiper, Enmark et al. 1996; Mosselman,
Polman et al. 1996). In vitro both proteins are functional and both bind oestradiol
with a high affinity (Mosselman, Polman et al. 1996).
1.2.3 Co-regulators
In addition to regulating gene expression via direct interaction with the general
transcription machinery, steroid hormone receptor function is modulated by the
recruitment of co-activators and co-repressors. Examples include the pl60 or steroid
receptor coactivator (SRC) family (Lee, Lee et al. 2001), CREB-binding protein
(CBP), the CBP-related factors p300 and p/CAF (p300/CBP-associated factor) (Chen
and Li 1998; Lee, Lee et al. 2001). Co-regulators either possess chromatin-
remodelling activity or facilitate interaction between steroid receptors and the
transcription machinery (Brosens, Tullet et al. 2004).
As previously mentioned, two isoforms of the PR exist. Whilst the two forms of PR
have similar DNA- and ligand-binding affinities (Christensen, Estes et al. 1991), they
have opposite transcriptional activities (Tung, Mohamed et al. 1993; Vegeto,
Shahbaz et al. 1993; Chalbos and Galtier 1994; McDonnell, Clemm et al. 1994;
Zamir, Harding et al. 1996). In most contexts, PR B functions as an activator of
progesterone-responsive genes, while PR A is transcriptionally inactive (Tung,
Mohamed et al. 1993; Vegeto, Shahbaz et al. 1993). In addition, PR A also functions
as a strong transdominant repressor of PR B (Vegeto, Shahbaz et al. 1993) and human
oestrogen receptor (ER) transcriptional activity in the presence of both PR agonists
and antagonists (Vegeto, Shahbaz et al. 1993; McDonnell and Goldman 1994; Zamir,
Harding et al. 1996; Giangrande, Pollio et al. 1997). The lower transactivation
potential of PR A may be explained by its higher affinity for the co-repressor SMPT
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(silencing mediator of retinoid and thyroid hormone receptor) and its less efficient
recruitment of the co-activator SRC-1 (Giangrande, Kimbrel et al. 2000).
1.2.4 Oestrogen and progesterone receptor localisation across
the normal menstrual cycle
Several immunohistological studies within the human endometrium have described
the distribution and cyclical variation of oestrogen and progesterone receptor
expression within the epithelial and stromal compartments in both the functional and
basal layers of endometrium (Garcia, Bouchard et al. 1988; Lessey, Killam et al.
1988; Snijders, de Goeij et al. 1992; Critchley, Bailey et al. 1993; Snijders, de Goeij
et al. 1996; Wang, Critchley et al. 1998; Critchley, Kelly et al. 2001; Slayden, Nayak
et al. 2001). These studies report that both receptors are immunolocalised within cell
nuclei. Previous studies have reported that PR isoforms levels change throughout the
normal menstrual cycle with the PR A: PR B ratio greater premenstrually and
immediately after menstruation (Mangal, Wiehle et al. 1997). In addition, the PR B
isoform is differentially regulated in endometrial stroma (Wang, Critchley et al.
1998). PR A and PR B are located in the glands and stroma during the proliferative
phase. During the secretory phase, PR A and PR B expression decreases in the
epithelium but the PR A isoform persists until the late secretory phase in the stromal
cells, particularly those in the perivascular region (Wang, Critchley et al. 1998). PR B
is reported to be present in the stromal cells until the mid secretory phase and it is
suggested that this isoform may be responsible for the progestogenic effects which
cause glandular secretion (Mote, Balleine et al. 1999). These immunolocalisation
studies provide circumstantial evidence to imply that PR A is the isoform responsible
for the secretory phase actions of progesterone within the stroma, with particular
relevance to the initiation of decidualisation. In addition, the localisation of both PR
isoforms to the predecidual cells around the spiral arterioles suggests that
progesterone withdrawal effects may be profound in these cells (Wang, Critchley et
al. 1998).
In vitro studies have demonstrated that PR A is more abundant that PR B during the
process of decidualisation (Brosens, Hayashi et al. 1999). Interestingly, Brosens et al
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also report that PR A was augmented with the progression of decidualisation and that
this reduction was accelerated with addition of MPA, a synthetic progestin (Brosens,
Hayashi et al. 1999). In addition, transient transfection of either PR A or PR B
promoter-reporter constructs resulted in inhibition of dPRL in response to cAMP.
Exposure of the endometrium to locally delivered high dose progestins, as with the
Levonorgestrel-releasing intrauterine system (LNG-IUS), down-regulates ERa, PR A
and PR B in both glandular and stromal cells (Critchley, Wang et al. 1998). The
administration of RU486, a PR antagonist, in the early secretory phase of the cycle
prevents progesterone-induced down regulation of PR and ERa, confirming the role
of progesterone in mediating uterine functions (Maentausta, Svalander et al. 1993;
Cameron, Critchley et al. 1996).
Both ERa and ER(1 have been detected in glandular epithelium, stroma and
perivascular cells. Immunoexpression of ERa increases in both endometrial
epithelium and stroma of the functionalis throughout the proliferative phase and
reaches maximal expression in the late proliferative endometrium, at the time of
ovulation. Levels then decline in the glandular and stromal compartments of the
functional layer during the secretory phase (Critchley 2000). In situ hybridisation has
detailed the localisation of mRNA for both ER isoforms within the human
endometrium (Matsuzaki, Fukaya et al. 1999) and found an identical pattern of
expression to that of the ERa protein. ERp mRNA was expressed predominantly by
the glandular epithelium with only faint stromal staining (Matsuzaki, Fukaya et al.
1999). Again, decreased expression was apparent in the functionalis of secretory
phase endometrium (Matsuzaki, Fukaya et al. 1999; Critchley, Brenner et al. 2001;
Lecce, Meduri et al. 2001).
1.3 Mechanisms ofMenstruation
The physiological withdrawal of progesterone from an oestrogen-progesterone
primed endometrium is the triggering event for the cascade of molecular and cellular
interactions that result in menstrual bleeding. Several key inflammatory mediators,
many of which have a key perivascular location, are involved in the current
hypothesis of the causes of menstruation, which is based on lines of evidence derived
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from studies on local endometrial response to progesterone withdrawal (Critchley,
Kelly et al. 2001).
1.3.1 Prostaglandins
The vascular changes found to be associated with menstruation have implicated the
vasoactive substances present in the endometrium, PGE2 and PGF2a (Lumsden, Kelly
et al. 1983; Lumsden, Brown et al. 1984) as key regulatory molecules. Prostaglandins
(PGs) are lipid mediators that are produced from arachidonic acid (AA). Two rate-
limiting steps, phospholipase A2 activity, and activity of the two Cyclooxgenase
enzymes, COX-1 and 2, control the production of prostaglandins (PGs). Free AA is
initially converted to prostaglandin H2 (PGH2) by COX-1 and -2. Subsequently, the
action of specific synthases on PGH2 directs the synthesis of the five primary
prostanoids, namely PGD2, PGE2, PGF2a PGI2 and TXA2 (Smith 1986; Smith and
Dewitt 1996; Smith, Garavito et al. 1996). PGs were first implicated in the process of
menstruation approximately 40 years ago (Pickles 1967). Subsequently, increases in
PG synthesis and decreases in metabolism have been reported in response to falling
progesterone levels (Ylikorkala and Makila 1985). Furthermore, the vasoconstrictive
actions of PGF2« have been implicated in the initiation of menstruation (Baird,
Cameron et al. 1996). The ratio of PGE2: PGF2a is reported to be increased in the
menstrual fluid of women suffering from excessive menstrual bleeding (Rees,
Anderson et al. 1984; Cameron, Leask et al. 1987) and administration of nonsteroidal
anti-inflammatory drugs (COX inhibitors) in menstrual pathologies reduces blood
loss suggesting that aberrant expression of the vasodilator PGE2 promotes increased
bleeding which can lead to menorrhagia (Fraser 1992).
In vitro tissue explant culture studies suggest that the endometrium has a greater
capacity to produce PGs in the progesterone-dominant secretory phase of the
menstrual cycle (Abel and Baird 1980). Furthermore, the PG metabolising enzyme,
prostaglandin dehydrogenase (PGDH), has been found to be under hormonal control
(Casey, Hemsell et al. 1980; Greenland, Jantke et al. 2000). Within the human
endometrium, PGDH is located within the cytoplasm of gland cells and levels were
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found to be highest in the secretory phase but lowest premenstrually and during
menstruation, consistent with the in vitro culture data (Casey, Hemsell et al. 1980).
This is in agreement with a study by Critchley et al who also report a significant
increase in PGDH levels in secretory phase endometrium (Critchley, Wang et al.
1998). In addition, these authors also demonstrated that PGDH activity is
significantly increased at 12 months post-insertion of a LNG-IUS and coincides with
a rise in PR A and PR B immunostaining, implicating both receptor levels and PGs in
the control of endometrial bleeding (Critchley, Wang et al. 1998). COX-2 expression
and immunoreactivity levels, while present in the glandular epithelium throughout
the menstrual cycle, are greatest in the perivascular region upon premenstrual
progesterone withdrawal coinciding with the recruitment of leukocytes into the
endometrium immediately prior to menstruation (Jones, Kelly et al. 1997; Critchley,
Jones et al. 1999).
Moreover, the actions of PGs on the blood vessels and perivascular cells are
underlined by the significant distribution of PG receptors in this locus (Milne,
Perchick et al. 2001; Milne and Jabbour 2003). There are 4 different PGE2 receptors
and these are referred to as EPi _ 4. The EP2 and EP4 receptors act via Gs proteins to
induce an increase in cAMP levels. The EP3 receptor exists as 7 splice variants
(Adam, Boie et al. 1994; Sugimoto, Narumiya et al. 2000) with the predominant
effect of decreasing cAMP levels. EPi acts via a different second messenger, Ca2+, to
exert its effects (Kennedy, Coleman et al. 1982; Watabe, Sugimoto et al. 1993).
1.3.2 Vascular Endothelial Growth Factor (VEGF) and Hypoxia
Coincident vasoconstriction of the endometrial spiral arteries (Markee 1940) and
vasoconstriction and contractions of the myometrium in response to increased
production of PGF2(1 (Ylikorkala and Makila 1985) are presumed to induce hypoxia
within the uppermost endometrial zone. Hypoxia is a potent inducer of angiogenic
and vascular permeability factors such as vascular endothelial growth factor (VEGF)
(Popovici, Irwin et al. 1999; Zhang and Salamonsen 2002). VEGF is expressed
across the menstrual cycle (Zhang, Scott et al. 1998) and is upregulated
premenstrually in response to the aforementioned hypoxic stimulus (Sharkey, Day et
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al. 2000). A recent microarray analysis has demonstrated that in vitro decidualised
ESCs express greater levels of VEGF as compared with their non-decidualised
counterparts (Popovici, Kao et al. 2000), implying a role for stromal decidualisation
in increasing VEGF levels. This is further supported by the observation that relaxin, a
decidualisation stimulus, increases VEGF expression in ESC in vitro (Unemori,
Erikson et al. 1999). The type 2 receptor for VEGF, kinase domain receptor (KDR),
is expressed only in endometrial endothelial cells until the premenstmal phase when
progesterone withdrawal upregulates expression of both KDR and VEGF in the
superficial stroma in both women and nonhuman primates (Nayak, Critchley et al.
2000; Nayak and Brenner 2002). Pro-MMP-1 is also induced in a coordinate manner
in the same stromal population in response to progesterone withdrawal (Nayak and
Brenner 2002). Hence, VEGF, KDR and MMPs are coordinately expressed by
stromal cells in the upper functionalis at the time of progesterone withdrawal,
intimating that they may act in concert to regulate the menstrual process.
1.3.3 Matrix metalloproteinases
At present, there is no certainty as to the source of the matrix metalloproteinases
(MMPs) which are enzymes thought to be released by both the invading immune
cells and by the stromal cells. There are several major subgroups of MMPs: the
collagenases (e.g. MMP-1), the gelatinases (MMP-2 and 9), the stromelysins (MMP-
3, 10 and 11) and the membrane-type MMPs. MMPs are secreted as inactive
zymogens, which are activated by proteases. The degeneration of the extracellular
matrix has been attributed to the actions of MMPs (Salamonsen 1996; Schatz, Papp et
al. 1997; Lockwood, Krikun et al. 1998; Salamonsen and Woolley 1999) and their
role in menstruation implied by the timing of their expression within the human
endometrium (Rodgers, Osteen et al. 1993; Hampton and Salamonsen 1994; Rodgers,
Matrisian et al. 1994). Additionally, progesterone withdrawal has been found to
increase MMP release in in vitro culture of endometrial stromal cells (Salamonsen,
Butt et al. 1997; Lockwood, Krikun et al. 1998). Withdrawal of progesterone from
cultures of endometrial stromal cells (ESCs) enhances proMMP-2 (Irwin, Kirk et al.
1996), proMMP-3 (stromelysin-1) production (Schatz, Papp et al. 1994) and
upregulation of MMP-1, -2, -3 and -4 in latent form (Salamonsen, Butt et al. 1997).
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The effects of progesterone on MMPs may be attributable to the progesterone-
stimulating enhancement of tissue inhibitors of MMPs (TIMPs) synthesis, such as
TIMP-3 (Higuchi, Kanzaki et al. 1995). TIMPs are endogenous inhibitors that act by
forming 1:1 complexes with the MMP. In addition, it has also been demonstrated that
progesterone inhibits MMP production by acting synergistically with TGFpi
(Bruner, Eisenberg et al. 1999; Yuan and Varga 2001; Jabbour, Kelly et al. 2006).
Although MMPs are clearly involved in the tissue breakdown involved in
menstruation their activation is likely to be several steps downstream of the initial
vasoconstriction events reported by Markee (Markee 1940).
1.3.4 Endothelins
Studies on the role of vasoactive mediators in menstruation have investigated a group
of 21 amino acid peptides, the endothelins (Marsh, Findlay et al. 1996). They are
cleaved from precursor (pro- and preproendothelins) proteins and to date, three
endothelins have been identified, endothelin-1, 2 and 3. Endothelin-1 (ET-1) is
reported to be the most potent vasoconstrictor identified. ETs signal via two G-
protein coupled receptors, ETa and ETB, it has been suggested that the endothelins
may act via the ETB receptor to cause vasoconstriction during menstruation (Collett,
Kohnen et al. 1996; Wang, Zheng et al. 1998). All three isoforms have been localised
to the glandular and luminal epithelium (O'Reilly, Charnock-Jones et al. 1992;
Salamonsen, Butt et al. 1992; Cameron, Plumpton et al. 1993) with ET-1 also present
in the stroma and in some endothelial cells (Salamonsen, Butt et al. 1992; Ohbuchi,
Nagai et al. 1995) across the menstrual cycle in human endometrium. ET-1 protein
(Ohbuchi, Nagai et al. 1995) and mRNA (Economos, MacDonald et al. 1992) levels
have been found to increase in the premenstrual-menstrual phase suggesting a role in
menstruation (Salamonsen, Marsh et al. 1999). This is further supported by ET-1
release in response to progesterone withdrawal from endothelial cells isolated from
human small uterine arteries (UtMVECs), serving to explain the vasoconstriction
seen in the coiled arteries during menstruation in humans (Edlund, Andersson et al.
2004). It has been reported that TGFpi dose-dependently increased ET-1 release
from 1st trimester decidual cells (Kubota, Taguchi et al. 1997). This may be explained
by TGFpi opposing the progesterone-induced increase in enkephalinase expression,
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the enzyme responsible for degradation of ET (Fagny, Michel et al. 1991), in
endometrial stromal cells, even in the continued presence of MPA (Casey and
MacDonald 1996). In addition ET-1 has been reported to induce PGF2Q release from
human endometrium (Cameron, Davenport et al. 1991). Together these studies have
highlighted ET-1 as a potent vasoconstrictor, involved in endometrial bleeding prior
to the onset of menstruation and, subsequently, in cessation of menstrual bleeding
(Salamonsen, Marsh et al. 1999).
1.4 Menstruation and Inflammation
In addition to hormonal control, menstruation is considered to be an inflammatory
event with many inflammatory mediators upregulated and localised to a perivascular
location (Finn 1986; Critchley, Kelly et al. 1994; Kelly 1994; Jones, Kelly et al.
1997; Critchley, Jones et al. 1999; Milne, Critchley et al. 1999; Salamonsen 2003).
Inflammation is characterised by tissue oedema, recruitment of inflammatory cells to
the area and the associated release of pro-inflammatory cytokines (Salamonsen
2003). Leukocytes invade the endometrium during the pre-menstrual phase,
coinciding with the withdrawal of progesterone. Indeed an elegant study in sheep
demonstrated that leukocytes migrate into the endometrium, but not the myometrium,
following ovarian progesterone withdrawal (Staples, Heap et al. 1983). In addition to
providing defence against pathogens, when activated, leucocytes produce a plethora
of regulatory molecules, including cytokines, chemokines and a range of enzymes
that are important either directly in matrix degradation, or indirectly by activation of
other proteases. The infiltration and functions of these different cells is discussed in
section 1.4.1.
1.4.1 Leukocyte subpopulations in endometrium
The number and type of leukocytes in human endometrium and decidua varies across
the menstrual cycle, with implantation and throughout pregnancy. Leukocytes
constitute approximately 8.2% of the stromal cells in the proliferative phase with this
figure rising to 31.7% in first trimester decidua (Bulmer, Longfellow et al. 1991).
Endometrial leukocytes include T and B cells, mast cells, macrophages, neutrophils
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and uterine Natural Killer (uNK) cells (King, Burrows et al. 1998; Trundley and
Moffett 2004). Lymphoid aggregates are present in the basalis region throughout the
menstrual cycle and contain T cells and B cells surrounded by a halo of macrophages
(Bulmer, Lunny et al. 1988; Bulmer 1994). T cells are also found scattered
throughout the endometrial stroma and have also been localised to an intraepithelial
location whilst B cells are rarely observed out with lymphoid aggregates. These cells
become activated during pregnancy at the site of large lymphoid cell clusters and it is
possible they are acting to provide constitutive immune defence at this critical time or
control trophoblast invasion (Mincheva-Nilsson, Baranov et al. 1994). Macrophages
constitute approximately 20% of the leukocytes present throughout the cycle with an
increase in number observed prior to menstruation and in decidua (Kamat and
Isaacson 1987; Bulmer, Lunny et al. 1988; Bonatz, Hansmann et al. 1992). A
scavenger role during menstruation has been suggested. In decidua, macrophages are
found at the implantation site often in contact with extravillous trophoblast (Bulmer,
Lunny et al. 1988; Loke and King 1995). Macrophages are also raised in number in
endometrium taken from women 48 hours after controlled progesterone withdrawal
compared to decidua from pregnant women (Critchley, Jones et al. 1999). Although
displaying a cyclical pattern of cell number regulation, macrophages do not express
classic ERa or PR (King, Gardner et al. 1996; Stewart, Bulmer et al. 1998).
Therefore, control by oestradiol and progesterone is likely to be indirect.
An influx of neutrophils occurs in the perimenstrual period at which point they
comprise approximately 6-15% of total cells, and they are thought to be important in
menstruation (Poropatich, Rojas et al. 1987; Salamonsen, Kovacs et al. 1999).
Neutrophils produce a plethora of immunoregulatory cytokines that are reported to
initiate and potentiate cellular and humoral immune responses. One example is the
anti-proteinase and antimicrobial molecule elafin, which is expressed by endometrial
neutrophils in a menstruation-dependent manner (King, Critchley et al. 2003). An
important chemotaxis stimulus for neutrophils is IL-8 (neutrophil chemotactic factor)
(Rampart, Van Damme et al. 1989; Colditz 1990). Eosinophils also rise immediately
prior to menstruation and make up around 3-5% of endometrial cells at this point
(Jeziorska, Salamonsen et al. 1995; Salamonsen and Lathbury 2000).
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A population of phenotypically unique lymphocytes (CD56bnght, CD16dim, CD3") has
been reported to cluster proximal to glands and spiral arteries, with cell number
altering in a cyclical manner increasing in the late secretory phase (King, Burrows et
al. 1998; King 2000). These cells are uterine Natural Killer cells (uNK) and exhibit
characteristic large granular lymphocyte morphology (Loke and King 1995). uNK
cells are the major leukocyte population present in the endometrial stroma at the time
when implantation, placentation and decidualisation occur (King 2000; Henderson,
Saunders et al. 2003). Figure 1.5 depicts the leukocyte populations present in

















Figure 1.5: Leukocyte populations in human endometrium and first trimester
decidua. Data and illustrations adapted from Loke and King, 1997.
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1.4.2 Uterine Natural Killer cells
Natural killer (NK) cells constitute a major component of the innate immune system
(Bancroft 1993; Scharton-Kersten and Sher 1997; Biron, Nguyen et al. 1999; Cooper,
Fehniger et al. 2001). Uterine NK cell have a unique phenotype (CD56bnght, CD16dim,
CD3-), which distinguishes them from the majority of peripheral blood NK (PBNK)
cells (CD56dim, CD16bright, CD3"). CD16 is a low-affinity receptor for IgG complexes
(FcRIII) and is responsible for NK-mediated antibody-dependent cellular
cytotoxicity. CD56 is an isoform of the neural cell adhesion molecule (NCAM)
(Nagler, Lanier et al. 1989). In addition, the CD57 antigen is also differentially
expressed among NK cell subsets, with expression observed on PBNK cells but
absent from uNK cells (Nagler, Lanier et al. 1989). NK cells are present in peripheral
blood, accounting for approximately 10% of total blood lymphocytes (Robertson and
Ritz 1990). However, the CD56Bnght subset comprises less than 2% of total blood
lymphocytes, approximately 10% of total blood NK cells (Lanier, Le et al. 1986).
The exact functions of these uNK cells in humans have yet to be elucidated, but may
involve a role in implantation and placentation (Loke and King 1995; Loke and King
1997; King, Burrows et al. 1998; King 2000; Loke and King 2000; Loke and King
2000).
1.4.2.1 Uterine Expression and Functions of uNK Cells
Uterine NK cells were originally termed Large Granular Leukocytes (LGLs) due to
their granular lymphocyte morphology (King, Balendran et al. 1991; Loke and King
1995). Upon activation CD56Bnght NK cells produce an array of cytokines such as
IFNy and GM-CSF, (Cooper, Fehniger et al. 2001) and demonstrate cytotoxic activity
upon IL-12 or IL-2 activation (Ellis and Fisher 1989; Gately, Desai et al. 1991;
Robertson, Soiffer et al. 1992). It has been demonstrated that the CD56Bnght NK
variety produce far greater levels of cytokines compared with the cytolytic CD56Dim
cells (Cooper, Fehniger et al. 2001). However, a study comparing cytokine
production by peripheral NK cells and decidual NK cells reported a very similar
cytokine repertoire (Saito, Nishikawa et al. 1993). Through their secretion of
cytokines it is likely uNK cells are having immunoregulatory effects. It has been
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suggested that CD56bnght uNK cells are derived from the small CD56bnght population
in peripheral blood (Dosiou and Giudice 2005). There are some notable phenotypic
differences between these two populations, uNK are KIR+, CD69+, CD62L", whereas
CD56bright peripheral NK cells are KIR- CD69-, and CD62L+ (Moffett-King 2002;
Dosiou and Giudice 2005). A recent microarray analysis identified significant
differences in gene expression between the CD56bnght uNK population in the decidua
with the CD56bnght and CD56dim peripheral NK cell populations, including selective
expression of CD9, galectin-1, and glycodelin, in the decidual NK population but not
in peripheral blood NK cells (Koopman, Kopcow et al. 2003; Dosiou and Giudice
2005). CD56bnght uNK cells were also reported to express significantly higher levels
of several other genes, including tetraspanins, integrins, lectin-like receptors, and
KIRs compared with peripheral CD56bnght cells (Koopman, Kopcow et al. 2003;
Dosiou and Giudice 2005).
Several changes occur in uNK cells during the normal menstrual cycle and human
pregnancy. Firstly, uNK cells are present in low numbers in the proliferative phase
but increase across the secretory phase, particularly around the time of implantation
(Loke and King 1997), with numbers peaking in the late secretory phase where they
comprise approximately 15-25% of the endometrial stromal cells (King, Wellings et
al. 1989), uNK cells are localised in clusters close to endometrial glands and spiral
blood vessels (King, Burrows et al. 1998; King 2000). uNK cell numbers fall prior to
menstruation. It was originally thought that uNK cells were undergoing apoptosis
(King 2000) however, a more recent study has failed to provide evidence of classical
apoptosis in uNK cells of the late secretory endometrium (Trundley and Moffett
2004) and their fate is therefore uncertain. In pregnancy uNK cells constitute
approximately 75% of the leukocytes in 1st trimester decidua and are present until
the 2nd trimester with numbers subsequently declining (Bulmer, Morrison et al. 1991;
Loke and King 1995). uNK cell phenotype changes across the menstrual cycle and
early pregnancy (Kodama, Hara et al. 1998). Expression of CD69, HLA-DR, CDlla
and CD18 are highest in the proliferative phase and decrease gradually during the
menstrual cycle (Kodama, Hara et al. 1998). Similarly, a decrease in expression of
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CD69, HLA-DR and CD45RA is observed during pregnancy (Kodama, Hara et al.
1998). In addition, uNK cells have been found to express one or more inhibitory
receptors in early pregnancy (Ponte, Cantoni et al. 1999).
The lineage, origin, and mechanism underlying the postovulatory rise of uNK cells
remain to be established. Two hypotheses exist: firstly that the increase in uNK
number in mid-to-late secretory endometrium is solely the result of in situ
proliferation and secondly that the increase is due to de novo migration from
peripheral circulation. In support of the first, proliferation of uNK cells within the
endometrium has been shown by staining with the proliferation marker, Ki67 (King,
Balendran et al. 1991; Kammerer, Marzusch et al. 1999). In contrast, a precursor cell
type may be selectively recruited into the endometrium, where it differentiates to
become the phenotypically unique uNK cell. In support of this theory, a subset of
peripheral NK cells have been identified that exhibit a similar antigenic phenotype to
uNK cells (Lanier, Le et al. 1986; Marzusch, Ruck et al. 1993; Perez, Sotiropoulou et
al. 2003). Chemokines are chemotactic cytokines that act via G protein-coupled
receptors (GPCRs) (Murphy 1996) and endometrial chemokines have been proposed
to be responsible for the increase in leukocytes in the secretory phase (Kamat and
Isaacson 1987). Chemokines are known to induce leukocyte migration via activation
of adhesion molecules expressed on their surface. Chemokines consist of four
cysteine residues and two disulphide bonds and are split into four sub-groups
according to the separation of the first two cysteines by amino acids: C, CC, CXC
and CXXXC (Zlotnik and Yoshie 2000). CD56bnght NK cells have been reported to
express the chemokine receptors, CXCR3, CCR5 and CCR7 at high levels
(Maghazachi 2003). Recent studies have proposed that Interleukin-8 (IL-8, CXCL8),
Interleukin-15 (IL-15), Interleukin-18 (IL-18), stromal cell-derived factor (SDF-1)
and macrophage inflammatory protein (MlP)-la are potent chemoattractants for
leukocytes and will be further discussed in this section.
Although the specific mechanism of uNK regulation in the uterus remains unknown,
the variation in uNK cell number across the menstrual cycle suggests ovarian steroid
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regulation (King, Burrows et al. 1998; Dunn, Kelly et al. 2003; Dosiou and Giudice
2005). uNK cell expansion across the progesterone-dominated secretory phase and
the association of uNK cell demise with falling levels of progesterone implicates
progesterone as a central regulator of their growth and this is compounded by
evidence that ovariectomised women lack uNK cells (Loke and King 1995; Flynn,
Byrne et al. 2000). However, a search for evidence of a direct hormonal effect on
uNK cells, failed to identify either PR or ERa in human uNK cells (King, Gardner et
al. 1996; Stewart, Bulmer et al. 1998; Henderson, Saunders et al. 2003). A more
recent study identified expression of ER(3 (full length and variant isoforms) and the
glucocorticoid receptor (GR) mRNAs in purified uNK cells, but confirmed that they
were negative for ERa and PR (Henderson, Saunders et al. 2003). In addition, protein
expression of ER|3 and the GR was confirmed (Henderson, Saunders et al. 2003).
However, ER expression by uNK precursor cells would not appear to be an essential
pre-requisite for successful proliferation and differentiation, at least in the mouse
model, as bone marrow from ERa knockout (aERKO) and ER|3 knockout (6ERKO)
mice transplanted into RAG-2_/7yc-/~mice, lacking all lymphocyte lineages, will both
successfully reconstitute the uNK population (Borzychowski, Chantakru et al. 2003).
The reconstituted uNK cells are reported to be capable of initiating appropriate
modification of spiral arteries in the uterus (Borzychowski, Chantakru et al. 2003),
but functionality has yet to be fully assessed. Therefore, a possible role for either ER
in regulating uNK cell function has not yet been conclusively established.
This absence of the genomic PR suggests uNK cells are not controlled directly by
progesterone but that it is possible that regulation is via paracrine signalling with
non-leukocyte ESCs since these cells do express the PR A isoform during the
secretory phase (Wang, Critchley et al. 1998). This is in agreement with studies
where the NK cells were co-cultured with endometrial stromal cells whose treatment
with progesterone upregulated the population of CD56Bnght NK cells, whereas culture
with prolactin, oestradiol or human chorionic gonadotrophin (hCG) did not induce
CD56Bnght cell proliferation (Inoue, Kanzaki et al. 1996). Interestingly, culture of
highly purified endometrial CD56bn8ht, CD16dim NK cells with 17P-oestradiol or
progesterone has no effect on uNK proliferation, cytotoxicity or IFNy production
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(Kitaya, Yasuda et al. 2003), in agreement with the suggestion that progesterone
regulates uNK cell function in a paracrine manner via action on intermediary cells,
for example, ESC or other immune cells. It is also possible that progesterone will
stimulate uNK cells via the GR, which have cross-reactivity with progesterone
(Kontula, Paavonen et al. 1983; Thomas, Liu et al. 2006).
1.4.2.2 Production of cytokines by uNK cells
Studies in vitro have demonstrated that uNK cells proliferate upon treatment with IL-
15 but other, as of yet, unidentified products of ESCs appear to increase their
proliferation further (Verma, Hiby et al. 2000). A study on isolated human decidual
NK cells revealed these cells express mRNA and secrete the protein for G-CSF, GM-
CSF, M-CSF and LIF (Saito, Nishikawa et al. 1993). This suggests that, in addition
to, or in place of an immune function, uNK cells may perform other functions. For
example, a close association exists between uNK cells and trophoblast cells in vivo
providing circumstantial evidence for a role in trophoblast invasion (Loke and King
1997). In culture experiments, MlP-la secreted from isolated human cytotrophoblast
cells has been shown to attract CD56Bri8ht cells (Drake, Gunn et al. 2001). The authors
interpret this as MlP-la having uNK-specific chemoattractant properties (Drake,
Gunn et al. 2001). This is in contrast to studies in the murine uterus where mice
genetically-ablated for MlP-la show no difference to wild type mice with regard to
uNK cell density at the implantation site (Chantakru, Kuziel et al. 2001). In addition,
murine uNK cells, which are present only in the metrial gland, the triangle at the apex
of the placenta where blood vessels feeding the placenta are in close proximity (Croy
and Kiso 1993), express mRNA for an array of cytokines including CSF-1, TNFa,
IL-1, LIF and TGFJ3 (Croy, Guilbert et al. 1991).
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1.4.2.3 Control of uNK activity
NK cell activity is controlled by the integration of both activating and inhibitory
signals. Notably, NK cells express receptors that upon engagement of class I MHC
proteins deliver inhibitory signals to the NK cytolytic machinery. The most studied
NK receptors are the KIRs, the immunoglobulin-like transcripts (ILTs), and the
CD94/NKG2 proteins. In contrast to blood where only approximately 50% of NK
cells express CD94/NKG2A, all decidual NK cells are characterised by the
expression of high levels of CD94/NKG2A (Borrego, Kabat et al. 2002; Trundley
and Moffett 2004). KIRs recognise groups of HLA alleles that have certain amino
acids in common, and in concert with CD94/NKG2A it is thought that these receptors
provide a means by which decidual NK cells differentially respond to trophoblast
cells, which display a specific complement of HLAs, and maternal somatic cells
expressing all the HLA class I proteins (Trundley and Moffett 2004). uNK cells
display no cytolytic activity against the invading cytotrophoblast but do against the
NK-sensitive cell line, K562 (King, Birkby et al. 1989).
Further evidence supporting the role of uNK cells in implantation and in the
pathogenesis of early pregnancy loss is gained from studies examining women
suffering from recurrent miscarriage who are reported to display both an increase in
PBNK cell number (Ntrivalas, Kwak-Kim et al. 2001) and a greater infiltrate and
activation of CD56bnght, CD16d,m uNK cells in utero (Clifford, Flanagan et al. 1999;
Quenby, Bates et al. 1999). In contrast, a study by Lachapelle et al demonstrated that
the CD56bnght, CD16dim NK cell subset was significantly decreased in favour of the
CD56dun, CD16bright NK cell subset in all patients with recurrent spontaneous abortion
(Lachapelle, Miron et al. 1996). However, a recent report evaluating the
immunophenotypes of endometrial leukocytes in women with history of recurrent
spontaneous miscarriage has concluded that endometrial biopsies from the peri-
implantation period in a menstrual cycle prior to pregnancy cannot predict
subsequent pregnancy outcome (Michimata, Ogasawara et al. 2002). These studies
implicate uNK cell involvement in early pregnancy maintenance, with aberrant
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expression leading to a failed pregnancy. However, these findings could alternatively
represent an attempt by uNK cells to "rescue" a failing pregnancy, although no
evidence is available to confirm or deny this.
1.4.2.4 uNK Cells and Decidualisation
uNK cells have been implicated in the process of decidualisation. uNK cells have
been specifically localised within regions of stroma exhibiting pseudodecidual
alterations (Bulmer, Lunny et al. 1988) and in the murine uterus, uNK cells are
proposed to be essential for maintenance of the decidual reaction rather than its
initiation (Croy, Ashkar et al. 1997; Croy, Chantakru et al. 2002; Croy, Esadeg et al.
2003). Evidence from studies on mice lacking IFNy implicates this cytokine, a major
product of uNK cells, in the decidual reaction and conversion of the uterine
vasculature (Ashkar and Croy 1999; Ashkar, Di Santo et al. 2000; Ashkar and Croy
2001; Croy, Chantakru et al. 2002; Ashkar, Black et al. 2003; Croy, Esadeg et al.
2003). In contrast, in vitro decidualisation of cultured human ESCs is antagonised by
treatment with IFNy, implying that the role of IFNy may differ between mice and
humans (Christian, Marangos et al. 2001). As previously mentioned, prolactin is
secreted by human decidualised stromal cells and regulation of prolactin receptor
mRNA expression is mediated by progesterone (Tseng and Mazella 1999). A recent
study has identified the prolactin receptor on uNK cells, suggesting that uNK cells
are a novel target for prolactin action representing a possible functional link between
uNK cells and ESCs, and providing an indirect connection between progesterone and
control of uNK cells (Gubbay, Critchley et al. 2002).
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1.4.3 Macrophage Mannose Receptor
The macrophage mannose receptor (MMR) was initially recognised as a receptor
involved in the clearance of endogenous glycoproteins (Stahl, Rodman et al. 1978;
Pontow, Kery et al. 1992). Named owing to its affinity for sugars terminated in
mannose, fructose or N-acetyl glucosamine, the macrophage mannose receptor has
been implicated in the recognition of exposed mannose residues on the surface of
selected pathogens and the intemalisation of mannosylated antigens. Therefore, these
receptors may play a role in microbial recognition and antigen presentation and in
lymphocyte adhesion (Wileman, Boshans et al. 1985; Taylor, Boland et al. 1991).
Natural ligands for the receptor include microbial polysaccharides, and glycoproteins,
such as LH and thyroid stimulating hormone (TSH), produced by the anterior
pituitary, glycolipids, and mammalian glycoproteins with N-linked high-mannose
(Fiete, Srivastava et al. 1991; Fiete, Beranek et al. 1997; Linehan, Martinez-Pomares
et al. 2000).
The MMR (CD206), a 180 kDa transmembrane protein, was the first member of a
family of four mammalian endocytic receptors to be discovered (Ancian, Lambeau et
al. 1995). All members share the same structure: an extracellular N-terminal cysteine-
rich (CR) domain, followed by a domain containing fibronectin type two repeats
(FNII), multiple C-type lectin-like carbohydrate recognition domains (CTLDs), and a
transmembrane domain and short cytoplasmic tail (Taylor, Conary et al. 1990). The
MMR CTLD mediates binding to carbohydrates terminating in mannose, fructose, or
N-acetylglucosamine, and the MMR CR domain recognises sugars terminating in 4-
sulfated ^-acetylgalactosamine 61-4 linked to A-acetylglucosamine (S04-4/3-
GalNAc) (Fiete, Beranek et al. 1997; Fiete, Beranek et al. 1998; Leteux, Chai et al.
2000; Liu, Chirino et al. 2000). The structure of the MMR is depicted in Figure 1.6.
The majority of cellular MMR is located within the endocytic pathway with only ~
15% localised to the cell surface (Pontow, Kery et al. 1992). A soluble form, sMMR,
which maintains its mannose-binding properties has been identified, and is reported
to be produced by proteolytic cleavage of the cell-associated MMR form by a MMP
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(Martinez-Pomares, Mahoney et al. 1998; Jordens, Thompson et al. 1999). The MMR
is expressed by most tissue macrophages, but is not macrophage-restricted and has
been identified in liver sinusoidal cells, non-vascular endothelia, skin dermis,
mucosal lamina propria and the T-cell areas of tonsil (Shepherd, Tarnowski et al.
1991; Linehan, Martinez-Pomares et al. 1999; Wilt, Greaton et al. 1999; Engering,
Geijtenbeek et al. 2002; Taylor, Gordon et al. 2005). As a consequence of its binding
properties and tissue distribution, the MMR can be placed at the interface between
homeostasis and immunity. Regulation of MMR expression and functionality by
cytokines, immunoglobulin receptors, and pathogens has been demonstrated. For
example, IFNy is reported to modulate the functional properties ofMMR and can act
in synergy with IL-4 to enhance MMR-dependent uptake (Marodi, Schreiber et al.
1993; Stahl and Ezekowitz 1998). Furthermore, in recruited inflammatory peritoneal
macrophages, MMR levels are increased in response to IL-4, IL-10, and IL-13 (Stein,
Keshav et al. 1992; Doyle, Herbein et al. 1994; Martinez-Pomares, Reid et al. 2003).
In contrast, IFNy is reported to decrease cell surface expression ofMMR and MMR-
mediated endocytosis (Harris, Super et al. 1992; Raveh, Kruskal et al. 1998).
However, both IL-4 and IFNy either alone, or together, are reported to increase
MMR-mediated phagocytosis (Raveh, Kruskal et al. 1998). These findings imply that
The type-1 and The type-2 cytokines at sites of inflammation are able to enhance
MMR-mediated phagocytosis, which may be important in the regulation of
menstruation or implantation in the human uterine environment. MMR knockout
mice (MMR~ ~) have a lethal phenotype and die in utero. Heterozygous female mice
have a smaller litter size that is reported to be a result of a reduction in the rate of
implantation (Mi, Shapiro et al. 2002), further supporting a role for MMR in uterine
functions. In addition, when MMR binds to microorganisms, a plethora of
intracellular responses have been reported, including cytokine secretion and
modulation of other cell surface receptors (Shibata, Metzger et al. 1997; Yamamoto,
Klein et al. 1997; Apostolopoulos, Barnes et al. 2000). Furthermore, MMR has
recently been demonstrated to be involved in antigen uptake and delivery to MHC
class 1 molecules (Apostolopoulos, Barnes et al. 2000; Apostolopoulos and
McKenzie 2001).
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Figure 1.6: Structure of the macrophage mannose receptor. Domain structure of the
MMR showing the proposed extended conformation and predicted N-linked
glycosylation (proposed sialylation indicated by red diamonds). The CR domain
(red), fibronectin type II (FNII) repeat (orange) and CTLD (green) are shown.
CTLD4, the CTLD mostly responsible for sugar binding, is shown in dark green.
Ligands for each of the binding regions have also been included (colours correspond
to the binding domain where known). Redrawn from Taylor et al (Taylor, Gordon et
al. 2005).
1.5 Cytokines
Cytokines are small glycoproteins with autocrine and paracrine interactions and are
predominantly associated with immune functions. Cytokines can be involved in both
the induction and resolution of an inflammatory response and are generally denoted
as "pro-inflammatory" or "anti-inflammatory". In the human endometrium, during
the peri-implantation phase, a reduction or absence of Th-1 and a dominance of Th-2
cytokines is observed (Lim, Odukoya et al. 1998). The general hypothesis, with
regard to pregnancy, is that a Th-1 response is considered detrimental and a Th-2
response is thought to be beneficial and supportive of pregnancy by contributing to
the local modulation of maternal adaptive immune response to facilitate successful
embryonic implantation and maintenance of pregnancy (Wegmann, Lin et al. 1993;
Hill, Polgar et al. 1995; Lim, Odukoya et al. 1998; Hill and Choi 2000). Some of the
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reproductive functions of cytokines are summarised in Table 1.1. The cytokines








Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Activation of T cells
TGF(31
Gland formation and Angiogenesis
Extracellular matrix formation
Modulating myofibroblast differentiation
Tissue remodelling and homeostasis
Regulation of TIMPs
IFNy




Chemotaxis and induction of lymphoid infiltration
Induction of HLA-DR and ICAM-1
TNFa




Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Injury to endometrial vessels
Activation of polymorphonuclear leukocytes
Table 1.1: Cytokine functions in the human endometrium. Adapted from Tabibzadeh
1994 (Tabibzadeh 1994).
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1.5.1 Cytokines involved in decidualisation and/or leukocyte
recruitment and proliferation
1.5.1.1 Activin
Activins are dimeric proteins consisting of two subunits (6A and BB) and they can
exist as 6A - 6A or BB - BB homodimers or the BA - BB heterodimer (Ying 1987;
Schwall, Nikolics et al. 1988). Activins can be inactivated by binding to follistatin
(Vale, Rivier et al. 1986; Ying 1987; Shimonaka, Inouye et al. 1991; Schneyer,
Rzucidlo et al. 1994) and act via the ActRIIB and ActRII receptors found on plasma
membranes (Massague 1992; Mathews and Vale 1993). Activins are highly
expressed in the endometrium, with both activin subunits primarily localised to
endometrial glands (Leung, Salamonsen et al. 1998; Otani, Minami et al. 1998;
Petraglia, Florio et al. 1998; Jones, Brauman et al. 2000), and maximal levels seen in
the secretory phase. Activin BA and BB subunits are both dramatically upregulated in
both in vivo and in vitro models of decidualisation (Otani, Minami et al. 1998; Jones
and Critchley 2000) and are highly expressed in the extensively decidualised
endometrium induced by intrauterine delivery of progestin (Jones and Critchley
2000; Roopa, Loganath et al. 2003). Furthermore, activin A promotes decidualisation
in vitro, while neutralisation of activin action by treatment with follistatin
significantly inhibits the decidual response (Jones, Salamonsen et al. 2002; Tierney,
Tulac et al. 2003). Activin BA subunits are intensely expressed by neutrophils and
macrophages in the premenstrual and menstrual endometrium and have been
proposed to have roles in menstruation and tissue regeneration (Leung, Salamonsen
et al. 1998).
1.5.1.2 Interleukin-1 (IL-1)
IL-l is a pleiotropic cytokine which exists in two isoforms: IL-1a and IL-1|3, they
have similar action and act via the same receptor, IL-1R type-1. A second receptor
sub-type, known as IL-1R type-2, exists and is found on B cells, neutrophils and
monocytes. This receptor preferentially binds IL-1(3 (Colotta, Re et al. 1993) and may
act as a decoy inhibitor of both isoforms of IL-1 (Colotta, Re et al. 1993). In the
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human endometrium IL-1|3 mRNA levels are undetectable in proliferative and early
secretory phase endometrium, whereas both IL-la and IL-lp are expressed in the
epithelial and stromal cells of secretory phase endometrium (Tabibzadeh and Sun
1992) and 1st trimester decidua (Kauma, Matt et al. 1990). Human serum IL-1 levels
are cyclically regulated and are reported to be highest in the secretory phase, post-
ovulation (Cannon and Dinarello 1985). IL-1 has also been implicated in blastocyst
implantation and is expressed in conjunction with the receptor in both trophoblast and
decidual cells (Simon, Frances et al. 1994; Simon, Frances et al. 1994; Simon,
Frances et al. 1995; Simon, Pellicer et al. 1995). ESCs have been reported to generate
an oestrogen receptor-dependent immune-related response upon treatment with IL-la
(Ruiz, Montes et al. 1997; Pioli, Weaver et al. 2006), which was reduced when cells
were cultured under decidualising conditions (Ruiz, Montes et al. 1997).
It has also been suggested that IL-1 may also be involved in the initiation of
menstruation by stimulating production of MMPs and PGs (Cole, Seki et al. 1995;
Ishihara, Matsuoka et al. 1995; Singer, Marbaix et al. 1997; Kawano, Nakamura et al.
2001; Nishiura, Noda et al. 2005; Rossi, Sharkey et al. 2005). In addition, aberrant
production of IL-1 has been implicated in disorders or menstruation and pregnancy,
such as impaired decidualisation (Mizuno, Tanaka et al. 1999), pre-eclampsia
(Lockwood, Matta et al. 2006) and endometriosis (Fakih, Baggett et al. 1987; Mori,
Sawairi et al. 1992; Lebovic, Bentzien et al. 2000; Hudelist, Lass et al. 2005; Yin,
Sun et al. 2006).
1.5.1.3 Interleukin-8 (IL-8)
IL-8 has been implicated in angiogenesis, mitogenesis of epidermal cells and
chemotaxis of leukocytes (Koch, Polverini et al. 1992; Tuschil, Lam et al. 1992). In
the human uterus, IL-8 has been localised to the perivascular cells in the late
secretory phase and first trimester decidua (Critchley, Kelly et al. 1994; Critchley,
Kelly et al. 1996; Critchley, Jones et al. 1999; Milne, Critchley et al. 1999),
choriodecidual cells (Kelly, Leask et al. 1992) and in amniotic fluid (Laham, Rice et
al. 1993). In vitro culture of human ESCs and epithelial cells has demonstrated that
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IL-la and TNFa regulate IL-8 production (Arid, Head et al. 1993). Progesterone has
been proposed to be a primary regulator of IL-8 expression and in human endometrial
explant studies, progesterone suppressed IL-8 secretion (Kelly, Illingworth et al.
1994). This is in agreement with in vivo data demonstrating an increase in IL-8
immunostaining in human endometrium 48 hours after progesterone withdrawal in a
study designed to stimulate the hormonal milieu of the late secretory phase (luteal
regression) (Critchley, Jones et al. 1999). Together, these studies provide evidence to
implicate IL-8 in regulating menstruation (Kelly, Illingworth et al. 1994; Critchley,
Jones et al. 1999).
1.5.1.4 Interleiikin-10 (IL-10)
IL-10 is a pleiotropic homodimeric cytokine secreted by leukocytes and somatic cells
with well-characterised anti-inflammatory and immune-deviating properties (Chabot,
Williams et al. 1999; Moore, de Waal Malefyt et al. 2001). IL-10 favours
differentiation and function of lymphocyte subsets with pivotal roles in immune
tolerance (Enk, Saloga et al. 1994). Moreover, IL-10 terminates inflammatory
responses and limits inflammation-induced tissue pathology by inhibiting synthesis of
TNFa, IL-1, and a large array of other pro-inflammatory cytokines and chemokines in
monocytes/macrophages (Moore, de Waal Malefyt et al. 2001). IL-2-induced
CD56Bnght NK cells are reported to proliferate and produce cytokines upon treatment
with IL-10 (Carson, Lindemann et al. 1995). The specific role of IL-10 in
reproduction is unclear, however IL-10 is among the cytokines aberrantly expressed
in decidual T-lymphocyte populations of women with unexplained recurrent
miscarriage (Piccinni, Beloni et al. 1998) and reduced IL-10 immunostaining was
observed in uNK cells from women with spontaneous abortion compared with those
from elective terminations (Plevyak, Hanna et al. 2002). In contrast to this, IL-10
production was increased in stimulated peripheral blood mononuclear cells from
women with recurrent pregnancy loss compared with those from pregnant and non¬
pregnant women (Bates, Quenby et al. 2002).
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1.5.1.5 Interleukin-11 (IL-11)
IL-ll is a member of the gpl30 cytokine family (Gadient and Patterson 1999) and is
reported to have effects in a wide range of environments including, haematopoietic
cells, the nervous system, and the gastrointestinal tract (Hawley 1994; Sands, Bank et
al. 1999). Within the human endometrium, IL-11 is expressed in all cell types with
greatest immunostaining intensities apparent in decidualised stroma, appearing before
prolactin (Dimitriadis, Salamonsen et al. 2000). In culture, human ESCs produce IL-
11 and express IL-11 receptor a (IL-llRa) during progesterone-induced
decidualisation (Dimitriadis, Robb et al. 2002). Moreover, treatment with an anti-
human IL-11 antibody results in a reduction in production of prolactin and IGFBP-1
implicating IL-11 in the induction and regulation of decidualisation (Dimitriadis,
Robb et al. 2002). In the murine uterus, IL-11 appears to be essential for female
fertility. Mice knocked out for the IL-llRa gene have a defective uterine response to
the blastocyst which fails to trigger a normal decidual transformation (Bilinski,
Roopenian et al. 1998; Robb, Li et al. 1998).
1.5.1.6 Interleukin-15 (IL-15)
IL-15, a member of the 4 a-helix cytokine family, exists in two forms due to
alternative splicing (Fehniger and Caligiuri 2001). The receptor complex for IL-15 is
composed of three subunits. The a-chain is unique to its receptor but both the -(3 and
y-chains are common to the IL-2 receptor (Carson, Giri et al. 1994; Grabstein,
Eisenman et al. 1994). Both the message and protein levels of IL-15 are increased by
IFNy and by ligation with CD-40 (Weiler, Rogashev et al. 1998; Weiler, Kachko et
al. 2001). Although the actions of IL-2 and IL-15 are reported to be similar, their
tissue distribution is distinct. The uterus and placenta were found to be negative for
IL-2 (Jokhi, King et al. 1994; King, Jokhi et al. 1995), but positive for IL-15 mRNA
and protein (Kitaya, Yasuda et al. 2000; Okada, Okada et al. 2000; Verma, Hiby et al.
2000). Gene profiling has demonstrated a three fold up-regulation of the IL-15
precursor, IL-15 and the a chain of the IL-15 receptor during the human
"implantation window" compared with the late proliferative phase, supporting the
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role of IL-15 in the role of implantation (Kao, Tulac et al. 2002; Giudice 2004). This
pattern of expression has been confirmed by other studies examining IL-15 mRNA
and protein expression across the cycle (Kitaya, Yasuda et al. 2000; Okada, Okada et
al. 2000; Verma, Hiby et al. 2000; Chaouat, Zourbas et al. 2002; Dunn, Critchley et
al. 2002). Expression of IL-15 is not limited to the cycling endometrium but has also
been observed in abundance in 1st trimester decidua (Kitaya, Yasuda et al. 2000;
Okada, Okada et al. 2000). In in vitro studies of human endometrial stromal cells,
incubation with either progesterone or a combination of progesterone and oestradiol
has resulted in enhancement of IL-15 production (Okada, Nakajima et al. 2000).
Furthermore, human decidual NK cells express the IL-15 receptor, in response to IL-
15 proliferate, and augment their cytolytic activity against an NK-sensitive cell line,
K562 (Verma, Hiby et al. 2000). uNK development and transformation of uterine
vasculature has been reported to be defective in IL-15 knockout mice (-/-)
(Greenwood, Minhas et al. 2000; Kennedy, Glaccum et al. 2000; Miyazaki, Tanebe et
al. 2002), further supporting the concept that uNK cells are involved in
transformation of uterine vasculature (King and Loke 1990). Taken together, these
studies support a role for IL-15 as the cytokine responsible for uNK cell proliferation
in vivo; it may therefore contribute to the increase in uNK cell numbers in the
secretory and early pregnancy endometrium by stimulating uNK proliferation.
1.5.1.7 Interleukin-18 (IL-18)
IL-18 has been reported to be implicated in the uNK activation pathway during the
implantation process. In mice, IL-18 was detected in decidual cells immediately after
implantation. However, after gestation day (GD) 8, IL-18 was produced solely by
uNK cells, and it has been suggested that uNK cells are initially activated by the
stromal compartment and thereafter, lymphocyte-derived signals maintain uNK cell
activation (Croy, Esadeg et al. 2003; Zhang, He et al. 2003). In a study using
secretory phase biopsies either from women who failed to become pregnant after
repeated IVF transfer, or from control fertile patients, the authors report the number
of CD56Bright cells were significantly different in fertile and infertile patients and
these differences were significantly correlated with IL-15 and IL-18 mRNA levels,
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further intimating that both IL-15 and IL-18 are intimately involved in the regulation
of uNK cells in vivo (Ledee-Bataille, Bonnet-Chea et al. 2005). Furthermore, IL-18
has been demonstrated to be negatively regulated by exogenous ovarian steroid
hormone treatment in women (Ledee, Dubanchet et al. 2006). Interestingly, IL-18
mRNA expression was not reported to change over two natural cycles, as measured
on day 21 of the cycle (Ledee, Dubanchet et al. 2006). In addition, Th-1 associated
cytokines, IFNy, IL-12 and IL-18, are increased in 1st trimester decidua in women
during miscarriage (Wilson, Moor et al. 2004).
1.5.1.8 Interferon y (IFNy)
IFNy is expressed by many cell types, including T cells (Sugawara, Kitagawa et al.
1986) and NK cells (Peritt, Robertson et al. 1998; Loza, Zamai et al. 2002; Perussia,
Chen et al. 2005). IFNy produced by murine NK cells has been suggested as a
mediator for promoting the development of Th-1 T cell responses and activation of
pro-inflammatory macrophages (Martin-Fontecha, Thomsen et al. 2004). The source
of IFNy within the human endometrium is thought to be the lymphoid aggregates
(Tabibzadeh 1994), polymorphonuclear neutrophils in non-pregnant endometrium
(Yeaman, Collins et al. 1998), and uNK cells in first trimester decidua (Saito,
Nishikawa et al. 1993; Jokhi, King et al. 1994). IFNy levels remain consistent across
the menstrual cycle in human non-pregnant endometrium (Yeaman, Collins et al.
1998). In the pregnant mouse IFNy can only be detected in supematants from first
trimester decidua after which it fails to be detected (Lin, Mosmann et al. 1993). IFNy
is reported to induce an increase in the levels of IL-6, MCP-1 and MCSF and reduce
IL-8 levels in cultures of ESCs, suggesting that IFNy produced by both decidual
inflammatory cells and the developing embryo could play a role in the maintenance
of early pregnancy by modulating the production of these cytokines by ESCs in vivo
(Nasu, Matsui et al. 1998). In a recent study using an ERa null mouse, oestradiol was
shown to selectively enhance the development of IFNy-producing T-cells, through an
ERa-dependent mechanism (Maret, Coudert et al. 2003). Moreover, oestrogen is
reported to increase activity of the IFNy promoter and has been demonstrated to
increase expression of IFNy mRNA in ConA-treated murine spleen cells (Fox, Bond
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et al. 1991). Further experiments with IFNy null mice have identified that IFNy is a
primary mediator of murine uNK cell function (Ashkar and Croy 2001). In addition
to its effects on the placental vasculature in the mouse, IFNy induces human
trophoblast cells to become partially protected from lysis by IL-2 stimulated decidual
NK cells (King and Loke 1993).
1.5.1.9 Monocyte Chemotatic Protein-1 (MCP-1)
Monocyte chemotactic protein-1 (MCP-1) (CCL2) is a product of a plethora of cell
types including fibroblasts (Yoshimura and Leonard 1990), endothelial cells (Sica,
Wang et al. 1990), and monocytes (Yoshimura, Robinson et al. 1989). MCP-1, as its
name implies, is a chemotactic agent for monocytes (Rollins and Pober 1991). MCP-
1 is co-expressed with IL-8 and COX-2 in perivascular cells in the human
endometrium in the late secretory phase (Jones, Kelly et al. 1997), suggesting a role
for these molecules in regulating perimenstrual infiltration of leukocytes. Cultures of
human ESCs and epithelial cells secrete MCP-1 (Arid, MacDonald et al. 1995) and
have been shown to respond to IFNy and CD40 ligand by releasing MCP-1 after 24
hours of treatment (King, Kelly et al. 2001). However, oestrogen has been shown to
inhibit secretion of MCP-1 by ESCs (Arici, MacDonald et al. 1995; Arici, Senturk et
al. 1999) and production by choriodecidual cells and the breast cancer cell line,
T47D, is suppressed by progesterone (Kelly, Carr et al. 1997). Steroid hormone
regulation was also reported by Arici et al who demonstrated that progesterone
treatment inhibited MCP-1 production in ESC, but this did not seem to be as potent
as oestradiol treatment (Arici, Senturk et al. 1999). However, a more recent study has
failed to replicate the inhibitory effects of progesterone on MCP-1 mRNA levels in
cultured human ESCs or epithelial cells (Arici, Senturk et al. 1999; DeLoia, Stewart-
Akers et al. 2000). MCP-1, in combination with oestradiol, has also been
demonstrated to augment the protein release of VEGF from ESC in culture (Lin and
Gu 2005).
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1.5.1.10 Macrophage Inflammatory protein-lp
Recent studies have suggested a potential role for MIP-1 p (CCL4) in the mechanism
of uterine recruitment of PBNK cells (Cook 1996; Kitaya, Nakayama et al. 2003).
The chemokine, MIP-1 p, has strong chemoattractant properties for PBNK cells. MIP-
1P expression is reported to increase in the secretory phase of the menstrual cycle, in
response to increasing progesterone levels (Kitaya, Nakayama et al. 2003).
Furthermore, MIP-ip secretion by cultured ESCs can be induced in vitro by
progesterone. The increase in MIP-ip expression observed in the secretory phase
parallels the increase in uNK cell number (Kitaya, Nakayama et al. 2003). The
specific receptor for MIP-ip, CCR5, is strongly expressed by uNK, consistent with a
role for MIP-ip as a chemoattractant for CD56bright NK cells, during the normal
menstrual cycle and in pregnancy (Red-Horse, Drake et al. 2001; Kitaya, Nakayama
et al. 2003). A recent microarray-based study has identified MIP-ip as a chemokine
upregulated during endometrial receptivity and early pregnancy (Jones, Hannan et al.
2004).
1.5.1.11 Tumor necrosis factor a (TNFa)
Tumor necrosis factor a (TNFa) is an inflammatory cytokine (Old 1985) with wide
ranging actions including, monocyte chemotaxis (Ming, Bersani et al. 1987 6951)
and angiogenic effects (Frater-Schroder, Risau et al. 1987). Cyclic changes in TNFa
have been reported in the human endometrium which has been localised to both
glandular epithelium and stroma (Hunt, Chen et al. 1992) with maximal stromal
expression observed in the late secretory phase (Hunt, Chen et al. 1992). Tabibzadeh
et al (Tabibzadeh, Zupi et al. 1995) described increasing TNFa production
throughout the cycle with a peak during menstruation, suggesting a role in
menstruation due to the ability of the cytokine to induce apoptosis and compromise
vascular integrity (Tabibzadeh, Zupi et al. 1995; Tabibzadeh 1996). Steroid hormone
control of TNFa expression has been described with progesterone suppression of
TNFa production reported in activated mouse macrophages (Miller and Hunt 1998)
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and in human endometrial epithelial cells derived from the secretory phase of the
cycle (Laird, Tuckerman et al. 1996). TNFa is reported to be produced from uNK
cells (Saito, Nishikawa et al. 1993) and to induce synthesis of IL-8 (Sica, Matsushima
et al. 1990; Ito, Nakamura et al. 1994; Goldstein, Strieter et al. 1996; Brasier,
Jamaluddin et al. 1998). TNFa has also been reported to inhibit in vitro
decidualisation of ESCs and prolactin release from term decidual cells (Inoue,
Kanzaki et al. 1994; Jikihara and Handwerger 1994). TNFa is elevated in pathologic
conditions such as endometriosis and has been shown to exhibit embryo toxicity
(Taketani, Kuo et al. 1992).
1.5.1.12 Transforming Growth Factor p (TGFP)
Transforming Growth Factor [1 (TGFP) belongs to a superfamily of structurally
related regulatory proteins; TGFpl, TGFP2, TGFP3, TGFP4 and TGFP5,
activins/inhibins, Miillerian inhibiting substance (MIS), bone morphogenic proteins
(BMP), and products of the Xenopus Vgl and Drosophila decapentaplegic (dpp)
genes (Reviewed in (Rizzino 1988; Massague 1990; Sporn and Roberts 1990)).
TGFpl, TGFp2 and TGFP3 are all expressed in mammals (Lawrence 1996).
TGFPs are multifunctional cytokines responsible for a plethora of cellular processes.
They are reported to regulate such diverse functions as cell proliferation,
differentiation and physiological events such as angiogenesis, immune function,
steriodogenesis and tissue remodelling and repair (Spom, Roberts et al. 1987;
Barnard, Lyons et al. 1990; Moses, Yang et al. 1990; Ruscetti and Palladino 1991;
Wahl 1991; Sporn and Roberts 1992; Wahl 1992). Since all of these events occur in
the uterine endometrium during the menstrual cycle and pregnancy, TGFP has been
implicated in regulating many reproductive functions (Godkin and Dore 1998).
The TGFP isoforms display amino acid sequence homologies in the order of 70 - 80
% (Derynck, Jarrett et al. 1986). TGFpi is expressed almost ubiquitously whilst the
other isoforms are expressed in a more specific manner. All the isoforms of TGFP are
encoded as large precursor proteins that are 390-412 amino acids in length (Derynck,
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Jarrett et al. 1985; Gentry and Nash 1990); each isoform is the product of a separate
gene (Derynck, Jarrett et al. 1985; Gentry and Nash 1990). Mature TGFp proteins
undergo a series of processing steps prior to their secretion from the cell. The most
important processing step appears to be the proteolytic digestion of the precursor by
the endopeptidase furin, which cleaves the TGFp protein between amino acids 278
and 279 (Dubois, Laprise et al. 1995; Blanchette, Day et al. 1997). This proteolysis
yields two products that assemble into dimers. The 65-75-kDa protein released from
the N-terminal region is called the latency-associated peptide (LAP), while the
second 25-kDa from the C-terminal portion of the precursor is called the mature
TGFp (Brown, Wakefield et al. 1990; Gentry and Nash 1990; Lawrence 1996;
Munger, Harpel et al. 1997). Despite the cleavage of the precursor a common feature
of all TGFPs is that the N-terminal portion remains noncovalently associated with the
rest of the protein (Lawrence 1996; Munger, Harpel et al. 1997; Khalil 1999; Khalil
2001). The presence of the LAP protein facilitates transit of TGFp from the cell
(Lopez, Cook et al. 1992) and makes the TGFp biologically inactive. Other post-
translational modifications of TGFp that take place before secretion include
glycosylation, mannose-6-phosphorylation of the glycoprotein and disulfide
isomerisation (Brunner, Gentry et al. 1988; Gentry, Lioubin et al. 1988; Purchio,
Cooper et al. 1988). These are processing steps and are distinct from activation
events required for the generation of biologically active TGFP from the latent
precursor.
1.5.1.12.1 Activation of TGFp
In vitro the LAP from all isoforms of latent TGFp (LTGFp) can be removed by
extremes of pH, such as 2 or 8, heat such as 100 °C, chaotropic agents, these are
agents which may distrupt the molecular structure, and substances like SDS and
urea (Brown, Wakefield et al. 1990; Lawrence 1996; Munger, Harpel et al. 1997). In
addition, many physiological substances have been reported to activate LTGFp in
vitro. Some examples are the serine protease, plasmin, other proteases such as
endoglycosidase F, sialidase, neuraminidase, cathepsins B and D, calpain, and the
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glycoprotein, thrombospondin-1 (Miyazono and Heldin 1989; Oursler, Riggs et al.
1993; Schultz-Cherry, Chen et al. 1995; Khalil, Corne et al. 1996; Khalil 1999).
Plasmin is derived from plasminogen by the enzymatic action of urokinase
plasminogen activator (uPA) or tissue-type plasminogen activator (tPA)
(Allan and Martin 1995; Reuning, Magdolen et al. 1998). uPA activation of
plasminogen to plasmin occurs while uPA is bound to a specific cell surface receptor
urokinase plasminogen activator receptor (uPAR). The binding of tPA to a cell
membrane receptor has not yet been confirmed, but tPA may be the major
plasminogen activator involved in release of plasmin from a blood clot (Allan and
Martin 1995; Reuning, Magdolen et al. 1998). tPA and uPA are not only inducible,
but their activity can also be inhibited by the actions of plasminogen activator
inhibitors (PAI) which exist in at least four isoforms (Vaughan 1998). Receptor-
bound uPA can be inactivated by PAI-1 when the PAI-l/uPAR/uPA complex is
internalised (Lyons, Keski-Oja et al. 1988; Allan and Martin 1995; Reuning,
Magdolen et al. 1998; Vaughan 1998). Once cell surface expression of uPA is
diminished, the generation of plasmin is also reduced (Lyons, Keski-Oja et al. 1988;
Allan and Martin 1995; Khalil, Corne et al. 1996; Reuning, Magdolen et al. 1998;
Vaughan 1998; Khalil 1999). A previous study reported that TGFfll stimulates the
synthesis of PAI-1, demonstrating a negative feedback loop on its own production. In
addition, progesterone has been shown to regulate the release of PAI-1 in stromal
cells in vitro (Casslen, Andersson et al. 1986). Furthermore, uPA is expressed in the
late secretory phase in co-ordinance with falling progesterone levels prior to
menstruation (Casslen, Sandberg et al. 1998), possibly indicating the existence of a
relationship between progesterone and TGF(31 (Sandberg, Eriksson et al. 1997). The
activation of TGF|31 is summarised in Figure 1.7.









Figure 1.7: Diagrammatic representation of the proposed mechanism for the
activation of TGFP from its latent to active form. Plasminogen is cleaved by uPA to
form plasmin, which in turn activates latent TGFp (L-TGFP) to its active form. In
turn, uPA is inhibited by PAI-1.
TGFpi, the prototype member of the TGFP superfamily, is a highly conserved
molecule, indeed, mature human, porcine, chicken, simian and bovine TGFpi are
identical and the amino acid sequence between human and mouse differs by only one
residue (Derynck, Jarrett et al. 1986). The biologically active 25 kDa TGFpi
molecule consists of two identical disulfide-linked 12.5 kDa polypeptide chains
(Assoian, Komoriya et al. 1983). The 12.5 kDa monomer contains 112 amino acids
and, as previously described, is synthesised as a larger latent TGFp molecule of 390
amino acid residues (Derynck, Jarrett et al. 1985). The carboxy-terminal 12.5 kDa
mature peptide is proteolytically cleaved from the amino-terminal at arginine 278
(Derynck, Jarrett et al. 1985; Gentry, Webb et al. 1987). TGFpi is reported to
regulate biological functions as diverse as embryogenesis, proliferation,
differentiation and extracellular matrix remodelling (Ignotz and Massague 1986),
including angiogenesis (Fajardo, Prionas et al. 1996; Sankar, Mahooti-Brooks et al.
1996; Sandberg, Casslen et al. 1998) and modulating myofibroblast differentiation
(Desmouliere, Geinoz et al. 1993; Jester, Barry-Lane et al. 1996; Serini, Bochaton-
1.5.1.12.2 TGFpi
Chapter 1 Literature Review 57
Piallat et al. 1998; Lewis, Lygoe et al. 2004; Shephard, Martin et al. 2004). TGFpi
has been shown to enhance tissue remodelling and homeostasis in endometrial cells
(Bruner, Rodgers et al. 1995; Ulloa, Creemers et al. 2001) and inactivation of TGFjll
has been implicated in endometrial carcinogenesis (Parekh, Gama et al. 2002).
Previous studies have identified that endometrial tissues as well as endometrial
stromal cells in culture express TGF(! type I and type II receptor mRNA and protein
(Chegini, Zhao et al. 1994; Tang, Zhao et al. 1994; Dumont, O'Connor-McCourt et
al. 1995; Piestrzeniewicz-Ulanska, Brys et al. 2002). It has previously been reported
that the level of TGFpi mRNA is higher in 1st trimester decidua as compared to
endometrial tissue from the proliferative and secretory phases of the menstrual cycle
(Kauma, Matt et al. 1990; Selick, Horowitz et al. 1994) and TGFp type I receptors
have been identified in term placenta (Dungy, Siddiqi et al. 1991; Mitchell and
O'Connor-McCourt 1991; Mitchell, Fitz-Gibbon et al. 1992; Schilling and Yeh
2000).
1.6 Signalling cascades
Although the steroid hormones exert a fundamental influence on the regulation of
inflammatory mediator expression in endometrium the precise mechanisms involved
remain unclear. The promoter regions for several cytokines do not contain GRE/PRE
response elements suggesting that progesterone cannot act directly to suppress
expression and, equally, progesterone withdrawal cannot directly influence
upregulation (McKay and Cidlowski 1999). Cross-talk between the steroid hormone
signal transduction pathways and other pathways is likely.
1.6.1 TGFpi/SMAD signalling
TGFpi initiates its diverse cellular responses by stimulating formation of specific
heteromeric complexes of type I (ALK 5) and type II serine/threonine kinase
transmembrane receptors located at the cell surface (Massague 1990; Massague 1992;
Massague and Wotton 2000). The type II receptor phosphorylates type I in the
juxtamembrane region (GS domain) rich in glycine and serine residues, which in turn
propagates the signal intracellularly via the phosphorlation of highly conserved
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members of receptor-regulated SMAD (Sma- and mothers against decapentaplegic
(MAD) -related protein) family of transcriptional regulators, SMAD 2 and 3 (Graff,
Bansal et al. 1996; Macias-Silva, Abdollah et al. 1996; Nakao, Imamura et al. 1997;
Massague and Wotton 2000; Shi and Massague 2003). Access of SMAD 2 and 3 to
the type I receptors is facilitated by auxiliary proteins, e.g. SMAD anchor for receptor
activation (SARA) (Shi and Massague 2003), a cytoplasmic protein that specifically
interacts with non-activated SMAD 2 and the receptor complex, thereby forming a
link between the receptor and SMAD 2, facilitating phosphorylation (Tsukazaki,
Chiang et al. 1998). Activated receptor-regulated SMADs form hetero-oligomeric
complexes with the common mediator SMAD, SMAD 4 (Zhang, Feng et al. 1996;
Kawabata, Inoue et al. 1998; Correia, Chacko et al. 2001). SMAD 4 has been
localised to the cytoplasm and requires oligomerisation with the receptor-regulated
SMADs in order to accumulate to the nucleus (Macias-Silva, Abdollah et al. 1996;
Nakao, Imamura et al. 1997), where it controls gene expression in a cell-type-specific
and ligand dose-dependent manner mediated via interactions with transcription
factors, coactivators and corepressors (Liu, Pouponnot et al. 1997). Inhibitory
SMADS, SMAD 6 and 7, act in an opposing manner to receptor-regulated SMADs
and antagonise signalling. They are reported to compete with receptor-regulated
SMADs for binding to activated type I receptors (Shi and Massague 2003). They
have subsequently been demonstrated to recruit E3-ubiquitin ligases, SMAD
ubiquitination regulatory factor (Smurf)l and 2, to the activated type I receptor, thus
facilitating receptor ubiquitination and subsequent degradation, thereby inhibiting the
signalling pathway (Shi and Massague 2003). The SMAD signalling pathway is
summarised in Figure 1.8.




Figure 1.8: Activation and inactivation of TGF|31-SMAD signalling. Binding of
transforming growth factor [1 (TGFfl) to its cell surface receptor Type II leads to the
phosphorylation of the Type I receptor by Type II. The Type I receptor is then able to
phosphorylate and activate the receptor-regulated SMAD 2/3 (R-SMAD) protein,
which is recruited to cell membrane by SARA. After activation of type I receptor, R-
SMAD, is phosphorylated and forms a hetero-complex with common SMAD 4 (Co-
SMAD). Subsequently, the hetero-complex translocates into the nucleus and
regulates the transcription of target genes. Inhibitory SMAD 6/7 (I-SMAD)
negatively regulates SMAD signalling by blocking the binding ofR-SMAD to type I
receptor, hetero-complex formation between R-SMAD and Co-SMAD, and the
transcriptional regulation by R-SMAD in the nucleus. Self prepared.
1.6.2 Wnt- signalling pathway
Recent microarray analysis of human endometrial gene expression during the
implantation window demonstrate expression and regulation of members of the
Wingless/INT-1-related (Wnt) signalling pathway, implying a role for the Wnt-
family in endometrial maturation and function (Carson, Lagow et al. 2002;
Borthwick, Charnock-Jones et al. 2003; Kao, Germeyer et al. 2003). Wnts are a
family of highly conserved lipid-modilied signalling proteins (Willert, Brown et al.
2003), pivotal in influencing cell proliferation and differentiation, embryogenesis and
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epithelial-mesenchymal cross-talk (Nusse and Varmus 1992; Cadigan and Nusse
1997; Wodarz and Nusse 1998). To date, at least 22 Wnts have been identified
(Church, Nohno et al. 2002; Miller 2002). Signalling is initiated by Wnt ligands
binding to two distinct families of cell-surface receptor molecules, Frizzed (Fzd)
proteins (Bhanot, Brink et al. 1996) and low-density lipoprotein (LDL) receptor-
related proteins 5 and 6 (LRP 5/6) (Rattner, Hsieh et al. 1997; Bafico, Gazit et al.
1999). The Fzd receptors, of which ten have been identified in humans to date, are a
family of seven-membrane-spanning domain receptors (Bafico, Gazit et al. 1999).
The LRP co-receptors are also essential for Wnt-signalling however, the mechanism
as to how these receptors mediate their effects is as yet unknown. Three distinct
intracellular pathways transduce Wnt signals: the canonical pathway which targets P-
catenin signalling, the Wnt/Ca2+ pathway and the Wnt/polarity pathway. In the
canonical pathway, downstream of Wntl, Wnt3a, Wnt7a and Wnt8c ligand binding
to Fz receptors at the cell surface activate Dishevelled (Dsh) leading to the
inactivation of glycogen synthase kinase-3p (GSK-3P) by phosphorylation (Willert,
Shibamoto et al. 1999). This results in the cytoplasmic accumulation of P-catenin
(Miller, Hocking et al. 1999; Weidinger and Moon 2003), which forms a complex
with its DNA binding partners, T cell factor (TCF) and lymphocyte enhancer factor-1
(LEF-1), and subsequent translocation to the nucleus where it regulates gene
transcription (Miller, Hocking et al. 1999; van Noort and Clevers 2002; van Noort,
Meeldijk et al. 2002; Weidinger and Moon 2003). In the absence of Wnt-signalling,
P-catenin levels are regulated by activated GSK-3p, which phosphorylates
adenomatous polyposis coli (APC) and Axin, thereby increasing their binding
affinities to P-catenin, identifying it for degradation by N-terminal phosphorlyation
(Nakamura, Hamada et al. 1998; Willert and Nusse 1998; Nusse 1999; Staal, Noort
Mv et al. 2002). The Wnt/Ca2+ pathway involves an increase in intracellular Ca2+ and
is activated by Wnt5a and Wntll (Miller, Hocking et al. 1999; Topol, Jiang et al.
2003; Weidinger and Moon 2003). Current downstream pathways are not yet
identified (Kuhl, Sheldahl et al. 2000). The Wnt/polarity pathway regulates cellular
polarity by controlling cytoskeletal organisation via a yet unidentified pathway
involving Dsh and in drosophila, the JNK pathway (Peifer and McEwen 2002). The
Wnt-signalling pathway is summarised in Figure 1.9
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Figure 1.9: The Wnt-signalling pathway. The Wnt ligand binds a Frizzled /low
density lipoprotein receptor related protein (LRP) complex, activating the
cytoplasmic protein dishevelled (Dsh) Dsh then inhibits the activity of GSK-3(3,
results in accumulation of (3-catenin. P-catenin will then form a complex with TCF
and LEF-1, before translocating to the nucleus leading to transcription ofWnt target
genes. DKK acts as an antagonist of Wnt-binding to LRPs. The Wnt-Ca2+ pathway
results in accumulation of Ca2+ and the Wnt-polarity pathway is thought to control
cytoskeletal organisation by an unidentified pathway. Self prepared.
1.6.2.1 Wnt antagonists
Wnt antagonists are divided into two functional classes, the sFRP class, and the
Dickkopf (DKK) class. Members of the sFRP class, which includes the eight known
members of the sFRP family, WIF-1 and Cerberus, bind directly to Wnts, thereby
altering their ability to bind to the Wnt receptor complex. Members of the DKK class,
which comprises the DKK family ofproteins, inhibit Wnt signalling by binding to the
LRP5/LRP6 component of the Wnt receptor complex. Therefore, theoretically, those
antagonists of the sFRP class will inhibit both canonical and noncanonical pathways,
whereas those of the DKK class specifically inhibit the canonical pathway.
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The DKK family comprises four members (DKK-1 to DKK-4) and a unique DKK-3-
related protein named Soggy (Sgy). DKKs contain two characteristic cysteine-rich
domains (Cys-1 and Cys-2) separated by a linker region of variable length (Glinka,
Wu et al. 1998; Krupnik, Sharp et al. 1999). The most studied member of the DKK
family is DKK-1. The characteristic developmental function of DKK-1 is its head-
inducing activity (Glinka, Wu et al. 1998). DKK-1 inhibits Wnt-induced stabilisation
of (3-catenin (Fedi, Bafico et al. 1999) and (3-catenin/TCF/LEF-dependent
transcription of both artificial and endogenous genes in mammalian and amphibian
cells, respectively (Wu, Glinka et al. 2000; Brott and Sokol 2002). However, unlike
sFRPs, DKK-1 prevents activation of the Wnt signalling pathway by binding to
LRP5/6 rather than to Wnt proteins (Fedi, Bafico et al. 1999; Bafico, Liu et al. 2001;
Mao, Wu et al. 2001; Semenov, Tamai et al. 2001). At present, not all Wnts are
characterised with regards to their downstream signals and second messengers. Less
is known concerning the interaction ofWnt with other signalling pathways.
1.6.2.2 Wnt signalling in the uterus
Several reports indicate that the Wnt pathway is likely to play an important role in
murine uterine physiology (Das, Tan et al. 2000; Hou, Tan et al. 2004). A recent
study has demonstrated that the Wnt/(3-catenin signalling pathway is activated in two
distinct stages during implantation in the TCF/Lef-LacZ transgenic mouse
(Mohamed, Jonnaert et al. 2005). The authors demonstrated that the Wnt/p-catenin
signalling is transiently activated in circular smooth muscle cells to form a banding
pattern of activity within the uterus (Mohamed, Jonnaert et al. 2005). Thereafter, the
Wnt/p-catenin pathway is activated at the luminal epithelium of prospective
implantation sites. Furthermore, this study demonstrates that activation at both sites
requires the presence of the blastocyst, which has also been reported to express
multiple Wnt genes (Mohamed, Dufort et al. 2004; Mohamed, Jonnaert et al. 2005).
The Wnt pathway may also be important in embryo implantation-related events in the
human endometrium. High-density cDNA microarray screening of changes in gene
expression across the menstrual cycle did not report any change in Wnts or their
receptors from the proliferative phase to the mid-secretory phase (Carson, Lagow et
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al. 2002; Kao, Tulac et al. 2002); however significant changes were observed in
expression ofWnt antagonists with marked increases observed in DKK-1 expression
(Tulac, Nayak et al. 2003; Tulac, Overgaard et al. 2006). The transcript encoding
DKK was localised to the uterine stroma and is reported to be progesterone-
dependent, implying a role in stromal differentiation (Giudice 2004; Tulac,
Overgaard et al. 2006).
1.6.3 Cyclic Adenosine Monophosphate (cAMP) and protein
kinase (PKA) pathway
As described briefly in section 1.1.4.2 cAMP is generated upon binding of a ligand to
a G-protein coupled receptor. Upon ligand binding, the Ga subunit is released from
the trimeric GaPy complex and regulates the activity of adenylyl cyclase. Two
molecules of cAMP bind to the cAMP-dependent PKA (which in its basal state is
composed of two regulatory and two catalytic subunits) (Skalhegg and Tasken 2000)
and induce a conformational change which results in dissociation and activation of
the catalytic subunits. The catalytic subunits may then phosphorylate target
molecules in the cytoplasm or diffuse into the nucleus and modulate the activity of
transcription factors by phosphorylation (Gellersen and Brosens 2003). Two primary
targets of PKA phosphorylation are the cAMP response element binding protein
(CREB) and the related cAMP response element (CRE) modulator (CREM) (Mayr
and Montminy 2001). The pathway is summarised in Figure 1.10. Phosphorylated
CREB binds to CRE sequences in the 5'-flanking region of cAMP-responsive genes
(Christian, Mak et al. 2002). Both CREM and CREB require binding to CREB
binding protein (CBP) for maximal transcription activity (Fimia, De Cesare et al.
1999; Christian, Mak et al. 2002). Human ESCs express CREB and six CREM
isoforms (Gellersen, Kempf et al. 1997). However, decidualisation in vitro is not
associated with altered expression of CREB or any of the CREM isoforms (Christian,
Mak et al. 2002). Moreover, the decidual PRL gene contains a single non-canonical
CRE, but mutation of this response element does not impair in vitro decidualisation
(Telgmann, Maronde et al. 1997). This would suggest that decidualisation requires
the induction or modulation of cell-specific PKA-dependent, intermediate factors.
One candidate is the CCAAT/enhancer-binding proteins (C/EBP), a group of
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conserved phosphorylation site in the kinase-inducible domain (Christian, Mak et al.
2002). Analysis of the decidual prolactin promoter revealed the presence of 20
C/EBP-binding sites, two of which are located within the minimal PKA-responsive
region, located between -332 bp and -270 bp relative to the transcription start site
(Berwaer, Martial et al. 1994). This region also contains a progesterone response
element-half site in close proximity to the two C/EBP-binding sites (Berwaer, Martial
et al. 1994). Recently a study has elucidated that a functional association exists
between PR and C/EBP to modulate in vitro decidualisation of human ESC
(Christian, Pohnke et al. 2002).
Active PKA
Figure 1,10: The cAMP and PKA pathway. Ligand binding to the G-protein coupled
receptor (GPCR) releases the Ga subunit, which regulates the activity of adenylyl
cyclase (AC), causing accumulation of cAMP. Active PKA catalytic units (C) are
released following cAMP binding to the PKA regulatory subunits (R). The active
catalytic subunits phosphorylate targets in both they cytoplasm and the nucleus, such
as CREB and CREM. Self prepared.
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1.7 Hypothesis
Decidualisation is governed by the steroid hormone progesterone acting via its
nuclear receptor (Huang, Tseng et al. 1987; Zhu, Huang et al. 1990; Tseng, Gao et al.
1992; Mizuno, Tanaka et al. 1998; Brosens, Hayashi et al. 1999), but at a paracrine
level may be regulated by a myriad of, cytokines and growth factors, including the
Wnt-signalling pathway antagonist, Dickkopf (DKK) (Tulac, Nayak et al. 2003;
Giudice 2004; Jones, Stoikos et al. 2006; Tulac, Overgaard et al. 2006). TGF(31 is
abundantly expressed in both endometrial epithelial and stromal cells and is thought
to play a critical role in cyclic tissue remodelling and inflammatory events associated
with menstruation (Bruner, Rodgers et al. 1995; Ulloa, Creemers et al. 2001). I
hypothesise that TGF(T1 may affect either PR or DKK to regulate the decidual
process, as investigated in Chapter 3. Additionally, I hypothesise that TGF(31 may
suppress the production of decidualisation marker proteins, as investigated in Chapter
4. Decidualisation is also associated with a unique immune environment,
characterised by the presence of large numbers of uterine-specific natural killer cells
(uNK) (Bulmer, Lunny et al. 1988). uNK cells increase in number in secretory phase
endometrial stroma, however, they lack the nuclear progesterone receptor
(Henderson, Saunders et al. 2003) and growth and differentiation may therefore
depend on interactions with other cell types and regulation by other cytokines
(Trundley and Moffett 2004). I hypothesise that uNK cell regulation may involve
hormones such as luteinising hormone (LH) and human chorionic gonadotrophin
(hCG), as investigated in Chapter 5.
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1.8 Aims of this project
The aims of this study were to investigate stromal cell function in non-pregnant
endometrium and decidua of early pregnancy. A major focus of these investigations
was the role played by TGF|31 in modulation of the regulators of decidualisation and
the decidualisation marker proteins. Initial studies used the ESC as a model for
inducing decidualisation in vitro. Later the studies used DSC cells as a model for
decidualisation in the presence of a blastocyst. The role of hCG on uNK cell function
and expansion was also investigated. Experiments in this thesis were designed to
address the following questions:
1. As PR is retained in the stroma throughout the cycle and TGF(31 is activated by
uPA at the late secretory phase of the cycle, does TGF(3 have any effect on PR?
2. As TGF(31 is present and in its active form at the time of decidualisation of the
stroma, does TGF(31 have any effect on the process of decidualisation, either by
regulating mediators of decidualisation or the decidualisation marker proteins?
3. Does TGFpl have any effect on expression of decidualisation markers in stromal
cells obtained from 1st trimester decidua?
4. Does TGF(31 signal via the SMAD signalling pathway in the culture experiments?
5. Are the TGFfll-induced responses mediated via the SMAD signaling pathway?
6. As the expansion of uNK cell numbers could be related to levels of LH/hCG, does
hCG have any effect on uNK cells and do uNK cells possess the LH/hCG receptor?
7. As the macrophage mannose receptor binds sulphated oligosaccharides, could the
presence of a mannose receptor on uNK cells facilitate LEl/hCG binding?
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Chapter 2
2 General Materials and Methods
2.1 Patient selection and recruitment
2.1.1 Tissue Collection, processing of human uterine tissue and
ethical approval
Human endometrial tissue specimens (n = 35) were obtained from women
undergoing surgery for non-malignant gynaecological conditions (see Table 2.1a,
patient numbers 1 - 35). Biopsies were collected with an endometrial suction curette
(Pipelle, Laboratoire CCD, Paris, France) or alternatively, full thickness endometrial
samples were obtained. These included superficial and basal endometrium plus the
endometrial-myometrial junction. All patients were of reproductive age, had regular
menstrual cycles between 25-35 days and had not received exogenous hormones or
used an intrauterine contraceptive device in the three months prior to surgery. All
subjects had a serum sample collected at the time of surgery for the determination of
circulating oestradiol (E2) and progesterone (P) levels by Radio Immunoassay (RIA). All
samples were consistent with the designated cycle stage based on standard histological
criteria of Noyes et al (Noyes, Hertig et al. 1950) and the patient's reported last
menstrual period (Critchley, Henderson et al. 2002) and, circulating E2 and P levels at
time of biopsy collection, see Table 2.1. Endometrial tissue was collected in sterile
Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma, Poole, Dorset, UK)
and processed in one of two ways, either for histology (fixation in 10% neutral
buffered formalin (NBF) 24 h at 4°C followed by storage in 70% ethanol prior to wax
embedding), or for tissue culture (separation of glandular epithelium and stromal
cells, in order to culture the stromal cells).
Decidual tissue specimens were obtained from women who had undergone surgical
termination by vacuum aspiration, during the first trimester of pregnancy. All patients
were operated on under general anaesthesia (see Table 2.1b, patient numbers 1 - 46).
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All women had an ultrasound scan to confirm viability of pregnancy and gestational
age. All material from the suction curettage procedure was collected. Decidual tissue
(n = 46) was selected by macroscopic inspection from the products of the termination
aspiration procedure. Sterile gauze was held taut over a waste collection vessel and
the contents of the tissue collection container poured over the gauze. Excess
blood/saline was removed by gentle compression. Sterile forceps were used to extract
the pieces of decidua parietalis (away from the site of implantation). Identification
was aided by gently washing the tissue in sterile saline. In this way it is possible to
distinguish between decidua parietalis, decidua basalis and trophoblast. Trophoblast
villi are readily identifiable by the light pink colour and frond-like appearance of the
tissue. Decidua parietalis is generally grey in appearance and quite smooth and solid
in consistency. Decidua basalis is distinguishable by its ragged, yellowish appearance
and often contains haemorrhagic areas. This procedure requires two people and was
performed by myself and a trained Research Sister.
Thereafter, decidual parietalis tissue was collected in sterile RPMI 1640 medium
(Sigma) in preparation for the uterine Natural Killer cell separation procedure
(detailed in 4.2.1.2). A 1 cm3 section of tissue was placed in "RNA Later" (Ambion
Europe Ltd., Cambridgeshire, UK), and stored at 4°C for a maximum of 2 months
prior to mRNA extraction (section 2.3.1). A second 1 cm3 section of tissue was
placed into 10 % NBF, fixed for 24 h then placed in 70 % ethanol prior to paraffin
wax embedding. Decidua was only collected from women with a pregnancy of
gestational age between 7 and 12 weeks. All work on human samples was performed
in a designated containment level one tissue culture room within class II
Microbiological Safety Cabinets. Due to the potential presence of infectious
pathogens both the research nurse and I were immunised and shown to be protected
against Hepatitis B.
Informed patient consent was obtained in writing from each patient prior to tissue
collection, by a dedicated research nurse, after local ethical committee approval for
the study was granted (Appendix 1).
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Table 2.1b: Patient sample details for human 1st trimester decidual tissue specimens.
LB = Live births, MT = Miscarriages/Terminations, STOP = surgical termination of
pregnancy, Miso = Misoprostol, n = 46 samples
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2.2 Cell separation and culture
Endometrial specimens (n = 35) were separated into epithelial and stromal cell
preparations after enzymatic digestion as follows. Samples were washed in
Dulbecco's phosphate buffered saline (PBS) (Sigma) and minced into 1 mm3 pieces.
The minced tissue was digested in collagenase (1 mg/ml; Sigma) and DNAase (0.1
mg/ml; Sigma) for 80 min at 37°C. Repeat passage through an 18 gauge needle was
used to aid tissue dispersion. Tissue was resuspended in 10 ml of RPMI 1640
medium (Sigma). The stromal and glandular epithelium cells were pelleted by
centrifugation (700 g, 3 min). The cells were then resuspended in 10 ml of RPMI
1640 medium (Sigma) supplemented with 10 % foetal calf serum (FCS) (Mycoplex,
PAA Laboratories, Kingston-Upon-Thames, UK), penicillin (50 pg/ml; Sigma),
streptomycin (50 pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma) and dispersed
endometrial stromal cells separated from endometrial glands by filtration through a
73 pm nylon sieve (Falcon, VWR International Ltd, Leicestershire, UK). The filtrate,
containing the stromal cells, was plated in 75 cm3 culture flasks (Corning
Incorporated, Corning, NY) for a minimum period of 5 days and allowed to reach
confluence in the presence of E2 (0.1 pM; Sigma), 6a-Methyl-17a-
acetoxyprogesterone (MPA) (1 pM; Sigma) and basic fibroblast growth factor
(bFGF) (5 ng/ml; Peprotec EC Ltd, London, UK) at 37°C in a humidified atmosphere
of 5 % CO2. These supplements were used to provide optimum conditions for ESC
growth (Irwin, Utian et al. 1991).
A Fluorescence Activated Cell Sorter (FACS) and immunohistochemical staining for
fibroblast markers were used to verify the purity of cells separated by this technique
(see section 2.7).
The cells were passaged every 3-4 days by trypsinisation. Media was aspirated from
the cells and discarded; cells were washed with 5 ml PBS (Sigma) to remove any
residual traces of media. PBS was removed by aspiration and the appropriate volume
of Trypsin/EDTA (PAA) added per flask (see Table 2.2). The cells were incubated at
37°C for 3-5 min until they had detached from the flask surface; thereafter the
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appropriate volume of RPMI 1640 medium (Sigma) supplemented with 10 % foetal
calf serum (FCS) (Mycoplex), penicillin (50 pg/ml; Sigma), streptomycin (50 pg/ml;
Sigma) and gentamycin (5 pg/ml; Sigma) was added to prevent any further action of
trypsin/EDTA.
Once passaged, cells were seeded at a concentration of 2 x 105 cells/ml in 6-well-
plates (Corning Inc, Costar, Sigma) or 2 x 105 cells/ml in 2-well chamber slides
(LabTec, VWR International Ltd) and incubated for 24 h to allow cell adherence. The
cells were cultured until they were 90 % confluent. 24 h prior to commencement of
treatment with test agents, the culture medium was changed to serum-free media or 2
% FCS RPMI 1640 for in vitro decidualisation. Two separate ESC culture
experiments were designed. In the first, the cells were treated with serum-free RPMI
1640 medium that contained test agents, for example, E2 (0.1 pM; Sigma), and/or
MPA (1 pM; Sigma) and/or TGF(31 (10 ng/ml; R&D Systems, Abington, UK). In the
second culture experiment, decidualisation of the cells was induced with RPMI 1640
medium containing 2 % FCS, 8-Bromoadenosine 3',5'-cyclic monophosphate
sodium salt (8-Br-cAMP) (0.5 mM; Sigma) and MPA (1 pM), ('decidualising
medium' - DM), for 6 days, thereafter, the cells were treated with RPMI 1640 2 %
FCS and DM containing TGF(11. Cells were maintained under these conditions for up
to 72 h.
T47D cells, the breast cancer epithelial cell line, known to constitutively over express
PR A and PR B (Horwitz, Mockus et al. 1982) and the recently identified PR C (Wei,
Gonzalez-Aller et al. 1990), were cultured in RPMI 1640 medium (Sigma)
supplemented with 10 % FCS (Mycoplex), penicillin (50 pg/ml; Sigma),
streptomycin (50 pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma) in the presence of
insulin-transferrin-sodium (5 pg/ml; Sigma), and selenite media supplement (5 ng/ml;
Sigma) (ITS). The cells were treated with serum-free RPMI 1640 medium
supplemented with ITS (Sigma) that contained test agents, for example, oestradiol
(0.1 pM; Sigma), and/or MPA (1 pM; Sigma) and/or TGF(!1 (10 ng/ml; R&D
Systems). Cells were maintained under these conditions for up to 72 h.
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Flask size (cm2) Volume of Trypsin/EDTA to
be added (ml)





Table 2.2: Appropriate volumes of Trypsin/EDTA and RPMI to be added for
passaging of cells.
2.3 RNA Extraction and Reverse Transcription-Polymerase
Chain Reaction (RT-PCR)
2.3.1 RNA Extraction
The supernatant from the treated cell cultures was aspirated, retained and either
frozen at -20°C or maintained at 4°C if being used immediately. Cells were washed
in PBS twice to remove any residual supernatant. Total RNA was isolated from the
cultured endometrial stromal cells using a guanidinium thiocyanate-based extraction
reagent, "Total RNA Isolation Reagent" (TRIR) (Abgene, Surrey, UK); 1 ml of TRIR
was added to each well of a 6-well plate. Cells were left for 5 min to facilitate cell
membrane rupture. The contents of the wells were then transferred to "phase lock
gel" tubes (Eppendorf, Hamburg, Germany) and kept on ice for the remaining
extraction. Chloroform (200 pl/ml) was added and the tubes shaken vigorously for
several seconds. The tubes were centrifuged in a pre-cooled, refrigerated centrifuge at
4°C, 12000 g for 20 min. Upon centrifugation the phase lock gel migrates to form a
tight seal between phases of an aqueous/organic extraction. The upper aqueous phase
above the phase lock gel contained RNA with the organic phase, containing DNA
and protein, trapped beneath the gel layer thus allowing easy isolation of the aqueous
phase. The aqueous layer was subsequently poured into labelled 1.5 ml Eppendorf
microcentrifuge tubes. An equal volume of isopropanol was added to each sample
and mixed by inverting the tubes. The mixture was left on ice for 1 h to allow for
RNA precipitation. The samples were centrifuged in a pre-cooled, refrigerated
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centrifuge at 4°C, 12000 g for 15 min to pellet the RNA. The supernatant was
removed using a sterile Pasteur pipette and the pellet was washed with 500 pi of 70
% ethanol. After gentle mixing of the solution by inverting the tubes, the samples
were centrifuged for 5 min in a pre-cooled, refrigerated centrifuge at 4°C, 12000 g.
The ethanol was removed from each tube and 20-50 pi RNA Storage Buffer (RSB)
(Ambion, Austin, TX, USA) was added depending on the size of the mRNA pellet.
Samples were dissolved in RSB and subsequently frozen at -80°C.
The concentration of total RNA in the samples was measured on a GeneQuant
spectrophotometer (WPA, Cambridge, UK). Each sample was vortexed and 1 pi
removed, which in turn was diluted in 9pl distilled water. All tubes were thoroughly
mixed before measuring the wavelength at both 260 nM and 280 nM. A blank used to
zero the machine consisted of 1 pi RSB diluted in 9 pi of distilled water. All samples
were diluted in diethylpyrocarbonate-treated water (DEPC water) to a concentration
of 100 ng/pl.
2.3.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA samples (at 100 ng/pl) were reversed transcribed using a multiscribe reverse
transcriptase (1.25 IU/pl), random hexamers (2.5 pmol/1), MgCl2 (5.5 mmol/1),
dNTPs (1 mmol/1) and an RNAase inhibitor (0.4 IU/pl) (PE Biosystems, Warrington,
UK). All reactions consisted of 16 pi of reverse transcription mix per tube and 4 pi of
mRNA. Once the contents of the tube were mixed, 50 pi of mineral oil was added to
prevent evaporation of the reaction mix during the reverse transcription process.
Samples were incubated for 20 min at 25 °C, 60 min at 42°C and then at 95 °C for 5
min (Omnigene PCR machine, UK). The resulting cDNA was diluted 2.5x with TE
buffer (10 mmol/1 Tris pH 8.0 and 1 mmol/1 EDTA in DEPC water) and stored at
4°C.
The precision of the reverse transcription (RT) reaction was previously calculated by
a colleague, Elena Faccenda (laboratory research support). An mRNA sample was
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taken and 8 RT reactions set up in 8 separate tubes. These were compared in a single
PCR run on one primer and probe set. The precision was found to be 3.6%.
2A Polymerase Chain Reaction (PCR)
2.4.1 Semi-quantitative PCR (PCR)
Polymerase chain reaction (PCR) was used for the amplification of a specific part of
a DNA molecule, which lies between two regions of known sequence, using a DNA
polymerase enzyme that is tolerant to elevated temperatures. The oligonucleotides act
as primers for the DNA polymerase and the denatured strands of the cDNA acts as
the template. Primers were designed individually for each DNA target sequence using
the Primer Express computer program. A reaction mix containing the reaction buffer,
2X BioMix; (125 mM Tris-HCL (pH 8.8 at 25°C), 32 mM (NH4)2S04, 3 mM MgCl2
(final concentration is 1.5 mM), 0.02 % Tween 20, 2 mM deoxyribonucleotides
(dNTPs), a stabiliser and an inert dye (BioMix Red, Bioline Ltd. London, UK) the
cDNA, and 0.5 pM of the primers specific for the gene of interest (see Table 2.3) and
a heat-stable polymerase, BIOTAQ DNA Polymerase (Bioline Ltd, London, UK) was
made up to 20 pi with sterile, nuclease-free water.
In a thermal reactor (Omnigene bioproducts, Cambridge, MA) the DNA was
denatured at 95 °C for 5 min, followed by 30 cycles of 94°C for 30 s, the annealing
temperature specific for each primer pair (Table 2.3) for 30 s and 72°C for 1 min, and
finally 72°C for 10 min. The PCR reaction products obtained were run on a 2 %
agarose gel with ethidium bromide, a dye that binds to double stranded DNA by
intercalations between the base pairs and fluoresces when irradiated in the UV part of
the spectrum. The products were visualised by UV illumination and subsequently
photographed. A DNA marker (Bioline Ltd) was run in an adjacent lane to allow
identification of the size of DNA fragments detected.






















































Table 2.3: Primers for PCR. All were designed by Dr Elena Faccenda, a member of
the laboratory group.
2.4.2 Quantitative Real-time PCR (Q-RT-PCR)
Quantitative Real-time-PCR provides an accurate method for determination of levels
of a gene-specific sequence of complimentary DNA (cDNA). This procedure of
quantitative measurement is based on detection of a fluorescent signal produced
proportionally during amplification of a PCR product. Primers and probes were
designed individually for each DNA target sequence using the Primer Express
computer program (see Table 2.4). Q-RT-PCR is characterised by the choice of a
relatively short sequence to allow maximum efficiency of amplification. The probe is
designed to anneal to the target sequence between the forward and reverse primers.
The probe is labelled at the 5' end with a reporter fluorochrome (FAM; 6-
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carboxyfluorescein) and a quencher fluorochrome (TAMRA; 6
carboxytetramethylrhodamine) added at 3' end. The probe is designed to have a
higher Tm than the primers. In the intact state the quencher, suppresses all
fluorescence by the reporter because of its proximity. If the target sequence is present
the probe anneals to the cDNA in between the forward and reverse primer sites and
this is referred to as the polymerisation step. When the target sequence is amplified
during a PCR reaction the probe is cleaved by AmpliTaq Gold (Applied Biosystems,
Warrington, UK) (which has Y shape structure and polymerisation dependent 5'-3'
nuclease activity (Holland, Abramson et al. 1991)). This results in separation of the
reporter dye from the quencher dye so that the quencher is no longer capable of
suppressing the reporter fluorescence with the result being an increase in
fluorescence. The amount of fluorescence released during the amplification cycle is
proportional to the amount of product generated in each cycle and can be measured
directly (Figure 2.1). Fluorescence is detected only if the target sequence for the
probe is amplified during the reaction thus preventing the detection of non-specific
amplification.
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Reverse primer cONA strand 2
Probe
Figure 2.1: Diagrammatic representation of Q-RT-PCR process. R = Reporter Dye
and Q = Quencher. Adapted from Taqman PCR Reagent Kit Protocol.
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Acquisition of data occurs when PCR amplification is still in the exponential phase.
This is the cycle number when the reporter dye emission intensities rises above an
arbitrary threshold value (background noise); this cycle number is the threshold cycle
(Ct). The 18S is a measure of the ribosomal RNA content of the sample and as 18S
levels remain relatively constant in cells this allows corrections to be made for the
total amount of RNA protein in the individual samples. The ACt is the difference
between the FAM Ct and the 18S Ct and enables the amplified signal to be
normalised against the total RNA content. The mean ACt between the duplicates on
the PCR plate was calculated. This was then used to calculate the AAC, which relates
the amount of cDNA of the specific amplicon to the ACt value and the control cDNA
in that experiment. Within each experiment the ACt was related to its own control.
The 2"AACt is then calculated which shows the fold increase or decrease in mRNA
expression of the samples in relation to their control. The control having a 2"AACt of 1.
Primers were diluted to 250 pM and probes to 50 pM in TE buffer (10 mM Tris; 1
mM EDTA in DEPC H20). PCR reaction mixtures contained TaqMan® Universal
PCR Master Mix, No AmpErase® UNG (Applied Biosystems) (7.2 mM MgCl2; 1.6
mM Stratagene dNTP mix; 1.6 mM Boehringer dNTP mix; 0.05 U/pl Taq
Polymerase; 2x PCR buffer and 0.06 % reference dye diluted in DEPC H20) and
specific forward and reverse primers (250 nM; Biosource, Nivelles, Belgium) and
probe (50 nM; Biosource) in a final volume of 25 pl/well. Ribosomal 18S primers
and probe (PE Biosystems, Warrington, UK) were added at a final concentration of
at 50 nM. PCR reactions were run on an ABI Prism 7900 (Applied Biosystems). For
each sample, a tube containing 45 pi PCR Master Mix and 5 pi cDNA was mixed
and 23 pi pipetted into two separate wells on the PCR plate. Two wells containing
5pi of DEPC H20 in place of cDNA were added to each run to serve as a negative
control. Samples were measured and mean values used in subsequent analysis.


























































































































Table 2.4: Taqman primers and probes. All were designed by Dr Elena Faccenda, a
member of the laboratory group.
2.5 Transient transfection and promoter/reporter studies
2.5.1 Reporter constructs and expression vectors
All promoter constructs were cloned in pGL3-Basic (Promega Corp, Southampton,
UK). The reporter vectors: dPRL-3000/luc3, dPRL-913/luc3, dPRL-601/luc3, dPRL-
332/luc,3 and dPRL-32/luc 3 carrying 3000, 913, 601, 332 and 32 bp, respectively,
of 5'-flanking DNA to the decidual-specific promoter of the hPRL gene, were
provided by Dr. Birgit Gellersen (Hamburg, Germany). The PRE/-32/luc3 and ERE-
tk/Luc3 vectors were obtained from Dr Jan Brosens (Imperial College London, UK).
The ARE and GRE share the same sequence as PRE. PCH110, (3-galactosidase
expression vector, was purchased from Pharmacia Biotech (Piscataway, NJ, USA).
Non-targeting siRNA and siRNA specific for SMAD 4 was purchased from
Dharmacon (Dharmacon, Perbio Science, Belgium).
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2.5.2 Calcium phosphate transfection of primary ESC
Calcium Phosphate co-precipitation was routinely used for transient transfection of
ESC (Graham and van der Eb 1973). First passage ESC cells were plated in 24-well-
plates in 0.5 ml DCC media, a 1:1 mixture of DMEM and Ham's F-12 containing 10
% FCS that had been depleted of steroids by treatmentwith dextran-coated charcoal,
100 U/ml penicillin, and 100 pg/ml streptomycin, and supplemented with 10"9 M
176- E2 and 1 pg/ml insulin, and incubated at 37°C. The media was changed to 2 %
FCS DCC the night prior to transfection then changed again to 5 % FCS DCC 1 h
prior to transfection. For each transfection, the DNA (500 pg/well reporter, 200
pg/well expression vector and 50 pg/well PCH110) and the 2xHEPES-buffered
saline (Promega Corp) were prepared in separate sterile tubes. Nuclease-free water
(Promega Corp) was added to the DNA plasmid and subsequently mixed by
vortexing. The calcium chloride (CaCl2) (Promega Corp) was added and the solution
mixed again. The solution was allowed to stand for 5 min before vortexing. Working
in a class II Microbiological Safety Cabinet, the tube containing 2x HEPES-buffered
saline was gently vortexed with the cap off to accommodate the addition of the
prepared DNA solution. DNA was added to the transfection mixture in a "dropwise"
fashion. Calcium phosphate precipitates were readily formed in the transfection
mixture. DNA was readily absorbed onto the precipitate, thereby changing the
characteristics of the particle. When complete, the solution appeared slightly opaque
due to formation of calcium phosphate-DNA co-precipitates. The tube containing
transfection mix was incubated at room temperature for 30 min, after which it was
finally vortexed prior to cell transfection. Transfection solution (120 pl/well) was
added in a dropwise fashion in order to evenly distribute the precipitate over the cells
and the plates were incubated at 37°C. The calcium phosphate- DNA co-precipitates
were taken up by the cells, via endocytosis or phagocytosis, within 1 h of contact.
The culture medium was changed 4-6 h after the addition of the
transfection mixture and replaced with 0.5 ml 2 % FCS DCC with or without the
following treatments; 8-Br-cAMP (0.5 mM), MPA (1 pM), dexamethasone (DEX,
0.25 pM, Sigma), dihydrotestosterone (DHT, 0.1 pM, Sigma), and TGF|31 (10
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ng/ml). Cells were incubated for a further 48 h after which the cell extracts were
harvested and assayed as below. Each transfection was performed in triplicate.
2.5.3 Promoter/reporter assay linked to luciferase
The chemical energy of Luciferin oxidation is converted through electron transition,
forming the product molecule oxyluciferin, thereby producing light which is
quantitatively read by a luminometer. The cell lysates were prepared by removing the
culture media from the cell by careful aspiration to avoid dislodging adherent cells.
The cells were subsequently washed with 0.5 ml of PBS prior to addition of 50 pi of
1 x reporter lysis buffer (RLB, Promega Corp), diluted in distilled H2O from 5 x
stock solution. The 24-well-plate was placed on a plate shaker at 4°C for 15 min to
ensure even coverage of all cells in each well. Complete lysis was ensured by a
single freeze-thaw at 70°C for 40 min followed by thawing on a plate shaker at room
temperature. The RLB was aspirated and placed in numbered Eppendorf
microcentrifuge tubes. The tubes were centrifuged at 10000 g for 2 min at room
temperature. 10 pi of cell lysate was added to a luminometer tube containing 50 pi of
luciferase assay reagent (Promega Corp). As the luciferase assay reagent is light-
sensitive only 12 samples were prepared at a time. The solutions were vortexed
briefly before being measured by the luminometer.
2.5.4 p-Galactosidase assay
A constitutively active (l-galactosidase control expression vector (PCH110) was co-
transfected to control for transfection efficiency. Endogenous p-galactosidase was
inactivated by incubating the cell lysate samples for 50 min at 48°C. The samples
were centrifuged for 1 min at max speed. 10 pi of cell lysate was added to a
luminometer tube containing 70 pi of reaction buffer (Galacton-plus substrate diluted
1 in 100 in reaction buffer dilutent; Tropix, Bedfort, MA, US), and incubated at room
temperature for 1 h. 100 pi of light emission accelerator (Tropix) was added to each
luminometer tube and each sample measured by the luminometer. To normalise the
transfection each sample's luciferase reading was divided by the corresponding |3-
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galactosidase reading. This numerical reading was used as a comparison against
other samples.
2.6 Protein analysis
2.6.1 Whole cell protein extraction
The supernatant was removed by aspiration and the cells placed on ice. The cells
were washed gently by the addition of 4 ml/well of ice-cold PBS, which was
subsequently removed. A volume of 250 pi/ 500,000 cells of lysis buffer (150 mM
NaCl, 50 mM Tris; pH 7.4, 10 mM EDTA, 10 mM EGTA, 0.6 % NP40, 10 %
glycerol, 10 pg/ml peptain and 1 mM PMSF) and protease inhibitor cocktail
(protease inhibitor mini Tablets (Sigma); 1 Tablet dissolved in 10 ml of lysis buffer)
was added to each well. The plate was rocked on ice for 15 min to ensure adequate
lysing of all cells, after which the surface of the wells were scraped, with a dedicated
cell scraper, and the lysate transferred into a fresh ice-cold Eppendorf
microcentrifuge tube. The samples were centrifuged at 12000 g/15 min at 4°C. The
resulting supernatant was aspirated into a fresh, ice-cold Eppendorf microcentrifuge
tube. The sample was stored at -70°C until used.
2.6.2 Protein Assay
Total cell protein concentration was quantified using the DC Protein Microassay
(Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK). The protein
assay is a dye-binding assay, based on the method of Bradford (Bradford 1976), in
which a differential colour change of a dye occurs in response to various
concentrations of protein. A control sample of distilled H20, bovine serum albumin
(BSA) protein standards (0.125 mg/ml to 1.5 mg/ml) and the samples to be measured
(25 pl/well) were aliquoted in duplicate to a clear 96-well Nunc-plate (Nunc,
Invitrogen, Paisley, UK). Reagent A/S (25 pl/well) was added (1 ml Reagent A plus
20pl Reagent S followed by 100 pl/well of Reagent B (Bio-Rad Laboratories Ltd).
The plate was incubated at room temperature for 15 min. The colour absorbance was
measured at 690 nm in a Multiscan plate reader (Multiscan EX Labsystems). The
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results were analysed by interpolation from the standard curve obtained from the
standards of known concentrations.
2.6.3 Protein samples and electrophoresis
Protein samples (40 pg) were mixed with 5x SDS loading dye (50 mM Tris-HCl; pH
6.8, 100 mM DTT (dithiothreitol) 2 % SDS, 0.1 % bromophenol blue and 10 %
glycerol with 0.01 % P-mercaptoethanol) and boiled for 3-4 min. The samples were
loaded onto wells in a precast 4 % to 20 % gradient Tris-Glycine gel (Novex,
Invitrogen) and immersed in lx electrolyte running buffer (25 mM Tris, 250 mM
glycine; pH 8.3 and 0.15 % SDS) in an X Cell Sure Lock electrophoresis tank
(Invitrogen). 14 pi of a pre-stained SDS-page standard, SeeBlue™ (Invitrogen), was
run in a parallel lane to the test samples to allow for identification of sample protein
size. The gel was run at 100 volts for 90 min until the dye had run to the bottom of
the gel.
2.6.4 Protein electrotransfer
Protein was electrotransferred onto polyvinylidene difluoride membranes (PVDF),
which had been previously washed in methanol for 15 sec, followed by a wash in
distilled water and finally a wash in transfer buffer (39 mM glycine, 48 mM Tris and
20 % methanol). The electrotransfer was performed on a Transblot® SD semi-dry
transfer cell unit (Bio-Rad Laboratories, Ltd) set at 14 volts per membrane for 90
min. See Figure 2.2 for diagram of the electrotransfer.











Figure 2.2: Electrotransfer apparatus
2.6.5 Western blot analysis
The electrotransferred membrane was removed form the unit and blocked for 1 h at
25°C with 15 ml of 4 % BSA + 4 % NaN3. The primary antibody was added at the
correct concentration diluted in 4 % BSA + 4 % NaN3 for 18 h at 4°C. After washing
three times with TNS Tween (50 mM Tris-HCl, 150 mM NaCl and 0.05 % Tween)
for 10 min each at room temperature, membranes were subsequently incubated for 1
h with an HRP-conjugated secondary antibody directed against immunoglobulins of
the host species in which the primary antibody was raised. After washing a further
three times with TNS Tween for 10 min each at room temperature, blots were
developed by chemiluminescence (ECL plus kit, Amersham Biosciences) for 20 min
at room temperature, protected from light. The HRP reacted with the
chemiluminescent substrate to create light emission at the site of antigen expression.
The Enhanced Chemi-Luminescence reagents (ECL Plus™, Amersham Life Science,
GE Healthcare, Buckinghamshire, UK) were prepared immediately prior to use, after
equilibration to room temperature, in accordance with the manufacturer's advice.
The chemiluminescence was detected using the typhoon 9400 phosphoimager
(Amersham Biosciences, GE Healthcare).
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2.6.6 Stripping and re-probe of membranes
Membrane-bound antibodies could be stripped away with stripping buffer (1.6 %
SDS, 200 mM Glycine; pH 2.5) for 45 min at room temperature on a plate rocker.
The membrane was washed and re-probed for p-Actin, which was used as an internal
control to indicate relative loading of the samples.
2.6.7 Enzyme-linked Immunoabsorbant Assay (ELISA)
An enzyme-linked immunoabsorbent assay (ELISA) can be used to detect and
measure various proteins released by cells during in vitro culture. The media in
which the cells have been grown and treated was collected and stored at -20°C. The
ELISA detects the amount of a particular protein present and measures this against a
standard curve to give the concentration of protein present in the media sample. The
assay is run on Maxisorp 96-well plates (Nunc). Method files for each ELISA were
constructed in Assay Zap™ (AssayZap™, BioSoft, Cambridge, UK) and contained
information concerning the range of standards used and the level of non-specific
binding. This allowed a standard curve to be produced against which the samples
were measured. In an ideal two site ELISA the response curve is a straight line, but
deviation from the ideal (i.e. due to sub-optimal capture antibody concentration) will
yield a sigmoid response curve. Results were analysed using a computer programme,
AssayZap™, specifically designed for this purpose.
2.6.7.1 Two-site Sandwich ELISA
Prior to the assay, plates were passively coated overnight at 4°C with 100 pl/well of
capture monoclonal antibody that was specific for the protein of interest (4 pg/ml).
After incubation, plates were washed in water and 100 pl/well of blocking and
protecting medium (2 % polyvinyl pyrollidone; 5 mg/ml BSA; 0.5 ml/litre
preservatives (200 mg/ml 5-bromo-5-nitro-l,3-dione and 200 mg/ml 2-methyl-4-
isothiazolin-3-one in DMF/DMSO 1:2); 5 mM EDTA; 50 mM EDTA) was added to
prevent non-specific binding and reduce background recordings across all samples.
After 30 min at room temperature the solution was discarded and plates were air
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dried and stored at 4°C. Standards were diluted in ELISA buffer (1 L distilled H20;
100 mM Tris; 2 mg/ml BSA; 9 g NaCl; 2 mM EDTA; 300 pi phenol red solution; 1
ml preservatives, pH 7.2). The standards, quality controls (of a set concentration in
multiple replicates), non-specific binding wells and finally the media samples to be
assayed were incubated together (100 pl/well). Any free, specific protein in the wells
spontaneously bound to the capture antibody on the base and sides of the well. Plates
were sealed and incubated overnight at 4°C. Excess media was discarded and plates
washed 4 times in wash buffer prior to addition of a biotinylated detection antibody
(secondary) (50 ng/ml at 100 pi/well) the plate was incubated for 90 min on a plate
shaker at room temperature, after which the plate was washed as aforementioned.
This secondary antibody formed a complex with the previously bound protein and
was detected with 100 pl/well of streptavidin peroxidase conjugate (SPC) (Roche,
Hertfordshire, UK), diluted 1:2000 in assay buffer. The plate was incubated for 20
min on a plate shaker at room temperature. Unbound SPC was removed by washing.
Subsequently, 200 pl/well peroxidase substrate, consisting of 20 ml sodium acetate
(pH 6; 100 mM), 2 ml 0.5 % urea hydrogen peroxidase (pH 6) and 2 ml tetramethyl
benzidine (3 mg/ml), was added. Any bound streptavidin peroxidase metabolised the
hydrogen peroxide present in the substrate and the tetra methyl benzidine was
converted into a coloured product. The reaction was stopped after 20 min incubation
by addition of 50 pl/well 2 N sulphuric acid. The colour was then measured on a
plate reader at 450nM. The details of the ELISA are summarised in Figure 2.3
Figure 2.3: Description of the stages and principles of a two-site sandwich ELISA.
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Stage 1:
The capture antibody is bound to the
base and sides of the wells.
Capture antibody
Stage 2:
Any antigens in the media specific to
the capture antibody bind.
Stage 3:
A biotin-labelled detection antibody is
added and it binds to the bound
antigen.
Stage 4:
Streptavidin peroxidase conjugate is
added to the wells.
Stage 5: This converts the substrate to





coloured 0. . ...Streptavidin
product peroxidase7
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2.6.8 Time-resolved fluoroimmunoassay of prolactin in culture
supernatants
Culture supernatants were stored at -20 °C until assayed. Decidual prolactin (PRL)
release was measured by a DELFIA® Prolactin time-resolved fluoroimmunoassay kit
(PerkinElmer Life Sciences, Belgium). The fluoroimmunoassay is a solid phase, two-
site assay based on the direct sandwich technique as described above. Briefly, 200 p.1
of anti-prolactin-EU tracer (see Figure 2.4), diluted 1:75, was added to the
microtitration strips. Standards provided in the kit (of a set concentration in multiple
replicates), and media samples to be assayed (all 25 pl/well) were added to the
microtitration strips and incubated for 90 min at room temperature on a plate shaker.
The standards and media samples reacted simultaneously with the immobilised
mouse monoclonal antibody directed against a specific antigenic site on the PRL
molecule and europium-labelled antibody directed against a different antigenic site.
After incubation the microtitration strips were washed in the wash buffer supplied
(Tris-HCL buffered (pH 7.8) salt solution with tween and Germall II as preservative)
and enhancement solution (200 pi) was added to each well so as to avoid touching
the sides of the wells. This enhancement solution dissociates europium ions from the
labelled antibody into solution, where they form highly fluorescent chelates with
components of the enhancement solution. The fluorescence of each sample is
proportional to the concentration of PRL in the media sample and was measured on a
time-resolved fluorometer, VICTOR™ 1420 Multilevel Counter (Wallac,
PerkinElmer LAS (UK) Ltd, Beaconsfield, UK). The concentration of prolactin was
determined by interpolation from a standard curve prepared from the prolactin
standards. The assay was conducted according to the manufacturer's protocol.
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Stage 1:
Solid phase anti-PRL IgG and
Eu-labelled hPRL IgG bind to different
antigenic sites on PRL.
Stage 2:
Enhancement solution is applied to the
wells, dissociating europium ions from the
Eu-labelled antibody.
Stage 3:
The dissociated Eu ions form fluorescent
chelates. This fluorescence is measured
by a time-resolved fluorometer and the
PRL concentration determined by interpolation





Figure 2.4: Description of the stages and principles of a solid phase, two-site
fluoroimmunometric assay based on the direct sandwich tequnique.
2.6.9 Immunolocalisation of proteins and tissue sections
2.6.9.1 Preparation of slides
Tissue sections, embedded in paraffin wax blocks were cooled from room
temperature prior to being cut. Cooling made the wax more rigid and easier to slice.
The blocks were cut into 5 pm sections using a hand operated microtome RM 2135
(Leica Microsystems (UK) Ltd, Milton Keynes, UK). Sections were floated on
distilled H20 (42°C) and placed on charged slides. The slides were dried for at least
3 h at 50-60°C, usually overnight (Lamb RA, East Sussex, UK. model E28.5). Once
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dry, the slides were dewaxed in xylene (Pioneer Research Chemicals Ltd) for 5 min
then transferred into a second vial of xylene for a further 5 min. The sections were
rehydrated in an alcohol series starting in absolute ethanol for 20 sec, and then into
95 % ethanol and finally 70 % ethanol, each for 20 sec. Slides were transferred into
distilled H2O and washed once in PBS. ESC, cultured on Labtec chamber well slides,
were washed with cold PBS (Sigma), fixed in 4 % NBF for 2 h and washed with
PBS.
2.6.9.2 Immunohistochemistry (IHC) and immunocytochemistry
(ICC)
The IHC/ICC method used was a standard avidin-biotin peroxidase (ABC) method
allowing specific proteins within fixed endometrial tissue/stromal cells to be detected
and visualised. This method is based on the principal that avidin has a high binding
affinity (K = 10"15M) for biotin. The primary antibody will bind specifically to the
protein of interest in the tissue section or cells. The biotinylated secondary antibody
that was raised against specific immunoglobulins of the species in which the primary
antibody was raised binds to antigenic sites on the primary antibody. Addition of an
avidin-biotin and horse-radish peroxidase (HRP) enzyme complex resulted in any
free sites on the avidin molecule binding to the biotin on the secondary antibody.
HRP activity in the presence of an electron donor, such as 3, 3-diaminobenzidine
(DAB), resulted in the formation of an enzyme-substrate complex and then oxidation
of DAB. The resulting colour change of the chromogen, DAB, produced a brown
precipitate, which was insoluble in alcohol and other organic solvents and was
formed at the site of the protein of interest.
2.6.9.3 Antigen retrieval
Fixatives work by inducing intra-molecular cross-linkages. These can mask target
proteins (antigens) and thus prevent their immunodetection. Antigen retrieval
describes the process by which the cross-linkages are partially undone by the
application of heat and change in pH. Treatment of the tissue sections to expose
masked antigens involved pressure-cooking (Tefal) the slides in 0.01 M citrate buffer
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(pH 6). Briefly, the slides were immersed in 2 L of boiling citrate buffer; the lid was
sealed and set to 13 psi. The slides were heated until full pressure was reached and
pressure cooked for 5 min. After which, the pressure was released and the pressure
cooker removed from heat. The slides were left to stand in the buffer for 20 min. The
sections were cooled and washed in distilled water followed by washing in PBS prior
to the next stage of the imunohistochemical procedure. Treatment of the cell
preparations to allow access to intracellular antigens involved permeabilisation of the
cell membrane by incubating the slides for 20 min at room temperature with 0.2 %
NP40 (Sigma), 1 % BSA (Sigma), and 10 % nonimmune goat serum (NGS;
Diagnostics Scotland, Carluke, UK). Slides were washed with PBS.
2.6.9.4 Blocking endogenous peroxidase
Endogenous peroxidase activity was blocked with 3 % H2O2 in 60 % (v/v) methanol
for 30 min at room temperature on a rocker. This step reduces background staining.
The slides were subsequently rinsed in PBS or TBS before the next stage of the
immunohistochemical procedure.
2.6.9.5 Normal serum block
Non-specific binding of components in the secondary antibody was minimised by the
application of a dilute solution of serum from the species in which the secondary
antibody was raised. For all IHC procedures goat serum, diluted 1:4 in TBS and
BSA, was applied to the slides for 30 min at room temperature to block tissue due to
be exposed to an anti-mouse secondary antibody raised in goats.
2.6.9.6 Avidin-biotin block
Endogenous biotin was blocked with the avidin-biotin blocking kit (Vector
Laboratories Ltd, Peterborough, UK) to reduce non-specific staining. Avidin was
added, neat, to the slides and incubated for 20 min at room temperature. The slides
were washed three times in TBS for 5 min before biotin was added (neat), incubated
at room temperature for 15 min followed by three washes in TBS for 5 min each.
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2.6.9.7 Primary antibodies
The appropriate primary antibody (Table 2.5) was diluted as required in blocking





















Table 2.5: Details of primary antibodies for IHC
2.6.9.8 Secondary antibody
After incubation with the primary antibody the slides were washed three times with
TBS for 5 min each, and incubated with the secondary antibody, goat anti-mouse
biotinylated (Dako UK Ltd, Cambridgeshire, UK) at a dilution of 1:500 in the
blocking serum (NGS/TBS/BSA) for 1 h at room temperature. The antibody was
washed off with TBS as before.
2.6.9.9 Horse-radish peroxidase
The ABC-HRP detection system (Dako UK Ltd) was used to amplify the signal
obtained from the biotinylated secondary antibody (Hsu, Raine et al. 1981). ABC-
HRP was prepared by adding 1 drop of solution A (Dako UK Ltd) and 1 drop of
solution B (Dako UK Ltd), approximately 20 pi each, to 5 ml of Tris-HCl. This was
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made up 30 min prior to application. The ABC-HRP was added to the slides for 30
min at room temperature followed by three washes in TBS for 5 min each.
The ABC-HRP complex works on the principal that avidin forms a tertiary structure
and possesses four binding sites for biotin. However, due to the molecular orientation
of the binding sites, fewer than four molecules of avidin are occupied with biotin
molecules complexed to HRP, leaving at least one site empty for binding to the
biotinylated secondary antibody (Figure 2.5).




Figure 2.5: ABC-HRP detection system (adapted from Dako UK Ltd. Handbook of
Immunochemical staining methods 3rd Edition, Boenisch et al, 2001).
2.6.9.10 Developing, counterstaining and mounting
The slides were developed and antigenic sites were visualised using DAB; 1 drop per
ml in DAB buffer (Dako UK Ltd). After DAB staining, the slides were
counterstained with Harris' haematoxylin (Pioneer Research Chemicals Ltd.,
Colchester, UK), differentiated in acid-alcohol and the nuclei developed in Scott's
tap water (Pioneer Research Chemicals Ltd). The slides were dehydrated in
increasing concentrations of alcohol and cleared in histoclear (Pioneer Research
Chemicals Ltd) and xylene for 5 min each before mounting under a borosilicate glass
coverslip (VWR) using Pertex™ (Cellpath pic, Hemel Hempstead, UK), a solvent
based glue.
AA
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2.6.9.11 Photomicroscopy
Tissue sections and cell preparations were examined and images captured using an
Olympus Provis microscope (Olympus Optical Co. London, UK) and a Kodak
DCs330 camera (Eastman Kodak Co. Hemel Hempstead, Hertfordshire, UK)
respectively. Images were compiled using the computer program, Photoshop CS
(Adobe Systems, California, USA).
2.6.10 Immunofluorescence
Immunofluorescence is the localisation of antigens in tissue sections or cell
preparations by the use of labelled antibodies as specific reagents through antigen-
antibody interactions that are visualised by a fluorescent dye marker. Fluorescence
results when sensitive materials are irradiated by light at a specific wavelength. This
excites atoms within the compound to a higher energy level so that when they drop
back down, the energy they release is detected as visible light. This emitted light has
a longer wavelength and lower energy than the "exciting" light, generated by a laser
beam incorporated into the microscope. To distinguish between the two types of
light, the microscope is fitted with two filters, one of which enables the sample to be
irradiated by light at a specific wavelength, the second separates out the excitation
light from the emitted light. The colour of emitted light seen depends on its
wavelength which varies depending on the sensitive chemical used. The fluorescent
chromagens used are summarised in Table 2.6.
2.6.10.1 Antigen retrival
The tissue sections and cell preparations were treated as described in section 2.6.9.3.
2.6.10.2 Blocking endogenous peroxidase
Endogenous peroxidase activity was blocked as described in section 2.6.9.4. This
prevents auto fluorescence.
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2.6.10.3 Normal serum block
Non-specific binding was blocked as described in section 2.6.9.5, the only exception
being that the serum was diluted 1:4 in PBS and BSA.
2.6.10.4 Avidin-biotin block
Endogenous biotin was blocked as described in section 2.6.9.6.
2.6.10.5 Primary antibodies
The appropriate primary antibody (Table 2.6) was diluted as required in blocking
serum/PBS/BSA, applied to the slides and incubated overnight at 4°C.
Antigen Dilution Antigen retrieval Species raised in Source














Table 2.6: Details of primary antibodies for IHF
2.6.10.6 Secondary antibody
After incubation with the primary antibody the slides were washed once with PBS
and 0.01 % Tween (PBST) for 5 min followed by two washes with PBS for 5 min
each. The slides were incubated with the appropriate secondary antibody, at a
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diltution of 1:500 in PBS for 30 min at room temperature. The antibody was washed
off with PBST and PBS as before.
Antibody
label
Dilution Species raised in Source
Biotinylated 1:500 Goat DAKO
Peroxidase 1:500 Goat DAKO
Table 2.7: Details of secondary antibodies for IHF
2.6.10.7 Streptavidin Alexaflour 488/546
The slides, which were previously incubated with a biotinylated-labelled secondary
antibody, were incubated in Streptavidin alexaflour 488/546 (Molecular Probes),
diluted 1:200 in PBS, for 1 h at room temperature, in a light protective humidified
chamber. The streptavidin alexaflour binds in a similar manner to the ABC-HRP
detection system described in section 2.6.9.9. After incubation with streptvidin
alexaflour 488/546 the avidin was washed off with PBST and PBS as described
previously and protected from light.
2.6.10.8 Tyramide detection
The slides, which were previously incubated with a peroxidase-labelled secondary
antibody, were incubated for 10 min with tyramide Cy3 (TSA plus cyanine 3 system;
Perkin-Elmer Life Sciences, Boston, MA) diluted 1:50 in the buffer supplied, to
amplify immunostaining and produce red fluorescence.



















1:200 lh 546/ red
To-Pro 3
(Molecular Probes)
1:2000 2 min 655/blue
DAPI
(Molecular Probes)
1:1000 10 min 405/ turquoise
Table 2.8: Details of fluorescent labelled complexes used.
2.6.10.9 Developing, counterstaining and mounting
The cells were counterstained with To-Pro-3 (Molecular Probes, Invitrogen), diluted
1:2000 for 2 min, or DAPI (Molecular Probes, Invitrogen), diluted 1:1000 for 10
min, in a light protective humidified chamber, to visualise the cell nuclei. The slides
were washed as described previously for a final time and mounted under a glass
coverslip using Permafluor™ mounting medium (Beckman Coulter, High Wycombe,
UK), a water based glue.
2.6.10.10 Confocal imaging
Slides immunostained with a fluorescent antibody were observed on a LSM 510 laser
scanning confocal microscopy (Zeiss, Hertfordshire, UK) using the 405 nm laser to
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visualise turquoise fluorescence, Argon 488 nm laser to visualise green fluorescence,
the HeNel 546 nm laser to visualise red fluorescence, and the HeNe2 633 nm laser
to visualise blue fluorescence. The images were compiled on the computer
programme, Photoshop CS.
2.6.10.11 Image analysis
Images captured on the confocal were analysed on the program, Image Pro Plus
(Media Cybernetics, USA). This program measures the mean optical density of the
fluorescence in the cell nucleus and allows comparison with other images when
captured at identical settings.
2.7 Fibroblast Cell Purity
Cultures of ESCs were grown for two weeks before the purity of fibroblasts in the
cultures (n = 6) was determined both by Fluorescence Activated Cell Sorting (FACS)
(Beckman Coulter) and IHC.
2.7.1 FACS
Cells were labelled using an antibody specific for a surface antigen found on human
fibroblasts (CD90, Oncogene, Dako UK Ltd). Approximately 1.5 million ESCs were
removed from culture following trypsinisation, re-suspended in 300 pi FACS buffer
(PBS, containing 0.1 % NaN3 and 1 % FCS) and split between three 1.5 ml
Eppendorf tubes: 10 pi of the anti-CD90 antibody was added to the first tube, 10 pi
anti-mouse IgG whole molecule with FITC conjugated (Sigma) was added to the
second tube and the third tube remained untreated. The cells and solutions within the
Eppendorfs were mixed and all three tubes were left on ice for 30 min in the dark.
All three tubes were centrifuged at 1500 g for 1 min to pellet the cells which were re-
suspended in 1 ml FACS buffer. This wash was repeated twice. To all tubes 100 pi
FACS buffer was added and cells re-suspended, tubes were wrapped in foil to
prevent light exposure. Before sorting the cells in a Beckman Coulter® FACS
caliber® Flow Cytometer the suspensions were passed though cell strainers (Becton
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Dickinson Labware, Europe, France) to ensure a single cell suspension. The cells
were passed through an aperture as single cells. The laser beam detected cells and
registered them as an event. The laser beam determined two properties of each cell:
the granularity and cell size. The granularity was read by the amount of side scatter
of the laser beam and the cell size determined by the degree of forward scatter. The
third measurement made by the laser beam was fluorescence, in this case fluorescein.
The three measurements combined illustrated the distinct populations of cells that
were present and the percentage of fluorescence provided the percentage of
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Figure 2.6: FACS analysis of ESC cell purity. Panel A shows unstained cells, panel
B shows isotype FITC control, panel C shows the forward and side scatter plot for
isotype control cells, red depicts cells without and green depicts cells with
florescence, panel D shows CD90 FITC stained cells, panel E shows the forward and
side scatter plot for CD90 FITC-stained cells, green depicts cells with florescence.
Representative scans from 35 samples are shown; cells are typically > 96 % pure.
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2.7.2 IHC detection of fibroblast purity
Cells were seeded in Labtec culture slides at a concentration of 500,000 cells per
well and immunostained using antibodies directed against vimentin, a cytoplasmic
fibroblast cell marker, or cytokeratin, an epithelial cell marker, as follows.
Cultured cells were washed with cold PBS (Sigma) and then fixed in 4 % NBF for 2
h. Thereafter, cells were washed with PBS and permeabilised by incubating the
slides for 20 min at room temperature with 0.2 % NP40 (Sigma), 1 % BSA (Sigma),
and 10 % nonimmune goat serum (NGS; Diagnostics Scotland). Non-specific
binding of primary antibody was blocked by incubating slides in a 1:5 dilution of
NGS in TBS (Tris-buffered Saline) containing 5 % BSA (NGS/TBS/BSA).
Endogenous avidin/biotin was blocked using a commercially available avidin-biotin
blocking kit (Vector Laboratories Ltd) then washed twice with PBS. Slides were
incubated at 4°C overnight in a 1:40 dilution of mouse monoclonal anti-human
vimentin (Dako UK Ltd) or a 1:40 dilution of mouse monoclonal anti-human
cytokeratin (Dako UK Ltd) made up in NGS/TBS/BSA. Antibody binding was
detected by applying a 1:500 dilution of biotinylated goat antimouse antibody (Dako
UK Ltd) in NGS/TBS/BSA, followed by an avidin/biotin horseradish peroxidase
complex (Dako UK Ltd), for 60 min and 30 min respectively, at room temperature.
Finally, antigenic sites were visualised by DAB (Dako UK Ltd) before
counterstaining in Harris's hematoxylin (Pioneer Research Chemicals Ltd),
dehydrating, and mounting with Pertex mountant (Cellpath pic). Fibroblast purity is
shown in Figure 2.7.
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Figure 2.7: Fibroblast purity demonstrated by IHC. Panel I shows ESCs stained for
vimentin, a fibroblast marker, and panel II shows ESCs stained for cytokeratin, an
epithelial cell marker. Insert shows negative control. Representative slides are
shown. Scale bars represent 100 pm.
2.8 Statistical Analysis
Prior to any statistical analysis data was tested for and shown to exhibit Gaussian
distribution. Gaussian distribution was determined by applying the Shapiro-Wilk
normality test to the data. Where appropriate, values were presented as means ±
S.E.M. Comparison of the different parameters for the various treatment groups was
determined by repeated measures analysis of variance (ANOVA). Significant
differences were assigned using Kruskal-Wallis post hoc test. The criterion for
significance for all tests was set at p < 0.05. Specific software was used to assist in
the data analysis (GraphPad Prism v4.0b for Macintosh, GraphPad Software, San
Diego, USA).
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Chapter 3
3 Impact of TGFp on gene expression in non-
decidualised and decidualised stromal cells
3.1 Introduction
3.1.1 Progesterone receptor
In the normal menstrual cycle, increasing concentrations of oestrogens, produced by
the ovaries, induce proliferation of endometrial glandular, stromal and vascular
endothelial cells, producing a notable thickening of the endometrium, across the
proliferative phase. Progesterone requires the presence of its nuclear receptor to
induce differentiation of the endometrium and progesterone receptor (PR) expression
requires prior exposure to oestrogen. Indeed, the presence of PR is considered
evidence of a functional ER-mediated pathway. In mice, functional PR is crucial to
female fertility with PR AJ PR B double knockouts displaying pleiotropic
reproductive abnormalities (Lydon, DeMayo et al. 1995). PR B -/- mice do not have
any impairment of ovarian or uterine function, but PR A -/- mice have severely
impaired ovulation and lack decidualisation of the endometrial stromal cells
(Conneely, Mulac-Jericevic et al. 2001).
In the human, expression of PR varies temporally and spatially, in both functional
and basal regions and within the epithelial and stromal compartments, across the
normal menstrual cycle (Garcia, Bouchard et al. 1988; Lessey, Killam et al. 1988;
Critchley, Bailey et al. 1993; Snijders, de Goeij et al. 1996; Wang, Critchley et al.
1998).
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3.1.2 Transforming Growth Factor p 1
Transforming Growth Factor p 1 (TGFpi), a secreted homodimeric protein, is the
prototypic member of a family of approximately 40 structurally related proteins
known as the "TGFP superfamily". TGFpi and its isoforms regulate a plethora of
diverse biological functions (Ignotz and Massague 1986; Desmouliere, Geinoz et al.
1993; Fajardo, Prionas et al. 1996; Jester, Barry-Lane et al. 1996; Sankar, Mahooti-
Brooks et al. 1996; Sandberg, Casslen et al. 1998; Serini, Bochaton-Piallat et al.
1998; Lewis, Lygoe et al. 2004; Shephard, Martin et al. 2004). TGFpi has been
shown to enhance tissue remodelling and homeostasis in endometrial cells (Bruner,
Rodgers et al. 1995; Ulloa, Creemers et al. 2001) and inactivation of TGFpi has
been implicated in endometrial carcinogenesis (Parekh, Gama et al. 2002).
TGFpi is present in its latent form in the endometrium until the late secretory phase
when it is activated by plasmin (Lyons, Gentry et al. 1990). Plasmin is formed from
inactive plasminogen by urokinase plasminogen activator (uPA), which is itself
regulated by plasminogen activator inhibitor (PAI-1) (Loskutoff, Sawdey et al.
1993), as detailed in section 1.5.1.12.1. A previous study reported that TGFpi
stimulates the synthesis of PAI-1, demonstrating a negative feedback loop on its own
production. In addition, progesterone has been shown to regulate the release of PAI-1
in stromal cells in vitro (Casslen, Andersson et al. 1986). Furthermore uPA is
expressed in the late secretory phase in co-ordinance with falling progesterone levels
prior to menstruation (Casslen, Sandberg et al. 1998), possibly indicating the
existence of a relationship between progesterone and TGFpi (Sandberg, Eriksson et
al. 1997).
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3.1.3 Transforming Growth Factor Beta 1 signalling
TGF(11 initiates its diverse cellular responses by stimulating formation of specific
heteromeric complexes of type I (ALK 5) and type II serine/threonine kinase
transmembrane receptors located at the cell surface. The type II receptor
phosphorylates type I in the juxtamembrane region (GS domain, rich in glycine and
serine residues), which in turn propagates the signal intracellularly via the
phosphorylation of highly conserved members of receptor-regulated SMAD (Sma-
and mothers against decapentaplegic (MAD) -related protein) family of
transcriptional regulators, SMAD 2 and 3 (Graff, Bansal et al. 1996; Macias-Silva,
Abdollah et al. 1996; Nakao, Imamura et al. 1997; Massague and Wotton 2000; Shi
and Massague 2003), as previously detailed in section 1.6.1.
3.1.4 Protein inhibitor of activated STATs
Protein inhibitor of activated STAT (signal transducer and activator of transcription)
(PIAS) represents a family of proteins originally identified through interaction with
cytokine-induced STAT (Chung, Liao et al. 1997). In mammals, five PIAS proteins
have been identified, PIAS 1,3, xa, x(3 and y (Liu, Liao et al. 1998). PIAS 1 and 3
bind and inhibit STAT 1 and STAT 3 DNA-binding activities, respectively (Chung,
Liao et al. 1997; Liu, Liao et al. 1998). PIAS 1, PIAS 3, PIAS xa and PIAS xp are
also reported to mediate steroid receptor-dependent transcriptional activation (Kotaja,
Aittomaki et al. 2000). Moreover, the PIAS family has been shown to possess
sumoylation ligase activity, which can promote the covalent addition of a small
ubiquitin-related modifier to target proteins (Johnson and Gupta 2001; Sachdev,
Bruhn et al. 2001; Nishida and Yasuda 2002; Lin, Liang et al. 2003). Sumoylation,
the addition of the small ubiquitin-related modifier (SUMO), is a post-translational
modification of proteins and can be involved in various cellular processes, such as
nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability,
response to stress, and progression through the cell cycle (Verger, Perdomo et al.
2003).
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PIAS y is reported to inhibit STAT 1 mediated transcriptional responses without
blocking their DNA-binding activities (Gross, Liu et al. 2001; Liu, Gross et al. 2001)
and antagonises Wnt-independent and Wnt-induced transcriptional activation of
lymphoid enhancer factor 1 (LEF 1) (Sachdev, Bruhn et al. 2001). Furthermore,
PIAS y has been reported to greatly augment the sumoylation of LEF 1 in an in vitro
system, indicating that PIAS y functions as a small ubiquitin-like modifier protein
(SUMO) E3 ligase (Sachdev, Bruhn et al. 2001). A possible explanation for the
repression of LEF 1 activity is facilitated via PIAS y-mediated sequestration of LEF
1 to subnuclear structures that colocalise with SUMO (Sachdev, Bruhn et al. 2001).
TGFjll induces expression of endogenous PIAS y and in turn, PIAS y interacts with
SMAD 3 and antagonises SMAD 3-dependent transcriptional activation by TGFp
type 1 receptor, thereby providing a negative feedback mechanism for regulation of
TGF(31 signalling (Imoto, Sugiyama et al. 2003). Recently, Zoumpoulidou et al
(Zoumpoulidou, Jones et al. 2004) reported that PIAS y is complexed to PR and its
ability to inhibit STAT signalling is dependent upon activation of PR. In human
endometrium, cAMP-activated PKA induces the expression and activation of several
transcription factors including STAT 5 (Mak, Brosens et al. 2002) capable of binding
to PR.
3.1.5 Transforming growth factor (31 and Wnt signalling cross¬
talk
Recent studies have shown that synergistic activation of Xtwn, a Wnt and TGF13
target gene, is mediated by a physical association between intracellular components
of these two pathways, namely, SMAD 3 and LEFl/TCFs (Letamendia, Labbe et al.
2001). The lymphoid enhancer binding factor/T-cell-specific factors (LEF1/TCF) are
a family of DNA-binding proteins that associate with 8-catenin and thereby the
activation of Wnt pathway gene targets. In addition, it has been reported that in
response to TGFpi binding to its receptors, and activating the SMAD signalling
pathway, expression of LEF 1 is induced (Medici, Hay et al. 2006). In Xenopus, p-
catenin and LEF1/TCF form a complex with SMAD 4 (Nishita, Hashimoto et al.
2000).
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It has been shown that Wnt-signalling is inhibited by the secreted protein DKK.
DKK has been demonstrated to inhibit Wnt-signalling by binding to a low-density
lipoprotein receptor-related protein, LRP 6 and inhibits signalling by disrupting the
binding of LRP6 to the Wnt/Fz ligand-receptor complex (Wodarz and Nusse 1998;
Tamai, Semenov et al. 2000; Mao, Wang et al. 2001). It has been reported that DKK
mRNA expression is significantly upregulated in the stromal cells in the secretory
phase of the cycle, suggesting that progesterone stimulates DKK expression and
implying a role for DKK in decidualisation of the endometrium (Tulac, Nayak et al.
2003).
3.1.6 Hypothesis
Decidualisation is governed by progesterone acting via its nuclear receptor (Huang,
Tseng et al. 1987; Zhu, Huang et al. 1990; Tseng, Gao et al. 1992; Mizuno, Tanaka
et al. 1998; Brosens, Hayashi et al. 1999), which is only retained in the stroma during
the late-secretory phase of the cycle (Wang, Critchley et al. 1998). Recently, the
Wnt-signalling pathway antagonist, DKK, has also been implicated in the process of
decidualisation ((Tulac, Nayak et al. 2003; Giudice 2004); (Tulac, Overgaard et al.
2006). In co-ordinance with decidualisation, TGF(!1 is active and abundantly
expressed in both endometrial epithelial and stromal cells, and is proposed to play a
critical role in cyclic tissue remodelling and inflammatory events associated with
menstruation (Bruner, Rodgers et al. 1995; Ulloa, Creemers et al. 2001). However
whether TGFfVl affects either PR or DKK to regulate the decidual process is as yet
unknown. We hypothesise that TGF(31 may interact with PR and/or DKK to
modulate the mechanism of decidualisation.
3.1.7 AIMS
The studies described in this chapter were designed to determine the effect of TGFp
on gene expression in non-decidualised and decidualised stromal cells. All studies
utilised primary endometrial stromal cells isolated from non-pregnant endometrium
as described in section 2.1.1. Some experiments included T47D cells, which were
Chapter 3 Impact of TGFp on gene expression in
non-decidualised and decidualised stromal cells
116
utilised to identify if TGFpi-induced responses were stromal cell specific.
Experiments in this chapter were designed to address the following questions:
1: Do non-decidualised and decidualised ESCs possess TGFP receptors, essential to
facilitate TGFP-induced responses (Massague and Wotton 2000)?
2: As previous studies suggest the existence of a possible relationship between TGFP
and progesterone (Sandberg, Eriksson et al. 1997), which isoform of TGFP is most
potent at inducing a change in PR expression?
3: Previous studies have also identified TGFpi as a potent inducer of a myofibroblast
phenotype (Desmouliere, Geinoz et al. 1993; Jester, Barry-Lane et al. 1996; Serini,
Bochaton-Piallat et al. 1998; Lewis, Lygoe et al. 2004; Shephard, Martin et al. 2004).
To ensure that TGFpi is acting in the expected manner does TGFpi upregulate
expression of SMAa in non-decidualised and decidualised ESC, and does a
correlation exist between endogenous TGFpi expression and SMAa expression?
4: In the normal menstrual cycle PR A + B is upregulated in response to ovarian
oestradiol. Does oestradiol upregulate PR A + B in the culture system used in this
chapter and does TGFpi negate this response? Furthermore, does TGFpi
downregulate PR A + B in decidualised ESCs and T47D cells?
5: Recent studies have identified a convergence between the Wnt-signalling pathway
and TGFP-signalling (Letamendia, Labbe et al. 2001). Does TGFpi interact with the
Wnt-signalling antagonist DKK?
6: Does TGFP 1-mediated signalling have an impact on hormone-response elements
of the steroid receptors (PR, ER, AR and GR) to inhibit the transactivation potential
of the receptor and hence provide a potential mechanism for TGFpi-induced
responses?
7: Does TGFpi signal via the SMAD signalling pathway in the culture system used
in this chapter, and does selectively silencing SMAD 4 prevent any of the observed
TGFP 1-induced responses?
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3.2 Methods
3.2.1 Human uterine tissue collection
Endometrial (n = 35) samples were collected as detailed in section 2.1.1 (Table 2.1a).
Biopsies utilised in this chapter are detailed in Table 3.1. All endometrial samples
were processed to isolate the stromal compartment from the glands, as described in
section 2.2. Endometrial biopsies were dated according to the criteria of Noyes et al
(Noyes, Hertig et al. 1950) and were found to be consistent with the patients'
reported last menstrual period. In addition, all subjects had a serum sample collected
at the time of biopsy for the determination of circulating oestradiol and progesterone
levels by RIA as described by Yong et al (Yong, Glasier et al. 1992). Biopsies were
classified as early, mid or late proliferative, or early, mid or late secretory, and a
significant reduction in circulating progesterone levels was evident between biopsies
collected in the mid and late secretory phases.
Chapter 3 Impact of TGFp on gene expression in












1 49 20 608 34.9 17
2 51 20 75 2.1 17
3 37 6 215 1.8 17
4 33 11 373 1.8 17
5 39 13 964 3.9 17
6 37 7 234 1.7 17
7 33 6 255 2.8 17
8 44 13 359 1.8 17
9 41 31 650 51 17
10 44 25 276 42.1 17
11 39 10 835 10.14 17
12 42 14 478 23.66 17
13 41 9 1002 13.68 17
14 42 18 401 72.28 17
15 37 23 745 127.2 17
16 48 20 552 78.9 17
17 37 10 N/A N/A 17
18 38 10 353 63 17
19 21 16 589 20.82 17
20 35 -27 398 63 17
21 47 11 1796 2.32 17
22 46 16 574 4.44 40
23 30 4 242 6.15 40
24 43 8 581 68.94 17
25 32 12 1651 4.04 17
26 33 22 520 62.68 17
27 40 12 667.03 10.86 17
28 43 16 607.2 146.41 17
29 42 8 208.52 0.88 17
30 39 22 516.89 93.23 73
31 46 15 641.34 2.5 17
32 35 9 278.52 2.45 17
33 47 26 113.18 60.4 17
34 30 -27 166.18 7.61 17
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Table 3.2: Summary of biopsy cycle stage from samples used in the studies
presented in Chapter 3. Biopsies were staged according to the criteria of Noyes et al,
with consistent E2 and P levels at time of biopsy.
3.2.2 In vitro primary cell culture experiments
ESCs and T47D cells were maintained at 37°C in 5 % (v/v) C02 in RPMI 1640
medium (Sigma) supplemented with 10% FCS (Mycoplex), penicillin (50pg/ml;
Sigma), streptomycin (50pg/ml; Sigma) and gentamycin (5pg/ml; Sigma) in the
presence of ITS (Sigma) for T47D cell culture (section 2.2). Passaging of the cells
was performed every 3-4 days by trypsinisation (section 2.2). The cells were seeded
in 6-well plates at a concentration of 2.5 x 105 cells/ml and allowed to adhere and
attain 90% confluence: 24 h prior to treatment the media was changed to serum-free
RPMI. Tables 3.3-3.9 detail the treatment regimes utilised. Each treatment was
duplicated and each experiment was repeated 3-9 times with separate endometrial
biopsies.
Experiment 3.1: Are TGFp receptors present in non-decidualised and decidualised
stromal cells?
Treatment Concentration Incubation period
Control ESC N/A 72 h
MPA+8-Br-cAMP lpM +250 pM 72 h
Table 3.3: Experimental regime for experiment 3.1
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Experiment 3.2: Which isoform of TGFp is most potent?
Treatment Concentration Incubation period
Control N/A 72 h
TGFpi 10 ng/ml 72 h
TGFP2 10 ng/ml 72 h
TGFP3 10 ng/ml 72 h
Table 3.4: Experimental regime for experiment 3.2
Experiment 3.3 Does TGFpi interfere with the expression of SMA in non-
decidualised and decidualised cells.
Treatment Concentration Incubation period
Control N/A 2,12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2,12, 24, 36, 48, 72 h
TGFpi 10 ng/ml 2,12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGFpl
1 pM + 250 pM +10
ng/ml
2,12, 24, 36, 48, 72 h
Table 3.5: Experimental regime for experiment 3.3
Experiment 3.4 Does TGFpi inhibit upregulation of PR in non-decidualised ESC in
response to Oestradiol treatment?
Treatment Concentration Incubation period
Control N/A 2,12, 24, 36, 48, 72 h
Oestradiol 0.1 pM 2,12, 24, 36, 48, 72 h
TGFpi 10 ng/ml 2,12, 24, 36, 48, 72 h
Oestradiol +TGFpi 0.1 pM +10 ng/ml 2,12, 24, 36, 48, 72 h
Table 3.6: Experimental regime for experiment 3.4
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Experiment 3.5: Does TGFpi interfere with the expression of PR in non-
decidualised, decidualised cells and T47D cells.
Treatment Concentration Incubation period
Control N/A 2,12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2,12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGFP1
1 pM + 250 pM +10
ng/ml
2,12, 24, 36, 48, 72 h
Table 3.7: Experimental regime for experiment 3.5
Experiment 3.6: Does TGFpi interfere with the expression of DKK in non-
decidualised, decidualised cells.
Treatment Concentration Incubation period
Control N/A 2, 12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2, 12, 24, 36, 48, 72 h
TGFpi 10 ng/ml 2, 12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGFpl
1 pM + 250 pM +10
ng/ml
2, 12, 24, 36, 48, 72 h
Table 3.8: Experimental regime for experiment 3.6
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Experiment 3.7: Does neutralising endogenous TGFpi abrogate TGFpi-induced
responses.
Treatment Concentration Incubation period
Control N/A 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 72 h
MPA+8-Br-cAMP
+TGFJ31





1 pM + 250 pM + 2
ng/ml
72 h
Mouse IgGl 72 h
Table 3.9: Experimental regime for experiment 3.7
3.2.3 RT-PCR
Total RNA was extracted from the ESC and T47D cells as described in section 2.3.1
and cDNA prepared from the experiments detailed in section 2.3.2.
3.2.4 Semi-Quantitative PCR
Primers were designed to amplify the TGFpi receptor type 1 (TGF[31 R1) gene. PCR
was carried out using BioMix Red (Bioline). Conditions for each sample were as
follows:
2 x Bioline Biomix Red lOpl
TGFpiRl sense primer (0.5 pM) 2 pi
TGFpiRl antisense primer (0.5 pM) 2 pi
RNAse-free H20 2 pi
cDNA 4 pi
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30 cycles of amplification were performed with an initial denaturing temperature of
95°C for 5 min for 1 cycle followed by 30 cycles of: denaturation at 95°C for 30 sec;
specific TGF(31 receptor type 1 primer annealing at 58°C for 30 sec and extention at
72°C for 1 min 30 sec. Final extension at 72°C was carried out for 10 min. The PCR
product was run on a 2% agarose gel (section 2.4.1), visualised, and recorded as
described in section 2.4.1. Primer pairs designed to amplify TGFpi receptor type 1




























Table 3.10: Primer sequences and product sizes
3.2.5 Q-RT-PCR
The relative levels of expression of SMAa, IGFBP-1, PR and DKK in ESC and PR
in T47D cells, both control and treated cells (Tables 3.3 - 3.9), were determined
using quantitative RT-PCR (TaqMan) using random primed cDNA as detailed in
section 2.4.2.
Results were analysed as in section 2.4.2. Primer pairs and probes specific to each
gene are given in Table 3.11.
Chapter 3 Impact of TGFP on gene expression in
























































Table 3.11: Primer and probe sequences
3.2.6 Transient transfection
Transient transfections were performed using a reporter construct containing a PRE,
ARE, GRE or ERE-linked to luciferase (section 2.5.1). A [3-galactosidase control
vector, (PCH110, Pharmacia), was co-transfected in all cases and used to measure P-
galactosidase to control for transfection efficiency (section 2.5.4). Transient
transfections were performed using the calcium chloride method as described in
section 2.5.2. All transfections were performed in triplicate, using DCC media, a 1:1
mixture of DMEM and Ham's F-12 containing 5% FCS that had been depleted of
steroids by treatment with dextran-coated charcoal, 100 U/ml penicillin, and 100
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pg/ml streptomycin, and supplemented with 1CT9 M 176-oestradiol and 1 pg/ml
insulin (section 2.5.2).
Six hours after transfection the media was replaced with 2 % FCS DCC. The
experiments were performed as detailed in Tables 3.12 - 3.15. The cells were
harvested 48 h after treatment for analysis with a luciferase assay (section 2.5.3).
Tranfection efficiency was analysed with a (3-galactosidase assay (section 2.5.4). The
samples were "normalised" by dividing each sample's luciferase reading with the
corresponding P-galactosidase reading. This numerical reading was used as a
comparison against other samples.
Experiment 3.8: Does TGFpl interfere with the transactivation potential of PR?
Treatment Concentration Incubation period
Control N/A 48 h
MPA lpM 48 h
TGFpl 10 ng/ml 48 h
MPA +TGFP1 1 pM +10 ng/ml 48 h
Table 3.12: Experimental regime for experiment 3.8
Experiment 3.9: Does TGFpl interfere with the transactivation potential ofAR?
Treatment Concentration Incubation period
Control N/A 48 h
DHT 0.1 pM 48 h
TGFpi 10 ng/ml 48 h
DHT +TGFP1 0.1 pM +10ng/ml 48 h
Table 3.13: Experimental regime for experiment 3.9
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Experiment 3.10: Does TGFpi interfere with the transactivation potential of GR?
Treatment Concentration Incubation period
Control N/A 48 h
DEX 0.25 pM 48 h
TGFpi 10 ng/ml 48 h
DEX+TGFpl 0.25 pM +10 ng/ml 48 h
Table 3.14: Experimental regime for experiment 3.10
Experiment 3.11: Does TGFpi interfere with the transactivation potential of ER?
Treatment Concentration Incubation period
Control N/A 48 h
Oestradiol 0.1 pM 48 h
TGFpi 10 ng/ml 48 h
Oestradiol +TGFP1 0.1 pM +10 ng/ml 48 h
Table 3.15: Experimental regime for experiment 3.11
3.2.7 siRNA for SMAD 4
Non-decidualised or decidualised ESCs were transiently transfected using the
calcium phosphate precipitation method, as previously described in section 2.5.2,
with 50 nM of the siRNA reagents (Dharmacon) detailed in Table 3.16. The RNA
and protein content was extracted 72 h later as described in sections 2.3.1 and 2.6.1
respectively.
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Experiment 3.13: Does interfering with the SMAD signalling pathway inhibit
TGFpi-induced responses?
Treatment Concentration Incubation period























1 pM + 250 pM
10 ng/ml
72 h
Table 3.16: Experimental regime for experiment 3.13
3.2.8 Western Blotting analysis
Total cellular protein was extracted from the experiments detailed in Tables 3.6, 3.7
and 3.16 using the method detailed in section 2.6.1 and quantified using the method
of Bradford (section 2.6.2). The protein samples were separated on a gel as described
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in section 2.6.3 and subsequently electrotransferred onto a PVDF membrane (section
2.6.4). After blocking with 15 ml of 4 % BSA + 4 % NaN3; the membrane was
incubated at 4°C overnight with an anti-PR mouse monoclonal antibody (directed
against both isoforms, PR A and PR B) (Novocastra), diluted 1:200 in the blocking
solution or anti-SMAD 4 mouse monoclonal antibody (Abeam), diluted 1.500 in the
blocking solution. After 3 washes with TNS Tween, the membrane was incubated for
1 h at room temperature with the secondary antibody; a rabbit anti-mouse IgG
(Sigma) diluted 1:5000 in TNS Tween. The membrane was subsequently washed 3
times in TNS Tween before developing with ECL plus detection kit (Amersham Life
Sciences) for 20 min, as described in section 2.6.5.
3.2.9 IGFBP-1 ELISA
Media collected from experiment 3.1 was assayed for IGFBP-1 using a two-site
sandwich ELISA as described in section 2.6.7.1. Plates were coated with the IGFBP-
1 capture antibody (R&D Systems) (2 pg/ml, 100 pi per well) and incubated
overnight at 4°C. The plates were washed prior to use. A standard curve, consisting
of eight standards, was added in duplicate to each plate. The standards were prepared
as follows: a stock solution of 8 ng/ml was used to produce a dilution series to
ultimately obtain a bottom standard of 0.06 ng/ml. Each standard was thoroughly
mixed before the next transfer. The undiluted standard served as the high standard (8
ng/ml) ELISA Buffer plus Tween (B+T) was used to dilute standards and antibodies
to be used later in the ELISA. ELISA buffer plus tween served as the NSB. A quality
control was made up at 700 pg/ml from the IGFBP-1 standard and added in duplicate
to each plate. The NSB, standards, and media samples to be assayed were added in
duplicate, 100 pi per well. Plates were sealed and incubated for 3 h on a plate shaker
at room temperature. The plates were washed four times each and residual wash
buffer removed by aspiration. The IGFBP-1 detection antibody (R&D Systems)
(100 pi per well) was added at a concentration of 0.1 pg/ml and incubated at room
temperature for 90 min on a plate shaker. Plates were washed and residual wash
buffer removed as before. Streptavidin peroxidase conjugate (Roche) (0.125 U/ml,
100 pi per well) was added and the plates incubated for 20 min on a plate shaker at
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room temperature. The plates were then washed as before and 200 pi of peroxidase
substrate added per well. Plates were developed for 10 min before stopping the
reaction with 50 pi of 2 N sulphuric acid per well. All plates were read on a plate
reader at 450 nM. The computer program, Assay Zap™, was used to analyse the
results and determine the concentration of IGFBP-1 in each sample by interpolation
from the standard curve.
3.2.10 DKK ELISA
Media collected from experiment 3.6 was assayed for DKK using a two-site
sandwich ELISA as described in section 2.6.7.1. Plates were coated with the DKK
capture antibody (R&D Systems) (2 pg/ml, 100 pi per well) and incubated
overnight at 4°C. The plates were washed prior to use. A standard curve, consisting
of eight standards, was added in duplicate to each plate. The standards were prepared
as described in section 3.2.9 for the IGFBP-1 ELISA. The NSB, standards, and
media samples to be assayed were added in duplicate, 100 pi per well. The remainder
%
of the assay was conducted as detailed in section 3.2.9.
3.2.11 Immunocytochemistry
Immunocytochemistry was performed on ESC using the protocol described in
section 2.6.9.2. Immunocytofluorescence was also performed using the protocol
described in section 2.6.10. The ESCs were cultured on 2-well chamber-well slides
(Nalgene, Nunc) and treated as detailed in Table 3.7 when 70-80 % confluence was
attained. Immunohistochemistry used Tris-buffered saline (TBS) and
immunohistofluorescence used Phosphate-buffered saline (PBS) in washes and
dilutions.
Cultured cells were washed with cold TBS/PBS (Sigma) and then fixed in 4 % NBF
for 2 h. Thereafter, cells were washed with TBS/PBS and then permeabilised by
incubating the slides for 20 min at room temperature with 0.2 % NP40 (Sigma), 1 %
Bovine Serum Albumin (BSA) (Sigma, Poole), and 10 % nonimmune Goat Serum
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(NGS) (NP40/BSA/NGS). Non-specific binding sites of the primary antibody were
blocked by incubating the slides in a 1:5 dilution of NGS in TBS/PBS containing 5
% BSA (NGS/TBS or PBS/BSA). Endogenous avidin/biotin was blocked using a
commercially available avidin-biotin blocking kit (Vector Laboratories Ltd,) then
washed twice with PBS. Slides were incubated at 4°C overnight in a 1:40 dilution of
mouse monoclonal anti-human PR A+B (Novocastra Laboratories Ltd, Newcastle-
Upon-Tyne, UK) or mouse monoclonal anti-human p-SMAD 2 (Abeam, Cambridge,
UK) made up in NGS/TBS or PBS/BSA. After washing once with TBS/PBS Tween
and once with TBS/PBS for 5 min each, PR antibody binding was detected by
applying a 1:500 dilution of biotinylated goat antimouse antibody (Dako UK Ltd) in
NGS/TBS/BSA, followed by an avidin/biotin horseradish peroxidase complex (Dako
UK Ltd), for 60 min and 30 min respectively, at room temperature. Finally, antigenic
sites were visualised by 3, 3-diaminobenzidine (Dako UK Ltd) before
counterstaining in Harris's hematoxylin, dehydrating, and mounting with Pertex
mountant. p-SMAD 2 binding was detected by applying a 1:500 dilution of
biotinylated goat antimouse antibody (Dako UK Ltd) in PBS followed by
streptavidin 546 (Molecular Probes) for 60 min each at room temperature. After
washing the slides as described above, cells were counterstained with DAPI (1:200 in
PBS) for 10 min at room temperature. The slides were mounted under a glass
coverslip using Permafluor™ mounting medium.
3.2.12 Statistical analysis
Prior to statistical analysis, all data was tested for either Gaussian or non-parametric
distribution. Where appropriate, values were presented as means ± S.E.M.
Comparison of the different parameters for the various treatment groups was
determined by repeated measures analysis of variance (ANOVA). Significant
differences were assigned using Kruskal-Wallis post hoc test. The criterion for
significance for all tests was set at p < 0.05. Specific software was used to assist in
the data analysis (GraphPad Prism).
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3.3 Results
3.3.1 Expression of TGFp receptors in non-decidualised and
decidualised stromal cells
Before embarking on a series of experiments to determine the impact of TGFpl on
gene expression in non-decidualised and decidualised stromal cells, the presence of
TGFP receptors had to be ascertained. It was also necessary to ensure that the ESCs
that had been decidualised in vitro were indeed expressing the classical
decidualisation marker, IGFBP-1.
Successful in vitro decidualisation was assessed by measuring the IGFBP-1 mRNA
expression and protein release in the decidualised ESCs compared with the non-
decidualised ESCs. Non-decidualised cells are shown in panel A (Figure 3.1) and in
vitro decidualised cells are shown in panel B (Figure 3.1). After decidualisation the
cells become more rounded in appearance and appeared to have an accumulation of
secretory products on the cell surface. Consistent with successful decidualisation,
expression of IGFBP-1 mRNA was significantly upregulated in decidualised cells as
compared with the non-decidualised samples (p<0.05, n=4) (Figure 3.2). This
significant increase in IGFBP-1 mRNA was mirrored in the amount of IGFBP-1
protein release as detected with a two-site sandwich ELISA (pcO.OOl, n=4) (Figure
3.3).
Expression of TGFpi receptor type 1 (TGFplRl) mRNA was detected in both non-
decidualised and decidualised ESCs (Figure 3.4. panel A). TGFpiRl mRNA
expression appears to be more pronounced in decidualised ESCs (samples 1, 3, 5 and
7) as compared with non-decidualised ESCs (samples 2, 4, 6 and 8) in the semi¬
quantitative PCR. Panel B depicts the same samples probed for GAPDH, which was
used as an internal control for integrity of the RNA samples) however this was not
seen to be significant when quantitative RT-PCR (TaqMan) was conducted on the
same samples (Figure 3.5).
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Figure 3.1: Photograph of non-decidualised (Panel A) and decidualised ESCs after
72 h treatment with 8-Br-cAMP and MPA (Panel B). The arrowhead highlights a cell














Figure 3.2: Relative expression of IGFBP-1 mRNA in non-decidualised and
decidualised ESCs. Cells were either untreated or decidualised in vitro with 8-Br-
cAMP and MPA for 72 h. IGFBP-1 mRNA was analysed by Q-RT-PCR. Results are
± SEM. (p<0.05) n= 4 endometrial samples.
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Figure 3.3: Quantitative analysis of IGFBP-1 protein release in non-decidualised and
decidualised ESCs. Cells were either untreated or decidualised in vitro with 8-Br-
cAMP and MPA for 72 h. IGFBP-1 protein release was analysed by ELISA. Results
are ± SEM. (p<0.001) n= 4 endometrial samples.
Figure 3.4: Expression of TGFfll R1 (150 bp) in non-decidualised and decidualised
ESCs. Cells were either untreated or decidualised in vitro with 8-Br-cAMP and MPA
for 72 h. The cultures were harvested and total cellular RNA probed for the
expression of TGFpi R1 (Panel A) and GAPDH (205bp) (Panel B), the
housekeeping gene. Sample M represents DNA hyperladder. Samples 1, 3, 5 and 7
depict non-decidualised ESCs. Samples 2, 4, 6 and 8 depict in vitro decidualised
ESCs.
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Figure 3.5: Relative expression of TGFpi R1 mRNA in non-decidualised and
decidualised ESCs. Cells were either untreated or decidualised in vitro with 8-Br-
cAMP and MPA for 72 h. TGFpiRl mRNA was analysed by Q-RT-PCR. Results
are ± SEM n = 4 endometrial samples.
3.3.2 Identification of the most potent TGFp isoform evoking an
inbititory effect on PR mRNA
To address the question of the potency of TGFpi in comparison with the other TGFp
isoforms, which have previously been localised within the endometrium (Arid,
MacDonald et al. 1996; Casslen, Sandberg et al. 1998), ESCs, decidualised in vitro,
were treated for 72 h with TGFpi, TGFp2 or TGFp3 (10 ng/ml). TGFpi alone
evoked a significant decrease in PR, as compared with TGFp2 and TGFp3 (p<0.001,
n = 6) (Figure 3.6). TGFp2 and TGFp3 were without significant effect, but displayed
a mild trend towards reduction.
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Control TGFpi TGFp2 TGFp3
Figure 3.6: TGFpi is the most potent isoform localised within the endometrium.
Cultured ESC, decidualised in vitro +/- either TGFpi, TGF(12, or TGF(13 (all at 10
ng/ml), for 72 h. TGFpi reduces expression of mRNA nuclear PR in a significant
manner (p<0.001). TGFp2 and TGFf33 show no significant effect. Results are ±
SEM. n = 6 endometrial samples.
3.3.3 TGF01 upregulates SMA in both non-decidualised and
decidualised ESCs
To address if TGFpi was acting as expected on ESC to induce a myofibroblast
phenotype, ESC were cultured in the presence or absence of TGFpl (10 ng/ml)
(Figure 3.7) or were cultured, decidualised in-vitro with 8-Br-cAMP 0.5 mM and
MPA 1 pM (decidualising medium) for 6 d and then further cultured with
decidualising medium to maintain the decidualised phenotype with or without the
addition of TGFpi for up to 72 h (Figure 3.8). 10 ng/ml TGFpi up-regulated
expression of SMAa mRNA in both non-decidualised ESC (Figure 3.7) (p<0.01, n =
9) and decidualised ESC (Figure 3.8) (p<0.001, n = 9) after 36 h of exposure. This
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upregulation of SMAa continued in a time-dependent manner with a significant
increase in SMAa observed at 48 h (pcO.OOl, n = 9) and 72 h (p<0.001, n = 9) in
both non-decidualised (Figure 3.7) and decidualised cells (Figure 3.8) as compared to
unstimulated, time-matched controls.
To elucidate a possible correlation between SMAa and TGFpl, expression of
mRNAs in control ESCs was measured. Cells were cultured for 72 h in serum-free
medium without treatment. A significant positive correlation between endogenous






Control 2 h 12 h 24 h 36 h 48 h 72 h
Figure 3.7: Time course of SMA mRNA expression in cultured ESC ± TGFfVl
measured by Q-RT-PCR. TGF81 upregulates SMA mRNA in a time-dependent
manner in primary ESC. Results are ± SEM. (pcO.OOl) n = 9 endometrial samples.
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Control 2 h 12 h 24 h 36 h 48 h 72 h
Figure 3.8: Time course of SMA mRNA expression in decidualised ESC +/-TGFpl
measured by Q-RT-PCR. TGFpi increases expression of SMA mRNA in a time
































Figure 3.9: Correlation of SMAa mRNA expression with TGFpi mRNA expression
in control ESCs. Cells were cultured for 72 h in serum free media. Correlation
coefficient r = 0.7459. Significant correlation (p<0.05). n = 9 endometrial samples.
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3.3.4 TGFf31 downregulates PR in both non-decidualised and
decidualised ESC in a time dependent manner
3.3.4.1 Non-decidualised ESC
To address the role of TGFpi regulation of ESC PR expression, ESC were cultured
in the presence or absence of oestradiol (0.1 pM) and/or TGFpi (10 ng/ml) for up to
72 h. Results are presented in Figure 3.10 ; 10 ng/ml TGFpi up-regulated expression
of PR mRNA in non-decidualised ESCs 4-fold (p<0.001, n = 6) after only 2 h of
exposure, however, this increase was not maintained and PR mRNA was comparable
to control cells. Incubation with TGFpi for 48 h and 72 h resulted in a significant
downregulation in the level of PR mRNA expression as compared to unstimulated,
time-matched controls (p<0.05, n = 6) (Figure 3.10). Treatment with oestradiol
significantly up-regulated PR mRNA expression, in a time-dependent manner as
compared to unstimulated, time-matched controls (p<0.001, n = 6) (Figure 3.10).
Inclusion of TGFpi negated the oestradiol-induced response (Figure 3.10). The
changes in mRNA expression were mirrored in PR protein expression, analysed by
Western blotting (gel not shown). Densometric analysis of PR compared with P-actin
(72 h treatment, Figure 3.11) revealed that TGFpi significantly downregulates
(p<0.001, n = 3) and E2 upregulates (p<0.001, n = 3) PR expression compared to
control (Figure 3.11). Cells treated with E2 plus TGFpi contained concentrations of
PR comparable to those of untreated controls (Figure 3.11).
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Figure 3.10: Time course of PR mRNA expression in cultured ESC ± TGFpi ±
oestradiol measured by Q-RT-PCR. Oestradiol increases whilst TGFpi reduces
expression of PR mRNA in a time dependent manner in primary ESC. Results are ±
SEM. (p<0.05). n = 6 endometrial samples.
Figure 3.11: Densometric analysis of PR protein expression in whole cell lysates
from cultured primary ESC ± TGFpl (10 ng/ml) ± oestradiol (0.1 pM), subjected to
Western blotting analysis. The cultures were harvested and total cellular protein
probed for the expression of PR A + B (120 kDa and 90 kDa respectively) and P
Actin (48 kDa) the housekeeping gene. Results are ± SEM. (p<0.001) n = 3
endometrial samples.
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3.3.4.2 Decidualised ESC and T47D cells
To further address the role of TGFpi in regulation of ESC PR expression, ESC were
cultured, decidualised in vitro with 8-Br-cAMP (0.5 mM) and MPA (1 pM)
(decidualising medium) for 6 d and then further incubated with decidualising
medium with or without the addition of TGFpi for a maximum of 72 h. Results are
presented in Figure 3.12, Graph A. TGFpi upregulated expression of PR mRNA in
decidualised ESCs 2-fold (p<0.001, n = 6) after only 2 h of exposure, however, at 24
h and 36 h this up-regulation was not observed (Figure 3.12, Graph A). At 72 h PR
mRNA expression levels were significantly downregulated 2-fold as compared to
unstimulated controls (p<0.05, n = 6) (Figure 3.12, Graph A). Similar results were
observed in T47D cells (Figure 3.12, Graph B). Immunoexpression of PR was
localised to nuclei staining for in primary ESC (Figure 3.13), Panels I and II depict
ICC on both control and TGF|31-treated cells. Panel III and IV depict ICC on T47D
cells, again on control and TGFpi-treated cells. Comparison of staining intensities
indicates a decrease of immunoreactive PR in the nuclei of both cell types.
Representative examples are shown (Figure 3.13).
control 2h 24h 48h 72h control 2h 24h 48h 72h
TGFpi + + + + TGFpi + + + +
Figure 3.12: Time course of PR mRNA expression in A: Cultured ESC, decidualised
in-vitro +/-TGFP1 and B: T47D cells +/- TGFpi measured by Q-RT-PCR. TGFpi
reduces expression of PR mRNA in a time dependent manner in both primary ESC
and T47D cells. Results are ± SEM. (p<0.05) n = 6 endometrial samples.
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Figure 3.13: Immunohistochemical analysis of PR expression in control and TGFpi-
treated ESC and T47D cells. PR immunostaining in I; ESC decidualised in vitro, II;
ESC decidualised in vitro + TGFpi (10 ng/ml). III; T47D cells, IV; T47D cells +
TGFpi (10 ng/ml). Inserts show negative controls (no primary antibody). Scale bars
represent 100 pin.
3.3.4.3 Comparison of non-decidualised and decidualised ESCs
Protein expression of PR and PIAS y in non decidualised and decidualised ESCs was
analysed by Western blotting (Figure 3.14). On Western blots we observed reduced
expression of PR A and PR B following treatment of decidualised ESCs with TGFp 1
(Figure 3.14). This response appears more marked in cells exposed to decidualising
agents for 72h (Figure 3.14). No response was observed in non-decidualised ESCs.
This data is unconvincing and may be an abstract result; therefore, further Western
blots should be performed on additional samples with densometric analysis
conducted to quantify any change in protein expression between treatment groups. It
would appear that TGFpi treatment potentiates protein expression ofPIASy in a time
dependent manner in both non-decidualised and decidualised cells (Figure 3.14).
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Figure 3.14: Whole cell lysates from untreated primary ESC or cultures decidualised
in vitro for 12, 24 or 72 h, +/- TGF(31 (10 ng/ml), were subjected to Western blotting
analysis. TGFfVl treatment reduced protein expression of both PR A and PR B in
decidualised ESC and increased protein expression of PIASy in both non-
decidualised and decidualised ESC. Marius Jones performed this nuclear protein
extraction and Western Blot in Jan Brosens lab group.
3.3.5 TGF01 does not affect the transactivation potential of
steroid receptors
In order to elucidate if the TGF|f 1 mediated-signalling can have a direct effect on the
progesterone response element (PRE) or response elements for other steroid
receptors, (AR, GR and ER) a luciferase promoter/reporter assay was conducted. The
presence of an appropriate steroid receptor-agonist, but not addition of TGFpl,
induced reporter gene expression for all steroid response elements (Figure 3.15). Co
incubation with steroid agonist and TGF(31 did not have a significant impact on
reporter gene activation (Figure 3.15).
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D ER
control Oestradiol TGFpl Oestradiol
+TGFp1
Figure 3.15: ESCs were transiently transfected with either, A: PRE-luc, B: ARE-luc,
C: GRE-luc or D: ERE-luc expression vector and cells were treated with +/- MPA
(PRE), DHT (ARE), DEX (GRE), E (ERE) or +/- TGFpl. Results are ± SEM n = 3
endometrial samples. TGFpi was without effect, either alone or in combination with
the steroid-specific agonist, on induction of reporter gene activation for all response
elements.
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3.3.6 TGFpi downregulates DKK in non decidualised and
decidualised stromal cells
3.3.6.1 Non-decidualised ESCs
To address the question as to whether TGFpi interacts with the wnt-signalling
antagonist DKK in non decidualised stromal cells, ESCs were cultured in the
presence or absence of TGFpl (10 ng/ml) for up to 72 h. Results are presented in
Figure 3.16; 10 ng/ml TGFpi significantly downregulated expression of DKK
mRNA after only 2 h of exposure (p<0.001, n = 5), however, at 12 h and 24 h this
downregulation was not observed (Figure 3.16). At 36 h and 48 h after TGFpi
exposure DKK mRNA expression levels were significantly downregulated as
compared to unstimulated, time-matched controls (p<0.05 and p<0.001 respectively,
n = 5) (Figure 3.16). At 72 h after treatment DKK mRNA levels were comparable
with the unstimulated, time-matched controls (Figure 3.16). DKK protein release was
also measured. Results are presented in Figure 3.17: 10 ng/ml TGFpi does not
significantly inhibit DICK protein release until 24 h after treatment (p<0.001, n = 5)
(Figure 3.17). This shows some discrepancy from mRNA data in Figure 3.16,
although it can be explained by the normal mRNA and protein kinetics, in that any
changes in mRNA levels would be detected prior to protein changes.
Chapter 3 Impact of TGFp on gene expression in
non-decidualised and decidualised stromal cells
145
1.25-1
Control 2 h 12 h 24 h 36 h 48 h 72 h
TGF(]1 - + + + + + +
Figure 3.16: Time course of DKK mRNA expression in cultured ESC ± TGFpi
measured by Q-RT-PCR. TGFpi downregulates DKK mRNA in a biphasic manner
in primary ESC. Results are ± SEM. * = p<0.05, *** = p<0.001, n = 5 endometrial
samples.
Control 2 h 12 h 24 h 36 h 48 h 72 h
TGF(31 - + + + + + +
Figure 3.17: Time course of DKK protein release in cultured ESC +/- TGF(11
measured by ELISA. TGFfll significantly reduces protein release of DKK over a
period of 24 h, 36 h and 48 h (** = p<0.01, *** = p<0.001), but displays a return to
control levels if cultured for 72 h or more. Results are ± SEM. n = 5 endometrial
samples.
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3.3.6.2 Decidualised ESC
To further address the role of TGFpi in regulation of DKK expression, ESC were
cultured, decidualised in vitro with 8-Br-cAMP (0.5 mM) and MPA (1 pM)
(decidualising medium) for 6 d and then further cultured with decidualising medium
to maintain the decidualised phenotype with or without the addition of TGF(31 for a
maximum of 72 h. Results are presented in Figure 3.18. TGF(31 significantly
downregulates DKK mRNA expression over a period of 24 h (p<0.05, n = 5) (Figure
3.18) but displays a return to control levels if cultured for 48 h or more (Figure 3.18).
Protein release was also measured in the same samples as shown in Figure 3.19: 10
ng/ml TGFpl significantly reduces protein release of DKK in a time-dependent
manner over a period of 48 h (p<0.001, n = 5) (Figure 3.19). Downregulation of
DKK is seen at 72 h also (p<0.001, n=5). It is also apparent from comparison of
Figures 3.17 and 3.19 that DKK production is upregulated with decidualisation; non
decidualised cells release approximately 2000 pg/ml DKK (Figure 3.17) whereas
decidualised cells release approximately 8500 pg/ml DKK protein (Figure 3.19).
This is further corroborated by results presented in Figure 3.21; treatment with
decidualising medium significantly upregulated protein release of DKK after 72 h
(p<0.001, n = 5) (Figure 3.21). No results are available for 36 h time point in
decidualised cells as these cells became infected during the experiment. The
remainder of cells were infection-free.
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Figure 3.18: Time course ofDKK mRNA expression in decidualised ESC +/-TGF(31
measured by Q-RT-PCR. TGF(31 reduces expression of DKK mRNA over a period
of 24 h, but displays a return to control levels if cultured for 48 h or more. Results
are ± SEM. (p<0.05) n = 5 endometrial samples.
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Figure 3.19: Time course of DKK protein release in cultured ESC, decidualised in
vitro +/-TGFpi (10 ng/ml) quantified by ETISA. TGFpi significantly reduces
protein release ofDKK in a time-dependent manner over a period of 48 h (p<0.001).
Downregulation of DKK is seen at 72 h also (p<0.001). Results are ± SEM. n = 5
endometrial samples.
Chapter 3 Impact of TGFf> on gene expression in
non-decidualised and decidualised stromal cells
148
3.3.7 Blocking endogenous TGF(31 action
In an attempt to elucidate if blocking endogenous TGF(31 production would negate
the TGFpl-induced responses, ESC were cultured in the presence and absence of
decidualising medium for 6 d and then further cultured with decidualising medium to
maintain the decidualised phenotype in the presence or absence of TGFpi (10 ng/ml)
or anti-TGFpi antibody (1 pg/ml) for 72 h. As previously observed, TGFfU
significantly downregulated expression of PR mRNA (Figure 3.20). In contrast,
treatment with anti-TGFpi neutralises endogenous TGFpl and significantly
increased expression of PR mRNA (Figure 3.20) (p<0.001, n = 5). Protein release of
DKK was also measured; TGFJ31 significantly downregulated protein release of
DKK (Figure 3.21). Treatment with anti-TGF(31 neutralises endogenous TGF(31 and
significantly increased protein release of DKK (Figure 3.21) (p<0.001, n = 5).
Treatment with the isotype control, Mouse IgGl, evoked no response in either PR
mRNA expression or DKK protein release (Figures 3.20 and 3.21, respectively).
TGFpi + anti-TGFpi was not included as a treatment as it would be extremely
difficult to neutralise 10 ng/ml TGFfll and therefore any results obtained would be
inconclusive.
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Figure 3.20: Cultured ESC were decidualised in vitro +/- TGFpi-treatment. To
confirm the specificity of the TGFpi response anti-TGFp 1 (1 pg/ml) or mouse IgG
control was added, for 72 h. TGFpi reduces expression of mRNA nuclear PR, whilst
anti-TGFp 1 antibody increases nuclear PR. Results are ± SEM. (p<0.05) n = 5
endometrial samples.




Figure 3.21: Cultured ESC were decidualised in vitro +/- TGFpi-treatment. To
confirm the specificity of the TGFpi response anti-TGFp 1 (1 pg/ml) or mouse IgG
control was added, for 72 h. TGFpi reduces protein expression of DKK, whilst anti-
TGFp 1 antibody increases DKK. Results are ± SEM (p<0.05). n = 5 endometrial
samples.
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3.3.8 TGFpl signals via the SMAD-signalling pathway in non-
decidualised and decidualised ESC
To confirm that TGF(31 was signalling via the SMAD-signalling pathway, primary
ESC were cultured in the presence and absence of decidualising medium for 6 d and
then further cultured with decidualising medium to maintain the decidualised
phenotype in the presence or absence of TGF(T1 (10 ng/ml) or anti-TGFpi antibody
(1 pg/ml) for 72 h, prior to measuring any changes in phosphorylated SMAD 2 (p-
SMAD 2) protein expression. Changes in protein expression were detected by
Western blotting and immunocytofluorescence (ICF) (Figures 3.22 and 3.23
respectively). Consistent with successful TGF(3-signalling mediated via the SMAD-
signalling pathway, p-SMAD 2 protein expression is upregulated at every time point
in both non-decidualised and decidualised ESC (Figure 3.22). This is in agreement
with immunocytofluorescence staining (Figure 3.23). Panels I and III depict ICF on
control cells, panel III is a larger viewfield of panel I. Panels II and IV depict ICF on
TGF(31-treated cells, panel IV is a larger view field of panel II. Deciphering staining
intensities with the naked eye can be very subjective, for this reason the images were
quantitatively analysed as described in section 2.6.10.11. Results are presented in
Figure 3.24; 10 ng/ml TGFpi significantly upregulated p-SMAD 2 protein
expression in primary ESC (p<0.001, n = 3).
12 h 36 h 72 h
TGFp-1: T 1 1 +~" ~ + 1 +~"
cAMPfMPA: - - + + -- + +- - + +
p-SMAD 2
p-actin
Figure 3.22: Nuclear lysates from untreated primary ESC or cultures decidualised in
vitro for 12, 36 or 72 h, +/- TGFJ31 (10 ng/ml), were subjected to western blotting
analysis. Marius Jones performed this nuclear protein extraction and Western Blot in
Jan Brosens lab group, n = 5 endometrial samples.
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Figure 3.23: Immunocytofluorescence analysis of phosphorylated SMAD 2 (p-
SMAD 2) expression in control and TGFpi -treated ESC. p-SMAD 2
immunostaining in I; ESC without treatment, II; ESC + TGFpi (10 ng/ml), III; ESC
without treatment, larger view field, IV; ESC + TGFpi (10 ng/ml), larger view field.
Chapter 3 Impact of TGF(3 on gene expression in


















Figure 3.24: Quantitative analysis of average optical intensity of p-SMAD 2. 15
control and 15 TGFpi- treated ESCs (10 ng/ml) were analysed from each
endometrial biopsy. All settings were identical for control and treated cells. TGFpi
significantly upregulated p-SMAD 2 protein expression (p<0.001). n = 5 endometrial
biopsies.
3.3.9 Effect of abrogating the SMAD signalling pathway on
TGFpi - induced responses
SMAD 4 siRNA was used to investigate if selectively silencing the SMAD signalling
pathway would abrogate the TGFpi-induced responses. ESCs were transiently
transfected as detailed in Table 3.16. Successful silencing was assessed by detecting
the SMAD 4 mRNA and protein levels by non-quantitative PCR and Western
blotting respectively. SMAD 4 mRNA was detected in all samples (Figure 3.25,
Panel A). Sample 1 represents mock transfected cells. Sample 2 represents cells
transfected with control siRNA (a non-targeting siRNA). Sample 3 represents cells
transfected with SMAD 4 siRNA. Samples 2 and 3 were subsequently treated with
decidualising stimuli, 8-Br-cAMP (0.5 mM) and MPA (1 pM). Sample 4 represents
cells transfected with control siRNA, sample 5 represents cells transfected with
SMAD 4 siRNA and subsequently treated with decidualising stimuli and TGFpl (10
ng/ml). SMAD 4 mRNA would appear to be more pronounced in response to TGFpi
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treatment, as seen in sample 4, than in any other sample (Figure 3.25). When SMAD
4 siRNA is introduced to the cell the TGF(J1 -induced upregulation of SMAD 4 is not
seen (sample 5), however, there is still evidence of mRNA present (Figure 3.25).
Panel B shows the same samples analysed using primers directed against GAPDH,
which was used as an internal control for integrity of the RNA samples. Protein
analysis of the same treatments demonstrated effective silencing of SMAD 4 when
cells were transfected with SMAD 4 siRNA (Figure 3.26). Treatment with TGFfll
did not induce SMAD 4 protein expression in cells previously transfected with
SMAD 4 siRNA (Figure 3.26).
To elucidate if silencing SMAD 4 would abrogate the TGFfll-induced effect on PR
mRNA levels were measured. Results are presented in Figure 3.27; interestingly
treatment with cAMP and MPA evoked an increase in PR mRNA expression (Figure
3.27). This has not been observed previously. It is acknowledged that these data are
derived from a single experiment and require further confirmation. A significant
reduction in PR mRNA was observed in samples transfected with either the non-
targeting siRNA or the SMAD 4-specific siRNA (pcO.OOl) (Figure 3.27),
consequently, the treatments could not be analysed with regard to SMAD 4
dependent TGFfl-mediated PR downregulation. No significant reduction in PR
mRNA was observed with samples transfected with SMAD 4 siRNA when compared
to the non-targeting transfected samples (Figure 3.27). The transient transfection,
treatment of the cells and Western blot was performed by Marius Jones in Jan
Brosen'slab.
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Figure 3.25: Semi-quantitative PCR of SMAD 4. Sample 1 represents mock
transfected cells. Sample 2 represents cells transfected with control siRNA (a non-
targeting siRNA). Sample 3 represents cells transfected with SMAD 4 siRNA.
Samples 2 and 3 were subsequently treated with decidualising stimuli, 8-Br-cAMP
(0.5 mM) and MPA (1 pM). Sample 4 represents cells transfected with control
siRNA, sample 5 represents cells transfected with SMAD 4 siRNA and subsequently











Figure 3.26: Whole cell lysates from primary ESC transiently transfected with either
control siRNA or SMAD 4 siRNA subsequently cultured for 72 h, +/- 8-Br-cAMP
(0.5 mM) and MPA (1 pM) +/- TGF|31 (10 ng/ml), were subjected to Western
blotting analysis. Marius Jones performed this protein extraction and Western Blot in
Jan Brosens lab group.
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Figure 3.27: Cultured ESCs were transiently transfected with either control siRNA
or SMAD 4 siRNA and subsequently cultured for 72 h, +/- 8-Br-cAMP (0.5 mM)
and MPA (1 pM) +/- TGF(!1 (10 ng/ml). Treatment with decidualising stimuli
evoked an increase in PR mRNA. A significant reduction was observed with samples
transfected with the non-targeting siRNA and SMAD 4 siRNA, both treated with and
without TGF|31 (p<0.001). No significant difference was observed between samples
transfected with the non-targeting siRNA and the SMAD 4 siRNA. n = 1 endometrial
sample.
3.4 Discussion
The post-ovulatory rise in progesterone, acting via the nuclear progesterone receptor
(PR) (Conneely, Lydon et al. 2000; Mulac-Jericevic, Mullinax et al. 2000), induces
profound phenotypical and morphological remodelling of the E2-primed
endometrium resulting in decidualisation. Decidualisation is characterised by the
transformation of elongated fibroblast-like phenotype of endometrial stromal cells
(ESC) to a larger, spherical decidual cell coupled with the coordinate expression of
decidualisation products such as IGFBP-1 (Bell, Jackson et al. 1991; Bryant-
Greenwood, Rutanen et al. 1993). Several studies provide evidence that progesterone
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interacts with other factors e.g. cAMP, to mediate its effect on differentiating
endometrial stroma (Gellersen, Kempf et al. 1994; Brar, Frank et al. 1997; Brosens,
Hayashi et al. 1999; Mote, Balleine et al. 2000; Mak, Brosens et al. 2002). In this
study primary ESCs were treated with 8-Br-cAMP and MPA to induce a
decidualised phenotype. Herein successful in vitro decidualisation, as measured by
increase in IGFBP-1 mRNA and protein release (p<0.05 and p<0.001 respectively, n
= 4 endometrial samples) has been demonstrated (Figures 3.2 - 3.3).
Previous studies have identified that endometrial tissues as well as endometrial
stromal cells in culture express TGF(1 type I and type II receptor mRNA and protein
(Chegini, Zhao et al. 1994; Tang, Zhao et al. 1994; Dumont, O'Connor-McCourt et
al. 1995; Piestrzeniewicz-Ulanska, Brys et al. 2002). The results in this study are in
agreement with previous findings and demonstrated that cultured stromal cells (both
non-decidualised and decidualised) express the mRNA for type I receptors (Figure
3.24 and 3.25). It has previously been reported that the level of TGFpl mRNA is
higher in 1st trimester decidua as compared to endometrial tissue from the
proliferative and secretory phases of the menstrual cycle (Kauma, Matt et al. 1990;
Selick, Horowitz et al. 1994) and TGFfl type I receptors have been identified in term
placenta (Dungy, Siddiqi et al. 1991; Mitchell and O'Connor-McCourt 1991;
Mitchell, Fitz-Gibbon et al. 1992; Schilling and Yeh 2000). Initially it would appear,
in this study, that decidualised cells have higher levels of TGF|3 type I mRNA than
non-decidualised cells (Figure 3.4) however with quantitative analysis there is no
significant difference (Figure 3.5). The data from this study would suggest that
TGF(3 type I mRNA levels do not change in decidualised cells in vitro. This is in
contrast to recent immunohistological findings (Kim, Park et al. 2005) which state
that protein levels of both TGF(5 type I and type II receptors is significantly
upregulated in the stromal compartment within the secretory endometrium. The
tissue sections used in that study (Kim, Park et al. 2005) were not classified into
early, mid and late proliferative and secretory phases, so it is impossible to ascertain
if the upregulation in the recptors was associated with decidualisation of the stroma,
or just with increasing progesterone levels. To date, no data are presented to either
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confirm or refute any alteration in receptor level with pregnancy. The presence of the
receptors on the cells suggests that TGF|31 can form the signalling receptor complex
to mediate its biological effects locally not only in the culture system but also in vivo.
The initial objective was to identify whether TGFpl was responsible for the
myofibroblast differentiation associated with the perivascular stromal cells. With this
in mind, the ESCs were treated with TGFfll, a known inducer of SMAa (Koumas,
Smith et al. 2003). In this study, expression of SMAa did not significantly increase
in non-decidualised or decidualised cells until 36 h (p<0.001 and p<0.01
respectively, n = 9 endometrial samples) and this increase was maintained over a
period of 48 and 72 h of TGF(31 treatment compared with controls (p<0.001, n = 9
endometrial samples) (Figures 3.7 and 3.8). This is in agreement with Grotendorst et
al (Grotendorst, Rahmanie et al. 2004) who have also shown that fibroblast cells
treated with TGFpl were SMAa positive with maximal SMAa protein expression
observed at 36 h.
Prior to treatment with TGF(!1, we measured the correlation between endogenous
TGF(f l and endogenous SMAa expression in control ESC and found there to be a
strong, positive, significant correlation between the two (r=0.7459, n = 9 endometrial
samples) (Figure 3.9) suggesting that whilst both SMAa and TGFpl are present in
the cells prior to any TGF|31 treatment, further treatment with TGFfll can potentiate
SMAa expression.
We report that TGF(31 significantly inhibits mRNA and protein expression of PR in
both non-decidualised and decidualised endometrial stromal cells in a time-
dependent manner after an initial significant upregulation over a period of 2 h
(Figures 3.10 -3.14). No explanation has been elucidated for the initial upregulation
of PR at 2 h, but we have postulated that this could be attributed to the putative non-
genomic PRs that have recently been identified (Losel and Wehling 2003; Zhu, Bond
et al. 2003). The results presented herein demonstrated that this inhibition is not
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attributable to TGF|31 preventing PR gene transcription as presented in Figure 3.15.
Several studies have reported that PR is under dual control of both oestradiol and
progesterone acting at the oestrogen and progesterone response elements (Savouret,
Bailly et al. 1991; Tseng and Zhu 1997; Tang, Mazella et al. 2002). We have
demonstrated that our transient transfection of PRE and ERE into ESC was
successful, as assessed by reporter gene assays (Figure 3.15). When treated with the
appropriate steroid receptor-agonist, luciferase activity was increased demonstrating
functionality of the response elements (Figure 3.15). Furthermore, when TGFjll was
introduced into the culture it did not activate reporter activity and when introduced in
combination with the steroid receptor-agonist it did not have any effect on reporter
activity (Figure 3.15). In addition, TGF(31 was without effect on specific steroid
receptor-agonists binding to the ARE and GRE (which are identical to the PRE)
(Figure 3.15). We have also demonstrated that ESCs contain endogenous TGF|31 and
neutralising this will negate any TGFpl-induced effects, providing conclusive
evidence that the downregulation of PR is TGFpi-specific (Figure 3.20). This is the
first evidence of TGF|31 acting as a progesterone receptor modulator to inhibit
mRNA and protein expression of PR.
Previous studies have reported that TGF(31 inhibited expression of progesterone-
induced genes e.g enkephalinase (Casey and MacDonald 1996) which acts to
degrade bioactive peptides, and endothelin-1 (ET-1), a potent vasoconstrictor
implicated in promotion of vasospasm in the spiral arterioles just prior to menses. It
has been suggested that whilst TGFfll promotes selective progesterone-induced
modifications it opposes others, implying that TGFpl acts as a PR-independent, gene
specific anti-progestin though evidence to support such suggestions is scant. Further
evidence to support a relationship between progesterone and TGFp i are provided in
previous findings from Bruner et al (Bruner, Eisenberg et al. 1999), who report that
TGFfll and progesterone are intimately involved in the prevention of experimental
endometriosis in the nude mouse model. This may be due to impairment of MMP
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regulation and had lead to the suggestion that TGFpi could be used for treatment of
endometriosis (Dou, Williams et al. 1997).
In the studies presented herein, TGFpi upregulates protein expression of PIAS y
(Figure 3.14). This is in agreement with previous studies reporting that TGFpi
induced expression of endogenous PIAS y (Imoto, Sugiyama et al. 2003). PIAS y is
reported to inhibit SMAD transcriptional activity and other transcriptional responses.
PIAS y does not inhibit SMAD complex binding to DNA, but it represses SMAD
transcriptional activity (Imoto, Sugiyama et al. 2003). Interestingly, other studies
have elucidated that conditional overexpression of PIAS y selectively inhibits a
subset of endogenous TGF-beta-responsive genes, which includes PAI-1 further
providing evidence for the negative-feedback that TGFpi has on its own production
(Long, Matsuura et al. 2003). The story becomes more complex as recent studies
have demonstrated that PIAS y is complexed to the PR in human ESCs and that its
ability to repress STAT1 signalling is dependent upon activation of PR in response to
hormone binding (Zoumpoulidou, Jones et al. 2004). The same study reported that
IFNy and PIAS y synergistically inhibited PR-dependent transcription, demonstrating
that the progesterone and IFNy signalling pathways engage in reciprocal
transcriptional antagonism in human endometrium (Zoumpoulidou, Jones et al.
2004). The influx of uNK cells in the early secretory phase of the cycle coincides
with an acute increase in endometrial IFNy expression, a Th 1 -type cytokine strongly
implicated in effecting vascular remodelling necessary for embryo implantation and
subsequent placenta formation (Ashkar, Di Santo et al. 2000; Ashkar and Croy 2001;
Ashkar, Black et al. 2003; Croy, Esadeg et al. 2003). IFNy inhibits the TGF(J-
induced phosphorylation of SMAD3 and its attendant events, namely, the association
of SMAD 3 with SMAD 4, the accumulation of SMAD 3 in the nucleus, and the
activation of TGFp-responsive genes. Acting through its associated protein tyrosine
kinase, Jakl, and Statl, IFNy induces the expression of SMAD 7, an antagonistic
SMAD, which prevents the interaction of SMAD 3 with the TGFp receptors (Ulloa,
Doody et al. 1999; Eickelberg, Pansky et al. 2001). A more recent study has
elucidated that IFNy interferes with TGFp-signalling via direct interaction of Y-box-
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binding protein (YB-1) with SMAD 3 to prevent subsequent translocation to the
nucleus and TGF(3-induced gene transcription (Higashi, Inagaki et al. 2003). TGFpi
may act to upregulate PIAS y, which is complexed to PR, to interact with IFNy,
present in the late-secretory phase, to inhibit further production or activation of
TGF|31, hence limiting its own biological actions. Furthermore, in our findings PIAS
y protein expression is only modestly upregulated after 72 h, implying that its
regulatory effects on TGFpl function are delayed (Figure 3.14). Recent evidence
suggests that PLAS y also represses other transcription factors, including the activated
androgen receptor (AR), independent of its SUMO ligase activity (Gross, Yang et al.
2004).
Interestingly a recent study has provided evidence that DKK is up-regulated in
decidualising endometrial stromal cells during the secretory phase of the menstrual
cycle, suggesting regulation by progesterone (Giudice 2004). This finding was
supported by data from in vitro culture of ESC, showing upregulation by
progesterone of DKK mRNA synthesis and protein expression (Tulac, Overgaard et
al. 2006). It was also reported that the response could be abrogated by the
introduction of RU486 or progesterone withdrawal in long-term cultures, thereby
providing evidence that DKK upregulation is mediated specifically by progesterone
and independent of cAMP and oestradiol (Tulac, Overgaard et al. 2006). We are in
agreement with findings from Tulac et al and have demonstrated significant DKK
protein release with decidualisation in ESC (p<0.001, n = 6 endometrial samples)
(Figures 3.19 and 3.21). Accumulating data would suggest a role for DKK in
promoting cellular differentiation. It has been reported that Wnt-signalling in
maturing osteoblasts needs to be downregulated to enable the formation of a
mineralised bone matrix, and that this is, in part, due to DKK function (van der
Horst, van der Werf et al. 2005). A recent study has reported that DKK, is secreted
by human preadipocytes and promotes adipogenesis (Christodoulides, Laudes et al.
2006) further adding to the evidence that the normal Wnt-signalling pathway is
involved in proliferation and that antagonism of the pathway by DKK promotes
differentiation. The data herein demonstrate that TGF(31 significantly downregulates
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DKK mRNA expression in a biphasic manner (pcO.OOl, n=6 endometrial samples)
(Figure 3.16) and downregulates protein release (pcO.OOl, n = 6 endometrial
samples) (Figure 3.17) in non decidualised cells. The present studies also
demonstrate that TGFpi significantly downregulates DKK mRNA expression in
decidualised ESCs over a period of 24 h and 36 h, after which mRNA levels return to
control (p<0.05, n= 6 endometrial samples) (Figure 3.18). Protein release was also
significantly downregulated, but at a slower rate consistent with the expected mRNA
and protein kinetics (pcO.OOl, n=6 endometrial samples) (Figure 3.19). This response
is TGFpi specific as abolishing endogenous TGFpi prevents downregulation of
DKK protein release (Figure 3.21). The present results show that TGFpi
downregulates DKK mRNA before it downregulates PR mRNA. If DKK is indeed
involved in decidualisation then perhaps this initial inhibition heralds the onset of
TGFpi-induced abrogation of the decidualised phenotype in the ESC.
SMAD proteins transduce signals from TGFp binding to its serine/threonine kinase
receptors to regulate its biological actions (Graff, Bansal et al. 1996; Zhang, Feng et
al. 1996; Liu, Sun et al. 1997; Nakao, Roijer et al. 1997). The findings herein are in
agreement with those of (Graff, Bansal et al. 1996; Zhang, Feng et al. 1996; Liu, Sun
et al. 1997; Nakao, Roijer et al. 1997) who have reported that SMAD 2 and SMAD 3
are rapidly phosphorylated in response to TGFP signalling (Figures 3.22 - 3.24). To
determine if the TGFp-induced responses we have observed are mediated via the
SMAD-signalling pathway we attempted to selectively silence SMAD 4. Our
silencing was successful as shown in Figures 3.25 and 3.26. However, it is
impossible to determine whether the TGFpi-induced downregulation of PR is
SMAD dependent as the cells that had been transfected with the non-targeting
siRNA demonstrated a significant reduction in the expression of PR mRNA (Figure
3.27). Some recent publications have focused on this "off-target gene regulation" of
the non-targeting siRNA, and several groups are concentrating on designing an
effective non-targeting siRNA devoid of any "off-targeting" properties (Jackson,
Bartz et al. 2003; Birmingham, Anderson et al. 2006; Fedorov, Anderson et al.
2006).
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To summarise, the studies performed in this chapter have demonstrated that TGFpi
binds to its receptors in the ESC, both non-decidualised and decidualised, to promote
myofibroblast differentiation, downregulation of PR at a transcript and protein level,
induction of PIAS y and inhibition of DKK, and induces phosphorylation of SMAD
2, required for propagating its effects via the SMAD-signalling pathway. These
effects have potential consequences for regulating processes such as decidualisation,
perhaps by inducing the Wnt-signalling pathway, and in the absence of pregnancy,
menstruation.








Decidualisation, the process by which progesterone acts on the oestrogen-primed
endometrium to convert precursor stromal cells to decidual cells, epitomises the
extensive sequential development of the human endometrium essential for successful
implantation and continued pregnancy (Milligan, Cohen et al. 1995; Wilcox, Baird et
al. 1999; King 2000; Lessey 2000). This decidualisation reaction is initiated in the
perivascular stromal cells and under the continued influence of progesterone, spreads
wave-like throughout the stromal region, occurring independently of the presence of
a blastocyst, or with successful implantation, contributing to the formation of decidua
in pregnancy (Bell 1990). Decidualisation is characterised by the transformation of
the elongated fibroblast-like phenotype of endometrial stromal cells (ESC) to a
larger, spherical decidual cell with intracellular structural rearrangements and
concomittantly increasing stromal population. Studies in vitro on primary cultures of
human endometrial stromal cells (ESCs) have revealed that this process is complex
and likely to involve factors such as PGE2 (Frank, Brar et al. 1994), relaxin
(Tabanelli, Tang et al. 1992; Lane, Oxberry et al. 1994) and cAMP (Tang, Guller et
al. 1993; Yee and Kennedy 1993; Gellersen, Kempf et al. 1994; Brar, Frank et al.
1997; Brosens, Hayashi et al. 1999; Mote, Balleine et al. 2000; Mak, Brosens et al.
2002) in addition to progesterone. The relative activities of the endometrial cells and
their mediators may regulate the balance between tissue formation and breakdown.
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4.1.2 Decidualised stromal cell functions
The decidualised stroma undertakes more extensive functions than a mere supportive
structural role and a strong association exists between the degree of trophoblast
invasion and the extent of decidualisation in species with a hemochorial placenta
(Finn 1996). Not only does human trophoblast exhibit the greatest degree of
trophoblast invasion seen in all species, but human endometrium undergoes the most
extensive decidualisation reaction (Ramsey, Houston et al. 1976; Bell 1990).
Decidualised stromal cells are temporally and spatially positioned to promote local
homeostasis during implantation and counteract the threat of haemorrhage during
trophoblast invasion (Lockwood, Krikun et al. 1999). Progesterone receptor knock¬
out mice fail to exhibit decidualisation and this is associated with implantation
failure (Rider 2002). Trophoblast invasion in humans is significantly deeper in areas
where the uterus is deficient in decidua caused by scar tissue (King and Loke 1999;
Moffett and Loke 2006). Imbalances in implantation and placentation can result in
abnormal placentation and the later development of pre-eclampsia (Loke and King
1997) highlighting the necessity for tight regulation of these events. Decidual cells
are also thought to be important in preventing uterine bleeding in the peri-
implantation phase of the cycle (Schatz, Krikun et al. 2001).
4.1.3 Decidualisation and menstruation
A previous study has argued that menstruation appears to only occur in species in
which the decidualisation reaction in initiated spontaneously within the cycle in the
absence of a blastocyst (Finn 1987). In the non-pregnant endometrium the
interruption of the processes of decidualisation by steroid removal contributes to the
process of menstruation. The concept that loss of decidual cell function promotes
tissue breakdown mediated via loss of tissue breakdown suppressive properties or
direct activation of tissue breakdown activity was proposed by Bell et al (Bell 1990).
Although the classic "trigger" for the onset of menstruation is the withdrawal of
progesterone, multiple cytokines and growth factors have been reported to play a role
in this event e.g IL-1, IL-8 and PGs (Pickles 1967; Rampart, Van Damme et al. 1989;
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Critchley, Kelly et al. 1994; Baird, Cameron et al. 1996; Singer, Marbaix et al. 1997;
Milne, Critchley et al. 1999). Another potential candidate is transforming growth
factor pi (TGFpi), which was the subject of studies described in chapter three. It is
notable that several studies have reported a marked inhibitory effect of TGFpi on
basal and stimulated PRL secretion, mRNA levels and de novo PRL synthesis in rat
anterior pituitary cells (Herrlich, Kuhn et al. 1996; Telgmann, Maronde et al. 1997;
Coya, Alvarez et al. 1999), indicating a potential inhibitory regulatory role for
TGFpi.
A better understanding of the local mechanisms involved in the regulation of
endometrial events involved in menstruation is essential to understand the
mechanisms involved in aberrant and abnormal bleeding associated with distressing
menstrual disorders such as menhorragia (heavy menstrual bleeding) and
dysmenhorrea (painful periods) and early pregnancy complications. In the current
study we have therefore investigated the possibility that TGFpi may be involved in
the initiation of menstruation by inhibiting expression and function of decidualisation
products such as prolactin, IGFBP-1 and tissue factor.
4.1.4 Hypothesis
Although the studies in Chapter 3 have demonstrated that TGFpi is capable of
inhibiting the mediators of decidualisation, PR and DKK, the effect of TGFpi on the
classical decidualisation marker proteins; tissue factor (TF) (Lockwood, Krikun et al.
1994), IGFBP-1 (Irwin, Kirk et al. 1989) and dPRL (Maslar and Riddick 1979) is
unknown. We hypothesise that TGFpi may suppress the production of the
decidualisation marker proteins and therefore may play a role in the onset of
menstruation.




The studies described in this chapter were designed to determine the effect of TGFp
on gene expression of decidualisation marker proteins. All studies utilised primary
endometrial stromal cells isolated from non-pregnant endometrium and 1st trimester
decidua as described in section 2.1 and 4.2.1.2 respectively. Experiments in this
chapter were designed to address the following questions:
1: Recent studies have identified TGFpi as an in vitro inhibitor of pituitary prolactin
(Herrlich, Kuhn et al. 1996; Telgmann, Maronde et al. 1997; Coya, Alvarez et al.
1999) however, does TGFpi inhibit the expression of the decidualisation markers
decidual prolactin (dPRL), IGFBP-1 and TF in ESCs, decidualised in vitro?
Furthermore, does neutralising endogenous TGFpi negate any TGFpi-induced
responses?
2: Does TGFpi interact with the dPRL promoter to inhibit decidualisation by
preventing transcription of the prolactin gene?
3: Is the current well-characterised model of decidualisation the best in vitro model
with which to evaluate regulation of decidualisation markers?
4: Does TGFpi inhibit the expression of the decidualisation markers prolactin,
IGFBP-1 and TF in decidual stromal cells (DSC) obtained from 1st trimester
decidua?
5: Can selectively silencing SMAD 4, discussed in section 3.3.9, prevent any
TGFpi-induced responses?




4.2.1 Human uterine tissue collection
4.2.1.1 Endometrium from non pregnant women
Endometrial (n = 18) samples were collected as detailed in section 2.1.1 (Table 2.1a).
Endometrial biopsies utilised in this chapter are detailed in Table 4.1. All
endometrial samples were processed to isolate the stromal compartment from the
glands, as described in section 2.2. Biopsies were collected with an endometrial
suction curette (Pipelle, Laboratoire CCD) or alternatively, full thickness endometrial
samples were obtained. Such tissue samples included superficial and basal
endometrium plus the endometrial-myometrial junction. All women described
regular menstrual cycles (25-35 days) and had not received any form of exogenous
hormonal treatment in the 3 months preceding biopsy. Biopsies were dated according
to the patient's reported last menstrual period (LMP) and only included for analysis
if the histological dating according to published criteria (Noyes, Hertig et al. 1950)
and circulating sex steroid concentrations (E2 and P at time of endometrial biopsy)
were consistent with the LMP. Serum was separated (by centrifugation at 800 g for
7 min) from venous blood samples collected at the time of biopsy and oestradiol (E2)
and progesterone (P) concentrations were measured by radioimmunoassay.
4.2.1.2 Tissue Collection and processing of human decidual tissue
Decidual (n = 11) samples were collected as detailed in section 2.1.1 (Table 2.1b).
Decidual biopsies utilised in this chapter are detailed in Table 4.2. All decidual
samples were processed to isolate the stromal compartment, depleted of CD56bnght
uterine natural killer cells (uNKs), from the glands. Decidual tissue was finely
minced into 1 cm3 sections using surgical blades (Swann) and residual blood clots
were removed. Approximately 10 g of the minced tissue was placed in 20 ml of
RPMI with 10 % FCS, 4 ml of collagenase (2 mg/ml) and 0.5 ml of DNAse (0.1
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mg/ml; Sigma) for 1 h 20 min on a roller at 37 °C. After digestion, 30 ml of RPMI10
% FCS was added and the mixture was left to stand for 5 min to allow sedimentation.
The supernatant was decanted by aspiration and passed sequentially through 73 pm
and 40 pm filters (VWR). The filtrate was centrifuged at 400 g for 5 min and the
resulting cell pellet was resuspended in 15 ml of PBS supplemented with 2 % FCS
and 0.1 % NaN3 and subsequently overlaid onto 15 ml of Lymphoprep™ (Axis-
Shield, Oslo, Norway) before further centrifugation at 710 g for 20 min with no
brake. The cells at the interface were collected; these consisted of 60 to 80 % uNKs,
5 - 15 % CD14+ macrophages and 10 to 20 % T cells plus some stromal and
epithelial cells. The cells were washed in 20 ml of RPMI 10% FCS and pelleted by
centrifugation at 710 g for 5 min. CD56bnght uNKs were further purified by positive
selection using CD56 antibody-coated magnetic Microbeads and a magnet assisted
cell separation (MACS®) (Miltenyi Biotec Ltd, Surrey, UK) protocol, detailed in
section 5.2.1. After removing the uNKs from the cell preparation the remaining cells
were transferred to a 75 cm3 cell culture flask in 10 ml of RPMI 10 FCS and
incubated at 37°C in a humidified atmosphere of 5 % CO2. After 24 hours the media
was changed and the non-adherent cells discarded. The adherent cells, the decidual
stromal cells (DSC), were allowed to attain confluence and used for experimentation
at 1st passage.














1 37 6 215 1.8 17
2 33 11 373 1.8 17
3 39 13 964 3.9 17
4 37 7 234 1.7 17
5 33 6 255 2.8 17
6 44 13 359 1.8 17
7 39 10 835 10.14 17
8 42 14 478 23.66 17
9 41 9 1002 13.68 17
10 37 10 N/A N/A 17
11 38 10 353 63 17
12 47 11 1796 2.32 17
13 30 4 242 6.15 40
14 43 8 581 68.94 17
15 32 12 1651 4.04 17
16 40 12 667.03 10.86 17
17 42 8 208.52 0.88 17
18 35 9 278.52 2.45 17
Table 4.1: Details of biopsies used in the studies presented in Chapter 4.
Patient Age D.O.C Gestation
(Wks+day)
Ethics No
1 21 28/9/05 8 05/sl 104/12
2 30 28/9/05 9+2 05/sll04/12
3 18 29/9/05 8+5 05/S1104/12
4 20 4/10/05 9.3 05/sl 104/12
5 24 4/10/05 8.3 05/sl 104/12
6 30 12/10/05 9.3 05/S1104/12
7 24 12/10/05 9.6 05/sl 104/12
8 27 26/10/05 11+1 05/sl104/12
9 28 28/11/05 10+2 05/S1104/12
10 23 29/11/05 11 05/sl 104/12
11 24 2/12/05 10+3 05/S1104/12
Table 4.2: Details of 1st trimester decidual biopsies used in the studies presented in
Chapter 4. D.O.C. = Date of Collection.
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4.2.2 In vitro primary cell culture experiments
ESCs were maintained at 37°C in 5 % (v/v) CO2 in RPMI 1640 medium (Sigma)
supplemented with 10 % FCS (Mycoplex), penicillin (50 pg/ml; Sigma),
streptomycin (50 pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma). Passaging of the
cells was performed every 3-4 days by trypsinisation (section 2.2). The cells were
seeded in 6-well plates at a concentration of 2.5 x 105 cells/ml and allowed to adhere
and attain 90 % confluence: 24 h prior to treatment the media was changed to 2 %
FCS RPMI. Decidualisation of the cells was induced with decidualising medium
(DM) for 6 days, thereafter, the cells were treated with 2 % FCS RPMI 1640 and DM
containing TGFpi. Tables 4.3-4.6 and 4.8-4.9 detail the treatment regimes utilised.
Cells were maintained under these conditions for up to 72 h. Each treatment was
duplicated and each experiment was repeated 3-9 times with separate endometrial
biopsies.
Experiment 4.1: Does TGFpl interfere with the expression of dPRL in ESC and
DSC, decidualised in vitro?
Treatment Concentration Incubation period
Control N/A 2,12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2, 12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGFpl
1 pM + 250 pM +
10 ng/ml
2,12, 24, 36, 48, 72 h
Table 4.3: Experimental regime for experiment 4.1
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Experiment 4.2: Does TGFpi interfere with the expression of IGFBP-1 in ESC and
DSC, decidualised in vitro?
Treatment Concentration Incubation period
Control N/A 2,12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2,12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGFP1
1 pM + 250 pM +
10 ng/ml
2,12, 24, 36, 48, 72 h
Table 4.4: Experimental regime for experiment 4.2
Experiment 4.3: Does TGF(31 interfere with the expression of TF in ESC and DSC,
decidualised in vitro?
Treatment Concentration Incubation period
Control N/A 2, 12, 24, 36, 48, 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 2, 12, 24, 36, 48, 72 h
MPA+8-Br-cAMP
+TGF|31
1 pM + 250 pM +
10 ng/ml
2,12, 24, 36, 48, 72 h
Table 4.5: Experimental regime for experiment 4.3
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Experiment 4.4: Does neutralising endogenous TGF(31 abrogate TGFpi-induced
responses?
Treatment Concentration Incubation period
Control N/A 72 h
MPA +8-Br-cAMP 1 pM + 250 pM 72 h
MPA+8-Br-cAMP
+TGFP1





1 pM + 250 pM +
2 ng/ml
72 h
Mouse IgGl 72 h
Table 4.6: Experimental regime for experiment 4.4
4.2.3 RNA extraction
Total RNA was extracted from the ESC and DSC cells as described in section 2.3.1
and cDNA prepared from the experiments detailed in Tables 4.3-4.6 and 4.9 as
described in section 2.3.2.
4.2.4 Q-RT-PCR
The relative levels of expression of IGFBP-1, dPRL and TF in ESC and DSC cells,
both control and treated cells (Tables 4.3 - 4.6 and 4.9), were determined using
quantitative RT-PCR (TaqMan) using random primed cDNA as detailed in section
2.4.2.
Results were analysed as in section 2.4.2. Primer pairs and probes specific to each
gene are given in Table 4.7.









































Table 4.7: Primer and probe sequences
4.2.3 Transient transfection
Transient transfections were performed using the reporter vectors: dPRL-3000/luc3,
dPRL-913/luc3, dPRL-601/luc3, dPRL-332/luc3, and dPRL-32/luc3 carrying 3000,
913, 601, 332 and 32 bp, respectively, of 5'-flanking DNA to the decidual-specific
promoter of the hPRL gene, linked to luciferase (section 2.5.1) A P-galactosidase
control vector, (PCH110, Pharmacia), was co-transfected in all cases and used to
measure P-galactosidase to control for transfection efficiency (section 2.5.4).
Transient transfections were performed using the calcium chloride method as
described in section 2.5.2. All transfections were performed in triplicate, using DCC
media, a 1:1 mixture of DMEM and Ham's F12 containing 5% FCS that had been
depleted of steroids by treatment with dextran-coated charcoal, 100 U/ml penicillin,
and 100 pg/ml streptomycin, and supplemented with 10"9 M 1713-oestradiol and 1
fig/ml insulin (section 2.5.2).
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Six hours after transfection the media was replaced with 2% FCS DCC. The
experiments were performed as detailed in Table 4.8. The cells were harvested 48 h
after treatment for analysis with a luciferase assay (section 2.5.3). Tranfection
efficiency was analysed with a P-galactosidase assay (section 2.5.4). The samples
were "normalised" by dividing each sample's luciferase reading with the
corresponding P-galactosidase reading. This numerical reading was used as a
comparison against other samples.
Experiment 4.5: Does TGFpi repress the prolactin promoter transactivation
potential?
Treatment Concentration Incubation period
MPA +8-Br-cAMP 1 pM + 250 pM 72 h
MPA+8-Br-cAMP
+TGFP1
1 pM + 250 pM +
10 ng/ml
72 h
Table 4.8: Experimental regime for experiment 4.5
4.2.4 siRNA for SMAD 4
ESCs were transiently transfected using the calcium phosphate precipitation method,
as previously described in section 2.5.1, with 50 nM of the siRNA reagents
(Dharmacon) detailed in Table 4.9. The RNA and protein content was extracted 72 h
later as described in sections 2.3.1 and 2.6.1 respectively.
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Experiment 4.6: Does interfering with the SMAD signalling pathway inhibit TGF|31-
induced responses?
Treatment Concentration Incubation period























1 pM + 250 pM
10 ng/ml
72 h
Table 4.9: Experimental regime for experiment 4.5
4.2.5 Time-resolved fluoroimmunoassay of prolactin in culture
supernatants
Time-resolved fluoroimmunoassay of prolactin was conducted as described in
section 2.6.8.
Chapter 4 Impact of TGFpi on gene expression of
decidualisation marker proteins
176
4.2.6 Slide preparation and immunohistochemical staining of
cytokeratin
Slides were prepared as described in section 2.6.9.1 and immunohistochemical
staining conducted as detailed in section 2.6.9. Briefly, tissue sections were
incubated with mouse monoclonal anti-cytokeratin antibody (Dako UK Ltd) at a
1:100 diluition in blocking serum (section 2.6.9.5). After incubation with the primary
antibody the slides were washed three times with TBS for 5 min each, and incubated
with the secondary antibody, goat anti mouse biotinylated (Dako UK Ltd) at a
diltution of 1:500 in the blocking serum. Immunolocalised proteins were detected
with DAB.
4.2.7 Viable Cell Counts Using Trypan Blue
Trypan Blue is a vital dye which does not interact with the cell unless the membrane
is damaged. Therefore, all the cells that exclude the dye are viable.
After trypsinisation (section 2.2), the cells were centrifuged at 400 g for 3 min to
pellet the cells. Thereafter, the cells were resuspended in RPMI at a concentration of
2 x 105 cells per ml. 0.1 ml of 0.4 % Trypan Blue Stain (Sigma) was added to the
cells and the solution was vortexed to mix thoroughly. After 5 min at room
temperature the cell preparation was mixed again and 10 pi was added to a cell
counting chamber (SLS, UK). Using a light microsope (Leica), the cells were
observed to determine the number of viable cells.
4.2.8 Statistical Analysis
Prior to statistical analysis, all data were tested for Gaussian distribution. Where
appropriate, values were presented as means ± S.E.M. Significant difference of the
G-RT-PCR, ELISA and transfection data was determined by repeated measures
analysis of variance (ANOVA) using the computer package Prism 4.0. Significant
differences were assigned using Kruskal-Wallis post hoc test. The criterion for
significance for all tests was set at p< 0.05.




4.3.1 TGFpl downregulates the production of decidualisation
products
To determine the role of TGF(31 in mediating decidualisation in the endometrium,
ESC were cultured, decidualised in vitro for 6 d and then further treated with
decidualising medium in the presence or absence of TGFpl (10 ng/ml) for 72 h.
Quantitative RT-PCR analysis revealed that TGF(11 significantly downregulated the
expression of IGFBP-1 mRNA in a time-dependent manner with a 50 % decrease
observed at 48 h (Figure 4.1) (p<0.01, n = 8 endometrial samples) and 72 h (Figure
4.1) (p<0.001, n = 8 endometrial samples) in ESC, decidualised in vitro, as compared
to unstimulated, time-matched controls. Interestingly, it would appear that IGFBP-1
mRNA was potentiated at the 12 h time point; however this was not significant and
may be attributed to the individual variability between samples. This significant
decrease in IGFBP-1 mRNA was also observed in the amount of IGFBP-1 protein
release as detected with a two-site sandwich ELISA (Figure 4.2). Interestingly,
significant inhibition of protein release was seen after only 2 h of TGFpl treatment
and did not return to control levels throughout the duration of the experiment, with a
significant decrease observed at 12 h, 24 h, 48 h and 72 h (Figure 4.2) (All p<0.001,
n = 6 endometrial samples). TGF|31-induced inhibition of dPRL mRNA and protein
release mirrored that of IGFBP-1, with significant inhibition of mRNA levels
observed at 48 h (p<0.001, n = 6 endometrial samples) and 72 h (p<0.001, n = 6
endometrial samples), as measured by Q-RT-PCR (Figure 4.3). Protein release was
significantly suppressed after only 2 h of TGFpl treatment (p<0.05, n = 6
endometrial samples) (Figure 4.4). TGF(31 consistently evoked significant inhibition
of dPRL protein release at all time points; 12 h (p<0.01, n = 6 endometrial samples)
24 h (p<0.05, n = 6 endometrial samples) 48 h (p<0.01, n = 6 endometrial samples)
72 h (p<0.01, n = 6 endometrial samples), as measured by time-resolved
fluoroimmunoassay (Figure 4.4). In addition, TGF(31-induced inhibition of tissue
factor mRNA, with significant suppression of mRNA levels observed at 24 h
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(p<0.05, n = 6 endometrial samples), 48 h (p<0.001, n = 6 endometrial samples) and
72 h (p<0.001, n = 6 endometrial samples), as measured by Q-RT-PCR (Figure 4.5).
1.5 -|
control 2h 12h 24h 48h 72h
TGFpi - + + + + +
Figure 4.1: TGFpi inhibits expression IGFBP-1 mRNA expression. Cells were
decidualised in vitro and treated in the presence or absence of TGFpi for a maximum
of 72 h. TGFpi reduces expression of mRNA IGFBP-1 in a time dependent manner
measured by Q-RT-PCR. 48 h, p<0.01, 72 h, p<0.001 n = 6 endometrial samples.
Control 2h 12h 24h 48h 72h
TGFpi - + ++ + +
Figure 4.2: TGFpi inhibits IGFBP-1 protein release, measured by ELISA. Cells
were decidualised in vitro and treated in the presence or absence of TGFpi for a
maximum of 72 h. TGFpi reduces protein release of IGFBP-1 after only 2 h of
treatment (p<0.001, n = 6 endometrial samples). This continues in a time-dependent
manner (all time points pcO.OOl).




control 2h 12h 24h 48h 72h
TGFJ31 - + + + + +
Figure 4.3: TGF|31 inhibits expression of PRL mRNA expression. Cells were
decidualised in vitro and treated in the presence or absence of TGF(L1 for a maximum
of 72 h. TGFfl 1 reduces expression of mRNA PRL in a time dependent manner; 48 h




















Figure 4.4: TGF(31 inhibits prolactin protein release measured by time-resolved
fluoroimmunoassay. Cells were decidualised in vitro and treated in the presence or
absence of TGFpl for a maximum of 72 h. TGFpl significantly reduces protein
release of prolactin in a time dependent manner (72 h, p<0.01) (n=6 endometrial
samples).




Control 2h 12h 24h 48h 72
TGFJ31 - + ++ + +
Figure 4.5: TGFfVl inhibits expression of tissue factor mRNA as measured by Q-
RT-PCR. Cells were decidualised in vitro and treated in the presence or absence of
TGFpl for a maximum of 72 h. TGF(F1 reduces expression of tissue factor mRNA in
a time dependent manner; 24 h (p<0.05, n = 8 endometrial samples), 48 h (p<0.001,
n = 6 endometrial samples), 72 h (p<0.001, n = 8 endometrial samples).
4.3.2 TGFp 1 represses the prolactin promoter transactivation
potential
In order to identify if TGFpl could interact with the dPRL promoter to inhibit
decidualisation, primary cultures of undifferentiated ESC and decidualising cells
were transiently transfected with the dPRL. The results are presented in Figure 4.6:
TGF(F1 inhibited promoter activity (approximately 50% inhibition), in all constructs
containing the PRE half site. -50 % repression was still apparent with a promoter
construct containing 332 bp upstream of the decidual PRL transcription start site.
This construct contains the critical decidualisation region (-270/-332) that confers the
cAMP response as well as containing a PRE half site. No repression was seen with
the promoter construct containing 32 basepairs upstream of the decidual PRL
transcription start site (PRE negative).
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Figure 4.6: Inhibition of the dPRL promoter in ESC decidualised in vitro by TGFpl
in a transient transfection assay. ESCs were transfected with a decidual PRL
promoter containing 3000 kb of DNA flanking the decidual-specific start site (dPRL-
3000/luc), or truncated vectors containing the critical decidualisation region, -332 bp
to -270 bp, relative to the transcription site thereof. This site contains half site PRE's
(Christian, Pohnke et al. 2002). TGF(31 inhibits promoter activity of all constructs by
approximately 50 %. Compare white and black bars. NB. No repression was seen
with the promoter construct containing only 32 basepairs upstream of the decidual
start site (PRE negative).
4.3.3 Anti-TGF(31 neutralising antibody negates TGF(31 inhibition
of decidualisation genes
In an attempt to elucidate if blocking endogenous TGFpi action would negate the
TGFpi-induced responses, ESC were cultured in the presence and absence of
decidualising medium for six days and then further cultured with decidualising
medium to maintain the decidualised phenotype in the presence or absence of TGFpl
(10 ng/ml) or anti-TGFpi antibody (1 pg/ml) for a period of 72 h. As previously
seen, TGFpi significantly downregulates mRNA expression of dPRL (Figure 4.7.
graph A) (p<0.05, n = 6 endometrial samples) and IGFBP-1 (Figure 4.7. graph B)
(p<0.001, n = 6 endometrial samples). Treatment with anti-TGFpi abolishes this
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response and significantly potentiated expression of IGFBP-1 mRNA in comparison
with ESCs treated with decidualising mix alone (Figure 4.7. graph B) (p<0.001, n = 6
endometrial samples). Treatment with the isotype control, mouse IgGl, evoked no
response. In every sample, anti-TGFpi antibody increased mRNA expression of
dPRL; however the individual variability between samples prevented any statistically







Figure 4.7: Anti-TGFpi antibody neutralises endogenous TGFpi and potentiates the
decidualisation process. Cultured ESCs were decidualised in vitro +/- TGFpi-
treatment. To confirm the specificity of the TGFfll response anti-TGFpi (1 pg/ml)
or mouse IgG control was added, for 72 h. A: TGFpi inhibits expression of decidual
prolactin (p<0.05, n = 6 endometrial samples), whilst anti-TGFpi increases
expression of decidual prolactin (n = 6 endometrial samples). B: TGFpi reduces
expression of IGFBP-1 mRNA (p<0.001, n = 6 endometrial samples), whilst anti-
TGFpi antibody increases IGFBP-1 (p<0.001, n = 6 endometrial samples).
4.3.4 Is the current well-characterised model of decidualisation
the best in vitro model with which to evaluate regulation of
decidualisation markers?
4.3.4.1 Characterisation of decidual stromal cells (DSC)
Before embarking on a series of experiments to determine if using stromal cells
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regulation of decidualisation markers than the present model, the presence or
otherwise of trophoblast cells within the decidual tissue had to be confirmed, to
ensure decidua used in the experiments were distal from the implantation site and
free from trophoblast contamination. Figure 4.8 represents cytokeratin staining in
decidua parietalis, panel I, and decidua basalis containing trophoblast villi, panel II.
All decidual biopsies were stained for cytokeratin and proved to be negative from
trophoblast contamination.
Figure 4.8: Cytokeratin staining in decidual biopsies. Panel I depicts a tissue section
from a decidua parietalis biopsy. Panel II shows a tissue section from decidua
basalis. Scale bars represent 100pm.
4.3.4.2 DSC extracted from decidua parietalis de-differentiate
morphologically and release reduced concentrations of
IGFBP-1
In order to address whether decidualisation is a terminal differentiation or if cells,
exposed to decidualisation stimuli in vivo, can de-differentiate, DSC were cultured in
the absence of any decidualisation stimuli for 14 d and the IGFBP-1 protein release
measured at 3 d, 9 d and 14 d of culture. Results are presented in Figure 4.9; in each
sample long-term culture (9 d) in the absence of decidualising stimuli demonstrated a
significant reduction in IGFBP-1 protein release (p<0.001, n = 11 decidual samples)
(Figure 4.9, Panel A), but after 9 d of culture DSCs still release sufficient levels of
protein to be characterised as decidualised i.e. releasing >500 pg/ml/SxlO^ cells
IGFBP-1. After 14 d of culture, without decidualising stimuli, IGFBP-1 protein
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levels were significantly reduced 5-fold (pcO.OOl, n= 11 decidual samples) (Figure
4.9, Panel A), however approximately 3500 pg/ml/5xl05 cells IGFBP-1 was still
being released by the cells. Samples 8-11 were over 10 wks gestation at time of
collection. These samples released significantly greater levels of IGFBP-1 protein
than those samples from < 10 wks gestation (p<0.001) (Figure 4.9, Panel B) and still
released approximately 10000 pg/ml/5xl05 cells IGFBP-1 after 14 d in culture in the
absence of decidualising stimuli (p<0.001) (Figure 4.9, Panel B). Morphologically
the DSCs did appear to become more "fibroblast-like" over time, with an apparent
decrease observed in the spherical shape associated with decidualised cells (Figure
4.10). In addition, the cells remained healthy and the reduction in IGFBP-1 release







Figure 4.9: DSCs de-differentiate in culture. DSCs were cultured in the absence of
decidualising stimuli for 14 d. Panel A; IGFBP-1 protein release was abrogated in a
time-dependant manner after 9 d (p<0.001, n = 11 decidual samples). Continual
suppression was observed after 14 d (p<0.001, n =11 decidual samples). Panel B;
black bars denote samples < 10 wks gestation, chequered bars denote samples > 10
wks gestation. Samples <10 wks release significantly less IGFBP-1 and are seen to
(p<0.001) but samples > 10 wks gestation are still releasing ~ 10000 pg/ml/5xl05
cells IGFBP-1 after 14 d in culture without decidualising stimuli, n = 7 decidual
samples < 10 wks gestation, n = 4 decidual samples > 10 wks gestation.




Figure 4.10: Photograph ofDSC morphology in the absence of decidualising stimuli
after 3 d (Panel I) and 14 d (Panel II) in culture. Scale bars represent 100pm.
200000n
Figure 4.11: DSCs are still viable after 14 d in culture in the absence of
decidualising stimuli (n = 6 decidual samples).
4.3.4.3 DSC deciduaiise faster than ESC
In order to elucidate if DSC re-decidualised faster than ESC, stromal cells from non¬
pregnant endometrium and the 7 samples obtained from decidua < 10 weeks
gestation were cultured in the presence or absence of 8-Br-cAMP (0.5 mM) +/- MPA
(1 pM) for up to 72 h. Decidualisation markers, dPRL and IGFBP-1, were measured
by Q-RT-PCR and ELISA.




Decidual prolactin mRNA expression is significantly potentiated in DSC, re-
decidualised in vitro with MPA and cAMP, after only 24 h of treatment (Figure 4.12)
(p<0.001, n = 7 decidual and 7 endometrial) as compared with ESC treated
identically. A significant difference in dPRL mRNA is also observed at 48 h (Figure
4.12) (pcO.OOl, n = 7 decidual and 7 endometrial biopsies) and 72 h (Figure 4.12)
(p<0.01, n = 7 decidual and 7 endometrial biopsies) between DSC and ESC.
4.3.4.3.2 IGFBP-1
In contrast to dPRL findings, IGFBP-1 mRNA expression was significantly
potentiated in ESC compared to DSC after both were treated with MPA alone
(Figure 4.13) (pcO.OOl, n = 7 decidual and 7 endometrial biopsies) or MPA + cAMP
for 12 h (Figure 4.13) (p<0.001, n = 7 decidual and 7 endometrial biopsies).
However, after 48 h of treatment the opposite was observed in that IGFBP-1 mRNA
expression was significantly potentiated in DSC compared to ESC after both were
treated with MPA alone (Figure 4.13) (pcO.OOl, n = 7 decidual and 7 endometrial
biopsies) or MPA + cAMP (Figure 4.13) (pcO.OOl, n = 7 decidual and 7 endometrial
biopsies). No significant differences were observed at other time points. IGFBP-1
protein release in DSC compared with ESC after treatment with decidualising stimuli
further supports the argument that DSCs re-decidualise faster. After only 2 h of
treatment with MPA + cAMP IGFBP-1 release is significantly upregulated in DSC
as compared to identically-treated ESC (Figure 4.14) (pcO.OOl, n = 7 decidual and 7
endometrial biopsies). The same is true for 24 h of treatment with MPA + cAMP
(Figure 4.14) (pc0.05, n = 7 decidual and 7 endometrial biopsies). After 72 h of
treatment IGFBP-1 protein expression was significantly potentiated in DSC
compared to ESC after both were treated with MPA alone (Figure 4.14) (pcO.OOl,
n = 7 decidual and 7 endometrial biopsies) or MPA + cAMP (Figure 4.14) (pc0.05, n
= 7 decidual and 7 endometrial biopsies). No significant differences were observed at
other time points.
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MPA - - - + + + +
CAMP - + + + +
Figure 4.12: dPRL mRNA expression in DSC and ESC. DSC and ESC were
cultured in the presence or absence of decidualising stimuli, cAMP (250 pM) +/-
MPA (1 pM) (DM) for a maximum of 72 h. Black bars denote ESC from non¬
pregnant endometrium and chequered bars denote DSC from 1st trimester decidua.
Graph A depicts cells treated for 2h. Graph B depicts cells treated for 12 h. No
significant differences are seen between treatments. Graph C depicts cells treated for
24 h. Graph D depicts cells treated for 48 h and Graph E depicts cells treated for 72
h. dPRL mRNA is significantly potentiated in DSC compared to ESC after both were
treated with DM for 24 h, (p<0.01), 48 h, (p<0.001) and 72 h, (p<0.01). Note graphs
are on different scale axes to demonstrate differences at each time point. Graph F
depicts cells treated with DM for a maximum of 72 h demonstrating the dPRL
mRNA increase over time between ESCs and DSCs. n = 7 decidual biopsies and 7
endometrial biopsies.




Figure 4.13: IGFBP-1 mRNA expression in DSC and ESC. DSC and ESC were
cultured in the presence or absence of decidualising stimuli, cAMP (250 pM) +/-
MPA (1 pM) for a maximum of 72 h. Black bars denote ESC from non-pregnant
endometrium and chequered bars denote DSC from 1st trimester decidua. Graph A,
no significant differences were seen between treatments after 2 h incubation. Graph
B, IGFBP-1 mRNA was significantly potentiated in ESC compared to DSC after
both were treated with MPA alone (p<0.001) or MPA + cAMP (DM) for 12 h,
(p<0.001). Graph C, no significant differences were seen between treatments. Graph
D, IGFBP-1 mRNA was significantly potentiated in DSC compared to ESC after
both were treated with MPA alone (p<0.001) or DM for 48 h, (p<0.001). Graph E, no
significant differences were observed between treatments. Note graphs are on
different scale axes to demonstrate differences between ESCs and DSCs at each time
point. Graph F depicts cells treated with DM for a maximum of 72 h demonstrating
the IGFBP-1 mRNA increase over time between ESCs and DSCs. n = 7 decidual
biopsies and 7 endometrial biopsies.


















Figure 4.14: IGFBP-1 protein release from DSC and ESC. DSC and ESC were
cultured in the presence or absence of decidualising stimuli, cAMP (250 pM) +/-
MPA (1 pM) (DM) for a maximum of 72 h. Black bars denote ESC from non¬
pregnant endometrium and chequered bars denote DSC from 1st trimester decidua.
Graph A, IGFBP-1 protein release is significantly potentiated in DSC compared to
ESC after both were treated with DM for 2 h, (p<0.001). Graph B depicts cells
treated for 12 h. No significant differences are seen between treatments. Graph C,
IGFBP-1 protein release is significantly potentiated in DSC compared to ESC after
both were treated with DM for 24 h, (p<0.05). Graph D depicts cells treated for 48 h.
No significant differences were observed between treatments. Graph E, IGFBP-1
protein release is significantly potentiated in DSC compared to ESC after both were
treated with MPA alone (pcO.OOl, n = 7 decidual biopsies) or DM for 72 h, (p<0.05).
Note graphs are on different scale axes to demonstrate differences between ESCs and
DSCs at each time point. Graph F depicts cells treated with DM for a maximum of
72 h demonstrating the IGFBP-1 mRNA increase over time between ESCs and
DSCs. n = 7 decidual biopsies and 7 endometrial biopsies.
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4.3.4.4 TGF01 suppresses the expression and release of
decidualisation product genes
To address the question as to the effect of TGFfVl on decidualisation genes produced
by DSC, re-decidualised in vitro, cells obtained from < 10 wks gestation were
cultured, decidualised in vitro with 8-Br-cAMP (0.5 mM) and MPA (1 pM)
(decidualising medium) for 6 d and then further cultured with decidualising medium
to maintain the decidualised phenotype with or without the addition of TGF(11 for up
to 72 h. Results are presented in Figures 4.15 to 4.19; 10 ng/ml TGF(31
downregulated expression of dPRL at mRNA expression level in a time dependent
manner (Figures 4.15), with significant down-regulation seen at 72 h (p,0.001, n = 7
decidual samples), as compared to unstimulated, time-matched controls. No
significant effect was observed for dPRL protein release, but displayed a trend
towards reduction, as measured by time-resolved fluoroimmunoassay (Figure 4.16).
TGF(11-induced inhibition of IGFBP-1 (Figure 4.17) (p<0.05, n = 7 decidual
samples) and TF (Figure 4.19) (p<0.05, n = 7 decidual samples) mirrored that of
dPRL, in that a significant reduction was only observed after 72 h of treatment. No
significant effect was observed on IGFBP-1 mature protein secretion (Figure 4.18).
iiuii
Control 2h 12h 24h 48h 72
TGFpi - + ++ + +
Figure 4.15: TGF(31 inhibits expression of dPRL mRNA in DSC, as measured by Q-
RT-PCR. DSCs were decidualised in vitro and treated in the presence or absence of
TGFpi for a maximum of 72 h. TGF(31 reduces expression of dPRL mRNA after 72
h treatment. (p<0.001, n = 7 decidual samples).
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Control 2H 12h 24h 48h 72h
TGFpi - + ++ + +
Figure 4.16: TGFpi is without effect on prolactin protein release, measured by time-
resolved fluoroimmunoassay. Cells were decidualised in vitro and treated in the
presence or absence of TGFpl for a maximum of 72 h. TGFpi was without
significant effect on protein release of prolactin, although did display a trend toward
inhibition (n = 7 decidual samples).
Control 2h 12h 24h 48 h 72h
TGFpl - + ++ + +
Figure 4.17: TGFpi inhibits expression of IGFBP-1 mRNA in DSC, as measured by
Q-RT-PCR. DSCs were decidualised in vitro and treated in the presence or absence
of TGFpi for a maximum of 72 h. TGFpi reduces expression of IGFBP-1 mRNA
after 72 h treatment. (p<0.05, n = 7 decidual samples).





Control 2h 12h 24h 48h 72h
TGFpl - + ++ + +
Figure 4.18: TGF(31 is without effect on IGFBP-1 protein release, measured by
ELISA. Cells were decidualised in vitro and treated in the presence or absence of
TGFfll for a maximum of 72 h. TGF(31 was without significant effect on protein
release of IGFBP-1 (n = 7 decidual samples).
Iliiii
Control 2h 12h 24h 48h 72
TGFpl - + ++ + +
Figure 4.19: TGF(T1 inhibits expression of TF mRNA in DSC, as measured by Q-
RT-PCR. DSCs were decidualised in vitro and treated in the presence or absence of
TGFpl for a maximum of 72 h. TGF(M reduces expression of TF mRNA after 72 h
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4.3.4.5 Effect of abrogating the SMAD signalling pathway on
TGFpl- induced inhibition of dPRL in ESC
SMAD 4 siRNA was used to investigate if selectively silencing the SMAD signalling
pathway would abrogate the TGFpi-incuded responses. ESCs were transiently
transfected with either a non-targetting siRNA or SMAD 4 siRNA or were subjected
to a mock transfection. 4 hours after transfection the cells were then subsequently
cultured +/- 8-Br-cAMP (0.5 mM) and MPA (1 pM) +/- TGFfll (10 ng/ml) for 72 h.
Successful silencing was assessed by detecting the SMAD 4 mRNA and protein
levels by non-quantitative PCR and Western blotting respectively, results shown in
section 3.3.9.
To elucidate if silencing SMAD 4 would abrogate the TGFpi-induced effect on
dPRL mRNA levels were measured. Results are presented in Figure 4.20; as
observed previously, treatment with cAMP and MPA evoked an increase in dPRL
mRNA expression. Transfection with SMAD 4 siRNA significantly suppressed
dPRL mRNA as compared with the decidualised cells (Figure 4.20, p<0.001).
Treatment with TGF(T1 with either the non-targeting siRNA or SMAD 4-specific
siRNA transfected cells demonstrated a reduction in the level of dPRL mRNA in
comparison with decidualised cells (Figure 4.20, p<0.001). This was suppressed
further in the cells transfected with SMAD 4 siRNA (Figure 4.20). However, as
transfection with the non-targeting siRNA significantly inhibited dPRL mRNA
expression (Figure 4.20, p<0.001), no comparison can be drawn on the relevance of
the SMAD signalling pathway in TGF|31 -induced inhibition of dPRL mRNA
expression and protein release. The transient transfection and treatment of the cells
was performed by Marius Jones in Jan Brosen's lab.
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cAMP/MPA - + + + + +
TGF(31 ----+ +
Non-targeting siRNA -
SMAD 4 siRNA --- + - +
Mock transfection + +
Figure 4.20: Cultured ESCs were transiently transfected with either control siRNA
or SMAD 4 siRNA and subsequently cultured for 72 h, +/- 8-Br-cAMP (0.5 mM)
and MPA (1 pM) +/- TGF|31 (10 ng/ml). Treatment with decidualising stimuli
evoked an increase in PRL mRNA. A significant reduction was observed with cells
transfected with the non-targeting siRNA and SMAD 4 siRNA, both treated with and
without TGFpi (pcO.001). n = 1 endometrial sample.
4.4 Discussion
We have demonstrated that TGF|31 markedly inhibits the expression of mRNA's
encoding the decidual protein markers, PRL (Christian, Marangos et al. 2001),
IGFBP-1, and tissue factor (Figures 4.1, 4.3 and 4.5), and that this inhibitory effect at
the level of mRNA was reflected by a reduction in mature protein secretion of both
PRL and IGFBP-1 (Figures 4.2 and 4.4) which was in agreement with previous
published data (Mazella, Tang et al. 2004). It would appear that the normal protein
versus mRNA kinetics are not as expected which would suggest that TGF|31 may
also be repressing translation/export of protein processing. A number of studies have
reported a marked inhibitory effect of TGF(31 on basal and stimulated PRL secretion,
mRNA levels and de novo PRL synthesis in rat anterior pituitary cells (Herrlich,
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Kuhn et al. 1996; Telgmann, Maronde et al. 1997; Coya, Alvarez et al. 1999). These
authors report a time-dependent dual effect: a short-term inhibition (after 4 h) of
basal prolactin-secretion and a long-term inhibition (after 4 d) of basal and
stimulated prolactin expression. They also demonstrate that the short-term effect of
TGFpi was independent of cAMP reduction, and via pertussis toxin abolition of
inhibitory actions of TGFfLl, implicate the involvement of G-proteins as signal
transducers of TGFpl prolactin inhibition (Coya, Alvarez et al. 1999). It was
suggested that the long-term effect of TGFfll as regards PRL inhibition might be
attributed to decreased cAMP levels. Indeed, initiation of the decidual process in
endometrial stromal cells both in vivo and in vitro requires elevated intracellular
cAMP levels (Tanaka, Miyazaki et al. 1993; Herrlich, Kuhn et al. 1996; Telgmann,
Maronde et al. 1997). Telgmann, et al (Telgmann and Gellersen 1998), observed that
the major activation of the decidual PRL promoter depends upon the region located
between -332 bp and -270 bp relative to the transcription site, demonstrating that
deletion of this region significantly reduced cAMP induction. Subsequently, this
essential region was shown to contain a progesterone response element (PRE) half
site (Christian, Pohnke et al. 2002). The data presented herein confirms that TGFpi
abrogates the transactivation potential of the dPRL promoter-reporter, by more than
50%, acting at the minimal PKA-sensitive decidual PRL promoter construct (dPRL-
332/Luc), in response to cAMP- treated endometrial stromal cells (Figure 4.6). This
suggests that TGFpi acts upon the region critical for successful transcription.
In contrast to the findings of the present studies, Celikkanat et al (Celikkanat, Atac et
al. 2000), have reported that there is no direct effect of TGF|31 on the differentiation
of human ESC and on the production of dPRL. It would be unlikely that they would
have found any results to the contrary as the cells were not decidualised in vitro and
as such would only produce basal levels of prolactin. They do agree with the
suggestion, that TGFp l may be involved in a more complex role within regulation of
decidualisation. Also in contrast to the present data, Kim et al (Kim, Park et al.
2005), propose that TGFfll actually potentiates the decidualisation process in ESC
and report that progesterone is not required to induce decidualisation in ESC (Kim,
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Park et al. 2005). It must be noted that this is the only study to suggest that
decidualisation is a progesterone-independent event.
Previous studies have identified TGF(31 as an inhibitor of the relaxin receptor
(LGR7) and of IGFBP-1 production; both recognised markers of decidualisation. The
findings herein are in agreement with those of Mazella et al (Mazella, Tang et al.
2004) who also reported that TGFfll inhibited both IGFBP-1 mRNA and protein
production in a time-dependent manner and Vicovac et al and Jikihara et al (Jikihara
and Handwerger 1994; Vicovac, Starkey et al. 1994), who have both demonstrated a
TGF(11 dose-dependent inhibition of PRL by decidual stromal cells derived from
first trimester pregnancy and decidual cells from term pregnancy, respectively. The
cells in our study were obtained from non-pregnant endometrium and decidualised in
vitro and are more indicative of the cells which are seen to decidualise in the absence
of a blastocyst in vivo.
Tierney et al (Tierney, Tulac et al. 2003) reported that expression of TGFpl is
induced in response to cAMP within 12-24 h and suggested that TGF|31 is primarily
involved in cellular differentiation and the adoption of the morphologic and secretory
phenotype of the decidual stromal cell. However, due to the microarray-based nature
of Tierney's findings, they only report on mRNA levels and not protein, therefore, it
is unclear as to whether the cAMP-induced TGF(11 is latent or active. It is possible
that activation of TGFfl l may occur with cell-to-cell contact and may act locally to
inhibit the progression of decidualisation. Aberrant regulation of TGF(31 may
contribute to menstrual disorders, such as heavy menstrual bleeding and
dysmenhorrea, by preventing haemostasis and causing infertility by preventing
decidualisation of the endometrium.
Previous studies have sought to identify an in vitro model better placed to study the
effects and induction or inhibition of decidualisation (Schatz and Lockwood 1993).
Cultured 1st trimester decidual cells have been utilised and reported to retain key
morphological features indicative of their decidualised in vivo state, for example,
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they are reported to form multicellular clusters surrounded by patches of pericellular
basement membrane type ECM (Schatz, Papp et al. 1994), however the cells were
cultured in the presence of decidualising stimuli so it is impossible to ascertain if the
cells are capable of de-differentiating (Schatz, Papp et al. 1994). In our study,
experiments to determine if stromal cells from 1st trimester decidua de-differentiate
indicate that although the cells are seen to de-differentiate morphologically (Figure
4.10) there is still a notable production of the classic decidualisation marker, IGFBP-
1, even after 14 d of culture in the absence of decidualising stimuli (Figure 4.9, Panel
A). This could be in part due to individual variability and differences in gestation
between samples. For the most part, DSCs from gestations > 10 weeks take longer to
release reduced concentrations of IGFBP-1 and may need a longer time in culture to
de-differentiate (Figure 4.9, Panel B). Furthermore, DSCs re-decidualise faster than
ESC when treated in parallel (Figures 4.12 - 4.14), implying the presence of a
potential "decidualised phenotype memory" when cells are decidualised in vitro.
Indeed, DSCs display an increased sensitivity to MPA and can re-decidualise in
response to in vitro MPA treatment alone after a shorter treatment period than ESC
(Figure 4.13 and 4.14).
In addition, the present studies have demonstrated that TGF(31 markedly inhibits the
expression of dPRL, IGFBP-1, and tissue factor mRNAs in DSCs (Figures 4.15, 4.17
and 4.19). However, this downregulation was delayed by at least 24 h when
compared to the response seen in ESC. Furthermore, this inhibitory effect at the level
of mRNA was not reflected by a reduction in mature protein secretion of both PRL
and IGFBP-1 in DSC (Figures 4.16 - 4.18), implying that decidualisation in vivo,
confers some resistance to the actions of TGF(31. Perhaps the presence of blastocyst
and increasing concentrations of hCG in the 1st trimester of pregnancy evokes an
increase in cellular protection against potential pathogenic cytokines and growth
factors, or perhaps the role of TGFfl l in pregnant endometrium differs from that in
non-pregnant, pre-menstrual endometrium. This would seem to be in agreement with
data reporting high expression of TGFfll in 1st trimester decidua without any
detrimental effect to pregnancy (Lysiak, Hunt et al. 1995; Jokhi, King et al. 1997;
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Bennett, Lagoo-Deenadayalan et al. 1999; Simpson, Robson et al. 2002). Indeed,
maintaining homeostasis in decidua is of paramount importance to ensure the
successful continuation of pregnancy. Aberrant increases in active TGFpl may be
detrimental for the developing foetus.
In summary, the studies presented in this chapter have demonstrated that TGF(!1 is
capable of suppressing the decidualisation marker proteins. The results obtained
suggest that ESCs isolated from non-pregnant endometrium are a better model than
DSCs isolated from 1st trimester decidua for evaluating the events which occur in the
premenstrual endometrium, whereas the DSCs are a better model for evaluating the
events which occur in the presence of a blastocyst. The findings also suggest that
local TGFfJl signalling may coordinate de-differentiation of endometrial stromal
compartment and tissue remodelling associated with menstruation, but may have a
different role in pregnant endometrium.




5 Uterine natural killer cell interactions with human
chorionic gonadotrophin
5.1 Introduction
5.1.1 Uterine natural killer cells
CD56br'8ht lymphocytes (uterine natural killer cells; uNKs) increase in number in the
human uterus during every menstrual cycle (King 2000). The increase in uNKs
follows the surge in pituitary-derived luteinising hormone (LH), and is coincidental
with the increase in progesterone concentration during the secretory phase of the
cycle. While the uterus is host to some CD56bnght cells prior to ovulation, the rapid
increase is thought to be due to proliferation of the resident population, accompanied
by recruitment of CD56bnght lymphocytes from the circulation. The rapid increase in
CD56bn8ht cells is concurrent with the onset of decidualisation. Uterine CD56bnsht
cells are proposed to proliferate and differentiate to become the predominant
lymphocytes of the post-ovulatory uterus (Trundley and Moffett 2004). These
distinct, tissue-specific natural killer (NK) cells either decrease in number prior to
menses or increase in number during early pregnancy, and then decline toward the
end of the first trimester. The exact function of uNK cells remains unknown,
however, reduced NK cell populations are reported in pregnancies complicated by
foetal growth restriction (FGR) with or without the accompanying condition, pre¬
eclampsia (Eide, Rolfseng et al. 2006).
Ultrastructurally, a typical uterine CD56bnght cell is a large lymphocyte with a
reniform, eccentric nucleus and short, cytoplasmic projections. They also possess
varying numbers of membrane-bound cytoplasmic granules that contain cytolytic
molecules such as granzyme and perforin (Trundley and Moffett 2004). CD56Bright
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populations respond differentially to chemotactic signalling; CD56dim cells migrate in
response to CXCL8 (IL-8) and strongly express the receptor CXCR1. CD56bnght cells
express the chemokine receptors CCR5, which binds CCL3 (MlPal), CCL4 (MIPpi)
and CCL5 (RANTES), and CCR7, which binds CCL19 (MIPp3) and CCL21
(Campbell and Colonna 2001). uNK cells have a unique expression pattern, strongly
expressing, CCR1, 2, and 5, CXCR3 and 4, and CX3CR1 (Red-Horse, Drake et al.
2001). The expression of both phenotypic and chemokine receptors for each CD56+






CD56 + ++ +++
CD16 + — —
CD3 — — —
L-Selectin + ++ —
Alpha 4 integrin + ++ ++
LFA-1 + + +
CCR1 — — ++
CCR2 — — ++
CCR5 — ++ ++
CCR7 — ++ +/-
CXCR1 + — —
CXCR2 + — -
CXCR3 + ++ ++
CXCR4 ++ ++ ++
CX3CR1 + ++ ++
Table 5.1: The expression
pattern of both phenotypic and
chemokine receptors for each
CD56+ population. Adapted
from Van Den Heuvel et al
(van den Heuvel, Peralta et al.
2005).
(+) Expressed; (++) strongly expressed; (+++) very strongly expressed; (-) not
expressed.
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5.1.2 Macrophage Mannose Receptor
Macrophage mannose receptors (MMRs) are multivalent transmembrane receptors
capable of interacting with multiple ligands. The structure of the MMR is further
discussed in section 1.4.3. MMRs are expressed by most tissue macrophages, but are
not macrophage-restricted (Shepherd, Tamowski et al. 1991; Linehan, Martinez-
Pomares et al. 1999; Wilt, Greaton et al. 1999; Engering, Geijtenbeek et al. 2002;
Taylor, Gordon et al. 2005). A mannose-acetate-specific receptor was previously
identified on PBNK cells, and shown to be responsible for NK activity (Hauer,
Voetsch et al. 1994), however no studies have yet been undertaken to analyse the
uNK cell population for MMR. MMRs are able to bind foreign and endogenous
molecules (sulphated glycoproteins or glycoproteins containing mannose, fucose and
N glucosamine residues) in a Ca2+ dependent manner and thereafter endocytose them
by clathrin-mediated endocytosis (East, Rushton et al. 2002). MMRs are recycled
between the plasma membrane and the endosomal apparatus to mediate the uptake of
extracellular ligands (East and Isacke 2002). The MMR may also mediate
phagocytosis of a wide variety of microbes including fungi, protozoa, yeast and
bacteria, all of which display a high mannose cell surface expression (Taylor,
Bezouska et al. 1992). MMRs have also been demonstrated to bind sulphated
oligosaccharides, such as those present on the pituitary hormones LH and TSH
(Fiete, Beranek et al. 1998; Simpson, Hitchen et al. 1999). hCG and LH are both
oligosaccharide glycoproteins (Acevedo 2002), with identical a subunits, which act
via their common receptor (Rajaniemi, Ronnberg et al. 1981), and are recognised to
regulate non-gonadal and immune cell function (Rao 2001). For instance, LH has
previously been shown to suppress the lytic activity of PBNK cells (Sulke, Jones et
al. 1985) arid to increase the adhesion of PBNK cells to endothelium (van den
Heuvel, Peralta et al. 2005), however the LH/hCG receptor was never localised to
these cells (Sulke, Jones et al. 1985; van den Heuvel, Peralta et al. 2005). Recent
studies have localised the LH/hCG receptor to macrophages in late secretory phase
endometrium and term placenta (Zhang, Rao Ch et al. 2003). It is unknown whether
the MMR can bind and internalise hCG or LH, however, a previous study
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demonstrated that high doses of hCG promoted IL-8 production by peripheral blood
mononuclear cells (PBMC)s in the absence of detectable LH/hCG receptors (Kosaka,
Fujiwara et al. 2002). The authors further demonstrated that this production could be
abrogated by the addition of D-mannose and postulated that hCG effects on PBMCs
may be mediated via a C-type lectin (Kosaka, Fujiwara et al. 2002).
5.1.3 Hypothesis
In summary, previous studies have demonstrated a functional role of LH in
mediating NK lytic activity (Sulke, Jones et al. 1985) and adhesion properties (van
den Heuvel, Peralta et al. 2005). However, no NK locus has been identified for the
LH/hCG receptors in PBNK cells (Sulke, Jones et al. 1985; van den Heuvel, Peralta
et al. 2005). With the expansion of CD56Br'8ht uNK cells in the uterus following the
surge in LH (King 2000), and the maintenance of uNK cell numbers in 1st trimester
endometrium in accordance with hCG levels in maternal plasma (Jaffe, Lee et al.
1969; King 2000) it is unknown whether uNK cells express the LH/hCG receptor,
hence providing a possible mechanism for the recruitment and/or proliferation of this
cell population in utero. MMRs have been demonstrated to bind sulphated
oligosaccharide glycoproteins (Fiete, Beranek et al. 1998; Simpson, Hitchen et al.
1999) and both hCG and LH are both oligosaccharide glycoproteins (Acevedo 2002)
therefore it could be hypothesised that MMR may bind hCG and LH, so, does the
uNK cell possess MMRs?
5.1.4 AIMS
The studies described in this chapter were designed to investigate uNK cell
interactions with the maternal recognition of pregnancy hormone, hCG. All studies
utilised primary uNK cells isolated from 1st trimester decidua and non-pregnant late-
secretory endometrium as described in section 2.1 and 4.2.1.2. Experiments in this
chapter were designed to address the following questions:
1: Do uNK cells express the LH/hCG receptor?
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2: Does treatment with hCG induce proliferation of uNK cells derived from 1st
trimester decidua?
3: Does treatment with hCG effect production of uNK-associated cytokines, IL-10,
TNFa and IFNy?
4: Do uNK cell possess MMRs?
5: Does hCG colocalise with MMR?
5.2 Methods
5.2.1 Human uterine tissue collection
5.2.1.1 Tissue collection and processing of human decidual tissue
Decidual samples (n = 46) were collected as detailed in section 2.1.1 (Table 2.1b).
Decidual material utilised in this chapter are detailed in Table 5.1. All decidual
samples were processed to isolate the CD56bnsht uterine natural killer cells (uNKs) as
described in section 4.2.1.2. Cells were resuspended in 80 ml of MACS™ buffer
(500 ml PBS pH 7.2, 0.5 % BSA and 2 mM EDTA) (Miltenyi Biotec), to which 20
pi of CD56 microbeads (Miltenyi Biotec) were added. Thereafter, the cells were
washed in 10 ml MACS™ buffer (Miltenyi Biotec) and centrifuged at 400 g for 5
min. The supernatant was discarded. 500 pi of MACS™ buffer (Miltenyi Biotec)
was added to 108 cells. This mixture was subsequently passed through a 30 pm filter
to ensure no cell clumps. The MACS™ LD column (Miltenyi Biotec) was placed in
the magnetic field of the MACS™ separator (Miltenyi Biotec) and primed by rinsing
with 2 ml of MACS™ buffer. The cell suspension was then passed through the
columns. The unlabelled cells passed through the column and were thereafter treated
as described in section 4.2.1.2. The labelled cell fraction was eluted from the column
and treated as described in section 5.2.2.
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5.2.1.2 Late secretory endometrium from non pregnant women
An endometrial sample was collected as detailed in section 2.1.1 (Table 2.1a), and
was processed to isolate the CD56bnght uterine natural killer cells (uNKs) as described
in section 4.2.1.2. The sample included superficial and basal endometrium. The
patient, aged 45, described regular menstrual cycles (25-35 days) and had not
received any form of exogenous hormonal treatment in the 3 months preceding
biopsy. The biopsy was dated as day 27 of the menstrual cycle according to the
patient's reported last menstrual period (LMP) and was included for analysis as the
histological dating according to published criteria (Noyes, Hertig et al. 1950) and
circulating sex steroid concentrations (E2 and P at time of endometrial biopsy) were
consistent with the LMP. Serum was separated (by centrifugation at 800 g for 7 min)
from venous blood samples collected at the time of biopsy and E2,323 pg/ml and P,
27 ng/ml, concentrations were measured by RAI. The tissue sample was collected
under Ethics submission number 17 (Appendix).
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Sample D.O.C AGE PARITY PARITY Gestation Ethical
LB MT (Wks + day) approval ref
1 14/04/04 28 1 0 8+4 73
2 01/11/04 23 0 0 9+3 73
3 10/11/04 20 1 0 7+5 73
4 15/11/04 36 3 0 8+3 73
5 15/11/04 31 0 0 7+6 73
6 24/11/04 36 1 0 7+6 73
7 24/11/04 23 0 1 8+4 73
8 29/11/04 30 2 2 8+3 73
9 01/12/04 23 2 0 7+6 73
10 25/01/05 24 2 1 11 73
11 13/09/05 26 2 0 8 05/S1104/12
12 13/09/05 21 0 0 8 05/S1104/12
13 14/09/05 43 2 1 7+4 05/S1104/12
14 27/09/05 26 0 0 8+6 05/S1104/12
15 27/09/05 21 0 0 9+5 05/S1104/12
16 28/09/05 43 0 1 8 05/S1104/12
17 28/09/05 26 1 0 9+2 05/S1104/12
18 29/09/05 23 0 0 8+5 05/S1104/12
19 29/09/05 21 0 0 9+1 05/S1104/12
20 04/10/05 30 0 0 9+3 05/S1104/12
21 04/10/05 18 1 1 8+3 05/S1104/12
22 12/10/05 26 2 0 9+3 05/S1104/12
23 12/10/05 20 1 4 9+6 05/S1104/12
24 26/10/05 24 0 0 11+1 05/S1104/12
25 28/11/05 30 3 1 10+2 05/S1104/12
26 29/11/05 24 0 0 11 05/S1104/12
27 02/12/05 27 1 1 10+3 05/S1104/12
28 02/12/05 28 3 0 8+2 05/S1104/12
29 05/12/05 23 1 1 10+4 05/S1104/12
30 13/12/05 24 0 0 9+5 05/S1104/12
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31 16/02/06 36 0 0 10+3 05/S1104/12
32 21/02/06 21 0 0 8+1 05/S1104/12
33 22/02/06 19 0 1 10+2 05/S1104/12
34 02/03/06 25 0 0 10 05/S1104/12
35 02/03/06 43 2 0 9+2 05/S1104/12
36 02/03/06 18 1 0 9+6 05/S1104/12
37 09/03/06 19 0 0 11 05/S1104/12
38 15/03/06 25 0 0 10+4 05/S1104/12
39 15/03/06 25 0 0 <8 05/S1104/12
40 20/03/06 20 0 0 10+1 05/S1104/12
41 20/03/06 42 1 0 8+6 05/S1104/12
42 22/03/06 20 0 0 9+2 05/S1104/12
43 22/03/06 34 0 0 8 05/S1104/12
44 22/03/06 30 1 1 9+6 05/S1104/12
45 22/03/06 18 0 0 8 05/S1104/12
46 22/03/06 26 2 0 9+5 05/S1104/12
Table 5.2: Details of 1st trimester decidual biopsies used in the studies presented in
Chapter 5. D.O.C. = Date of Collection. Parity LB = number of live births. Parity MT
= number ofmiscarriage/terminations.
5.2.2 In vitro primary cell culture experiments
uNK cells were treated with hCG (10 ng/ml - 10000 ng/ml) in RPMI 1640 medium
(Sigma) supplemented with 10 % FCS (Mycoplex), penicillin (50 pg/ml; Sigma),
streptomycin (50 pg/ml; Sigma) and gentamycin (5 ug/ml; Sigma) for 2 h at 37°C in
5 % (v/v) CO2. The cells were seeded in 6-well plates at a concentration of 2.5 x 106
cells/ml. Each treatment was duplicated and repeated 9 times with separate decidual
biopsies.




Total RNA was extracted from the uNK cells as described in section 2.3.1 and cDNA
prepared from the experiments detailed in section 5.2.2 as described in section 2.3.2.
5.2.4 Semi-Quantitative PCR
Primers were designed to amplify the LH/hCG receptor or MMR cDNAs. PCR was
carried out using BioMix Red (Bioline). Conditions for each sample were as follows:
2 x Bioline Biomix Red lOpl
LH/hCG receptor/ MMR sense primer (0.5 pM) 2 pi
LH/hCG receptor/ MMR antisense primer (0.5 pM) 2 pi
RNAse-free H2O 2 pi
cDNA 4 pi
30 cycles of amplification were performed with an initial denaturing temperature of
95°C for 5 min for 1 cycle followed by 30 cycles of: denaturation at 95°C for 30 sec,
annealing for 30 sec and extension at 72°C for 1 min 30 sec. Final extension at 72°C
was carried out for 10 min. The PCR product was run on a 2% agarose gel (section
2.4.1), visualised, and recorded as described in section 2.4.1. Primer pairs designed
to amplify LH/hCG receptor, MMR and GAPDH cDNAs are given in Table 5.3.
Amplified products were visualised on agarose gels as described in section 2.4.1.








































Table 5.3: Primer sequences and product sizes
5.2.5 Q-RT-PCR
The relative levels of expression of IL-10, IFNy and TNFa mRNAs in uNK cells,
(control and treated cells; section 5.2.2), were determined using quantitative RT-PCR
(TaqMan) using random primed cDNA as detailed in section 2.4.2. Results were
analysed as in section 2.4.2. Primer pairs and probes specific to each gene are given
in Table 5.4. Primer pairs and probes were designed by Dr Elena Faccenda, a
member of the laboratory group.
















































Table 5.4: Primer and probe sequences
5.2.6 ELISA
5.2.6.1 IL-10 and TNFa
Media collected from uNK cell cultures was assayed for IL-10 and TNFa using a
two-site sandwich ELISA as described in section 2.6.7.1. Plates were coated with the
human IL-10 capture antibody (Pharmingen, Beckton Dickinson Company, Oxford,
UK) (2 pg/ml, 100 pi per well) or the human TNFa capture antibody (R&D Systems)
(2 pg/ml, 100 pi per well) and incubated overnight at 4°C. The plates were washed
prior to use. A standard curve for the IL-10 and TNFa assays, both consisting of
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seven standards, 500 to 7.8 pg/ml and 2000 - 31.2 pg/ml respectively, was added in
duplicate to each plate. The standards were prepared as described in section 3.2.9.
The non-specific binding control (NSB), standards, and media samples to be assayed
were added in duplicate, lOOpil per well. The remainder of the assay was conducted
as detailed in section 3.2.9.
5.2.6.2 IFNy
Media collected from uNK cell cultures was assayed for IFNy using a two-site
sandwich ELISA as described in section 2.6.7.1, except that plates were pre-coated
with antibody (Human IFNy Immunoassay, R&D Systems). Microplates were coated
with Assay Diluent RD1-51 (100 pi per well) (provided with kit). A standard curve
consisting of eight standards, 1000 to 7.8 pg/ml, was added in duplicate to each plate.
The standards were prepared as described in section 3.2.9. The NSB, standards, and
media samples to be assayed were added in duplicate, 100 pi per well. The
microplate was covered with the adhesive strip provided and incubated for 2 h at
room temperature. Excess media was discarded and plates washed 4 times in wash
buffer prior to addition of IFNy Conjugate (200 pi per well) (provided with kit).The
plate was incubated for 2 h on a plate shaker at room temperature, after which the
plate was washed as aforementioned. Subsequently, 200 pi of substrate solution
(provided with kit) was added to each well and incubated in a dark environment, at
room temperature for 30 min. The reaction was stopped by addition of 50 pl/well
Stop Solution (provided with kit). The colour was then measured on a plate reader at
450 nM. The details of the ELISA are summarised in Figure 2.3.
5.2.7 Immunocytofluorescence
uNK cells were prepared for immunostaining by Shandon Cytospin (Thermo
Electron Corporation, Cheshire, UK). Briefly, the slides and cardboard filters were
placed into appropriate slots in the cytospin with the cardboard filters facing the
centre of the cytospin, being sure that each filter and slide pair were flush with each
other and that the hole in the filter was in position to permit the cells to smear the
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slide. 100 pi of each sample was aliquoted into the appropriate wells of the cytospin
and spun at 80 g for 3 min. After which, the cardboard filter was removed with care
to ensure that the cell smear was not disturbed. The slides were allowed to dry
overnight at room temperature, protected from dust. Cells were fixed in methanol for
10 min at room temperature prior to immunostaining.
5.2.7.1 CD56 immunoreactivity
CD56 immunocytofluorescence was performed using the protocol described in
section 2.6.10. Briefly, 1st trimester uNK cells were prepared as described above.
Endogenous peroxidase was blocked by incubating the slides with 3 % H2O2 in 60 %
(v/v) methanol for 30 min at room temperature on a rocker and and non-specific
binding sites of the primary antibody were in a 1:5 dilution of NGS in PBS
containing 5 % BSA (NGS PBS/BSA). Endogenous avidin/biotin was blocked using
a commercially available avidin-biotin blocking kit (Vector Laboratories Ltd,
Peterborough, UK) then washed twice with PBS. Slides were incubated at 4°C
overnight in a 1:250 dilution of mouse monoclonal anti-human CD56 (Zymed) NGS/
PBS/BSA. After washing once with PBS/PBS Tween and once with PBS/PBS for 5
min each, CD56 antibody binding was detected by applying a 1:500 dilution of
peroxidase goat anti-mouse antibody (Dako UK Ltd) in NGS/PBS/BSA for 30 min
followed by a tyramide Cy3 (Perkin-Elmer Life Sciences), diluted 1:50 in the buffer
supplied for 10 min each at room temperature. After washing the slides as described
above, cells were counterstained with To Pro™ (Molecular Probes) (1:2000 in PBS)
for 2 min at room temperature. The slides were mounted under a glass coverslip
using Permafluor™ mounting medium (Beckman Coulter). Immunofluorescence was
visualised and recorded as described in section 2.6.9.10.
5.2.7.2 hCG and MMR immunoreactivity
hCG and MMR immunocytofluorescence was performed using the protocol
described in section 2.6.10. Briefly, 1st trimester uNK cells were prepared as
described above. Slides were incubated at 4°C overnight in a 1:20 dilution of rabbit
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polyclonal anti-human hCG (Abeam) NGS/ PBS/BSA. After washing once with PBS
Tween and once with PBS for 5 min each, hCG antibody binding was detected by
applying a 1:500 dilution of biotinylated goat anti-rabbit antibody (Dako UK Ltd) in
NGS/PBS/BSA for 30 min followed by streptavidin 546 (Molecular Probes) for 60
min each at room temperature. After washing the slides as described above, slides
were incubated at 4°C overnight in a 1:10 dilution of mouse monoclonal anti-human
MMR (Abeam) NGS/PBS/BSA. Anti-MMR antibody binding was detected by
applying a 1:500 dilution of biotinylated goat anti-mouse antibody (Dako UK Ltd) in
NGS/PBS/BSA for 30 min followed by streptavidin 488 (Molecular Probes) for 60
min each at room temperature. After washing the slides as described above, cells
were counterstained with To Pro™ (Molecular Probes) (1:2000 in PBS) for 2 min at
room temperature. The slides were mounted as described in section 5.2.7.1.
Immunofluorescence was visualised and recorded as described in section 2.6.10.10.
5.2.7.3 Haematoxylin and Eosin staining
Haematoxylin and Eosin staining was performed as described in section 2.6.9.10
with the exception that slides were immersed in Eosin for 3 min after developing the
nuclei in Scott's tap water. Thereafter, slides were dehydrated in increasing
concentrations of alcohol and cleared in histoclear and xylene for 5 min each before
mounting under a borosilicate glass coverslip (VWR) using Pertex™ (Cell Path,
UK), a solvent based glue.
5.2.8 FACS analysis of uNK cell surface marker proteins
FACS analysis was using performed as described in section 2.7.1 using the
antibodies detailed in Table 5.5.
For FACS analysis using both MMR and CD56 antibodies, 6 eppendorfs containing
5 x 105 cells each were re-suspended in 100 pi FACS buffer (PBS, containing 0.1 %
NaN3 and 1 % FCS): the first tube remained untreated, 10 pi anti-mouse IgG whole
molecule with FITC conjugated (Sigma) or PE conjugated was added to the second
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and third tube respectively, 10 pi of the anti-CD56 antibody was added to the fourth
tube, 20 pi of the anti-MMR antibody was added to the fifth tube and 10 pi of the
anti-CD56 antibody and 20 pi of the anti-MMR antibody was added to the sixth tube.
The remainder of the protocol was conducted as in section 2.7.1.
Antigen Dilution Species raised in Source
CD56 1:10 Mouse Serotec
MMR 1:5 Mouse Serotec
Table 5.5: Antibodies used in FACS anaylsis.
5.2.9 Statistical Analysis
Prior to statistical analysis, all data was tested for and shown to demonstrate
Gaussian distribution. Where appropriate, values were presented as means ± S.E.M.
Q RT-PCR and ELISA data were analysed by the methods described previously in
section 2.8.




5.3.1 Purity of uNK cells isolated from 1st trimester decidua
Before embarking on a series of experiments to determine the impact of hCG on
gene expression in uNK cells, the purity of isolated uNK cells had to be ascertained.
FACS analysis confirmed purity of >90% from 1st trimester decidua (Figure 5.1, I)
and > 95% from late secretory endometrium (Figure 5.1, II). This was further
confirmed by IHF analysis of CD56 immunoexpression (Figure 5.2). In addition,
uNK cells are reported to be highly granular and this was confirmed by
morphological analysis of H&E stained cells (Figure 5.3).
Figure 5.1: FACS analysis of uNK cell purity. Panel I, 1st trimester MACS®-isolated
uNK cells: unstained cells (A), isotype-matched negative control (B), CD56 FITC
stained cells (C); the y axis is the total cell count and the x axis is the FITC value.
The region represented by Ml indicates the number of cells that are positive for
FITC. Graph D shows sorting gate applied to isolated 1st trimester uNK cells.
Representative scans from 46 samples are shown; cells are typically > 90 % pure.
Panel II, non-pregnant late secretory MACS®-isolated uNK cells: The isotype-
matched negative control (A) incubated with the CD56 antibody (B); the y axis is the
forward scatter plot and the x axis is the FITC value- the total level of fluorescence
detected on the cells counted. Unstained cells (C), isotype-matched negative control
(D), CD56 FITC stained cells (E). The region represented by Ml indicates the
number of cells that are positive for FITC. This is ~ 1% in graph C (unstained) and D
(isotype control) whereas in graph E (CD56 stained) cells are ~ 95 % pure.
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Gated Events: 10000 Total Events: 12885
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All 10000 100.00 77.61 2.73 569.39 2.57
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Sample ID:Isotype FITC Gate: G1
Gated Events: 9669 Total Events: 11676
Marker Events % Gated % Total Geo Mean CV Median
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FL1-H
Sample ID: CD56 FITC Gate: G1
Gated Events: 9668 Total Events: 12375
Marker Events % Gated % Total Geo Mean CV Median
All 9668 100.00 78.13 130.24 89.74 158.20
M1 9441 97.34 76.29 139.12 87.64 159.63
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Figure 5.2: uNK cells immunostained for CD56. Red staining shows the localisation
ofCD56 antibodies; blue shows nuclear counterstain. To Pro. Panel I shows isolated
uNK cells stained with mouse anti-human CD56 viewed at x 40 magnification with
oil immersion. Panel II shows a cropped image of Panel I. Panel III shows a
formalin-fixed section of 1st trimester decidua, included as a positive control. Panel
IV shows the negative control. Note, not all cells stain positive for the nuclear
counterstain as they were not penneabilised.
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Figure 5.3: H&E staining of isolated NK cells from 1st trimester decidua. Panels I to
IV, show representative uNK preparations from lsV trimester decidua preparations.
Note the granularity of the cytoplasm, highlighted with black arrows, and the
reniform, eccentric nucleus and short, cytoplasmic projections. Scale bars represent
100pm.
5.3.2 Expression of LH/hCG receptors in uNK cells isolated from
1st trimester decidua
To elucidate if the LH/hCG receptor was present in the uNK cells isolated from Tst
trimester decidua, uNK samples were tested for the presence of LH/hCG receptor
mRNA. Expression of LH/hCG receptor mRNA was only detected in the corpus
luteum sample (positive control; kindly provided by Dr Colin Duncan) following
semi-quantitative RT-PCR (Figure 5.4 Panel A, sample 8). No expression was
observed in any of the samples of uNK cells isolated from 1st trimester decidua
(Figure 5.4 Panel A, samples 1-7). Therefore any action by hCG will not be mediated
by binding to the LH/hCG receptor. Panel B shows the same samples analysed using
primers directed against GAPDH, which was used as an internal control for integrity
of the RNA samples.
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Figure 5.4: Expression of LH/hCG receptor (203 bp) was not detected in isolated
uNK cells from 1st trimester decidua and late-secretory phase endometrium. A corpus
luteum sample was included as a positive control. Samples were harvested and total
cellular RNA was analysed by RT-PCR for the expression of LH (Panel A) and
GAPDH (205bp) (Panel B), the housekeeping gene. Sample M represents DNA
hyperladder. Samples 1 to 7 show uNK cells from 1st trimester decidua. Sample 8
shows uNK cells from non-pregnant late secretory phase endometrium. Sample 9
shows a corpus luteum sample.
5.3.3 hCG treatment increases uNK cell number in vitro
To elucidate if hCG has any effect on uNK cell proliferation, isolated uNK cells from
1st trimester decidua were cultured in the presence or absence of varying
concentration of hCG, and analysed by light microscopy (Figure 5.5). Panel I
represents cells exposed to no treatment, Panel II represents cells treated with 10
ng/ml hCG, Panel III shows cells treated with 100 ng/ml hCG, Panel IV shows cells
treated with 1000 ng/ml hCG and Panel V represents cells treated with 10000 ng/ml
hCG. All samples were treated for 2 h. No increase in cell number is observed with
10 ng/ml or 100 ng/ml hCG treatment (Figure 5.5, Panels II and III) when compared
to control cells (Figure 5.5, Panel I). However, an increase is observed with 1000
ng/ml and 10000 ng/ml hCG treatment (Figure 5.5, Panels IV and V). A photograph
from representative tissue culture of 12 decidual samples is shown (Figure 5.5). This
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method is non-quantitative and therefore further studies to quantify the increase in
proliferation are warranted.
Figure 5.5: Photograph of uNK cells from 1st trimester decidua in culture, treated
with increasing concentrations of hCG for 2h. Panel I shows no treatment, Panel II
shows 10 ng/ml hCG, Panel III shows 100 ng/ml hCG, Panel IV shows 1000 ng/ml
hCG and Panel V shows 10000 ng/ml hCG. Photograph from representative tissue
culture of 12 decidual biopsies. Scale bars represent 50pm.
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5.3.4 hCG-mediated effect on the production of uNK-associated
cytokines
To determine if hCG could affect cytokine release of uNK cells, the production of
several cytokines associated with uNK cells were measured after treatment with
hCG. No change in expression of TNFa (Figure 5.6, Panel A), IL-10 (Figure 5.6,
Panel B), and IFNy (Figure 5.6, Panel C) mRNAs and TNFa protein production
(Figure 5.7, Panel A) was observed with hCG treatment at any concentration, n = 8
uNK 1st trimester samples. In contrast, IL-10 protein release was significantly
increased with 10 ng/ml hCG treatment (Figure 5.7, Panel B, p<0.05), uNK 1st
trimester samples). No effect was seen with any other concentration used (Figure 5.7,
Panel B). IFNy protein release was significantly inhibited with treatment of 10 ng/ml
and 100 ng/ml hCG after 2 h (Figure 5.7, Panel C, p<0.01, n= 8 uNK 1st trimester
samples). Treatments with 1000 ng/ml and 10000 ng/ml hCG were without
significant effect, but displayed a mild trend towards augmentation.
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Figure 5.6: TNFa (Panel A),
IL-10 (Panel B) and IFNy
(Panel C) mRNA expression
in uNK cells incubated with
increasing concentrations of
hCG. No significant effect
was observed in any cytokine
with all concentrations of
hCG treatment, 2h. n = 8
uNK lsl trimester samples.
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Figure 5.7: IL-10 (Panel A),
TNFa (Panel B) and IFNy
(Panel C) release from uNK
cells incubated with increasing
concentrations of hCG.
Treatment with hCG, 2h, failed
to induce a response in TNFa
protein release, n = 8 isolated
uNK samples. The lower
detection limit of the ELISA was
31.2 pg/ml. Treatment with 10
ng/ml hCG, 2h, evoked a
significant increase in IL-10
protein release from uNK cells
(Panel B, p<0.05, n = 8 isolated
uNK samples). The lower
detection limit of the ELISA was
7.8 pg/ml. Treatment with 10
ng/ml and 100 ng/ml hCG, 2 h,
evoked a significant reduction in
IFNy protein release from uNK
cells (Panel C, p<0.01, n = 8
isolated uNK samples).
Treatment with 10 ng/ml and
100 ng/ml hCG show no
significant effect. The lower
detection limit of the ELISA was
7.8 pg/ml.
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5.3.5 Expression of MMR on uNK and PBNK cells
Expression of MMR mRNA was detected in both 1st trimester uNK cells and in the
decidual sample (Figure 5.8 samples 1 to 6 and 8, panel A). MMR mRNA was low in
non-pregnant secretory phase uNK cells (Figure 5.8, panel A, sample 7) in the semi¬
quantitative PCR. Panel B shows the same samples analysed using primers directed
against for GAPDH, which was used as an internal control for integrity of the RNA
samples. This was further corroborated with quantitative RT-PCR (TaqMan)
conducted on the same samples (Figure 5.9). Protein expression was identified with
IHF and FACS analysis. Isolated 1st trimester uNK cells were immunoprobed for
MMR (Figure 5.10). Although MMR is a cell surface receptor it is internalised upon
glycosylation, therefore the cells were permeabilised prior to immunostaining. The
staining pattern of MMR is not uniform but would appear to be quite clustered.
Isolated 1st trimester uNK cells were stained for MMR, CD56 and both in
combination and analysed by FACS to identify the population of uNK cells positive
for MMR. Results are presented in Figure 5.11; panel A shows cells without staining,
Panels B and C show cells stained with the mouse isotype control FITC and PE
respectively, Panel D shows cells stained with CD56, Panel E shows cells stained
with CD206 (MMR) and Panel F shows cells stained with both CD56 and CD206.
As reported previously, isolated cells are >90 % pure (Figure 5.11, Panel E, lower
right quadrant (LR)). Not all CD56 positive cells stain positive for CD206, indeed
only approximately 40% of these cells are positive for CD206 (Figure 5.11, Panel E,
upper left quadrant (UL)). -35 % of CD206 positive cells also stain positive for
CD56 (Figure 5.12, Panel F, upper right quadrant (UR)). Anomalies in percentages
may be attributable to either antibody masking antigenic sites or preventing binding
of the other antibody to the cells. Neither isotype control was seen to induce changes
(Figure 5.11, Panels B and C).




Figure 5.8: Expression of MMR niRNA (203bp) in isolated uNK cells from 1st
trimester decidua and late-secretory phase endometrium, A decidual sample was
included as a positive control. Samples were harvested and total cellular RNA probed
for the expression of MMR (Panel A) and GAPDH (205 bp) (Panel B), the
housekeeping gene. Sample M represents DNA hyperladder. Samples 1 to 6 show
uNK cells from 1st trimester decidua. Sample 7 shows uNK cells from non-pregnant
late secretory phase endometrium. Sample 8 shows a decidual sample.
Figure 5.9: Preliminary data on the relative expression ofMMR gene in uNK cells
isolated from Is1 trimester decidua (P) or from late secretory non-pregnant
endometrium (NP). A decidual sample was included as a positive sample. MMR
mRNA was analysed by Q-RT-PCR. Results are ± SEM n = 6 uNK (P) samples, n =
1 uNK (NP) sample and n = 1 decidual sample. All samples were run in triplicate.
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Figure 5.10: uNK cells immunoprobed for MMR. Green shows MMR staining; blue
shows nuclear counterstain, To Pro. Insert shows negative control.
Figure 5.11; FACS analysis ofuNK cell surface antigen expression. On graphs A to
F, axis y is the PE value and axis x is the FITC value; Panel A shows unstained cells
(B), i so type-matched negative controls for FITC and PE respectively (B and C), 1st
trimester MACS'isolated uNK cell sample stained for CD56 (D) and MMR (E),
respectively. Graph F shows representative co-expression analysis of CD56 and
MMR. One representative data set is shown of nine experiments performed. FITC,
fluorescein isothiocyanate; PE, phycoerythrin; UL, upper left quadrant; UR upper
right quadrant; LL, lower left quadrant; LR, lower right quadrant.
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5.3.6 hCG colocalises with MMR in uNK cells isolated from 1st
trimester decidua
To elucidate if hCG may bind to MMR, uNK cells treated with hCG were
immunoprobed for both hCG and MMR (Figure 5.12). Panels I, II and III shows 1st
trimester uNK cells stained with rabbit anti-human hCG (red) and mouse anti-human
MMR (green). Panels IV, V and VI show cropped images of the samples in the
panels above. Panel VII shows placenta stained for hCG as a positive control. Panels
VII and IX shows negative controls, placenta and uNK cells respectively. As
observed with FACS analysis, less than half of the isolated 1st trimester uNK cells
stained positive for MMR, localised predominantly to the cell surface (Figure 5.12,
panels I, II, III). All cells stained postitive for hCG, again predominantly in a cell
surface location (Panels I to VI). Areas of colocalisation were observed and appear
as yellow in the images.





Figure 5,12: Staining ofuNK cells withMMR staining illustrated by green and hCG
staining by red. Yellow staining shows areas of colocalisation. Blue shows nuclear
counterstain. To Pro. Panel A: panel I, II and III shows uNK cells at x 40
magnification with oil immersion. Panels IV. V and VI show cropped image of
panels I, II and III respectively. Panel VII shows a formalin fixed placenta section.
Panels VIII and IX show negative controls, both uNK cells and placenta,
respectively. Panel B: shows split image of panel IV; panel I shows MMR alone,
panel II shows hCG alone, panel III shows panels I and II superimposed.




This study has demonstrated that low doses of hCG, <1000 ng/ml, promoted IL-10,
and inhibited IFNy protein release by uNK cells, isolated by MACS® separation
from 1st trimester decidua (Figure 5.7, Panels B and C). Previous studies showed that
hCG enhanced TNFa and IFNy protein production by PBMC (Schafer, Pauli et al.
1992; Yousefi, Karamlou et al. 1993). The results in this study are in contrast to the
previous findings, and demonstrate that, in uNK cells; hCG inhibits protein release of
IFNy and is without effect on TNFa mRNA or protein. The inhibitory effect of hCG
on IFNy and stimulatory effect on IL-10 protein release was not observed at mRNA
level. The observed hCG responses may be cell-specific. Treatment with 10,000
ng/ml hCG also appeared to increase uNK cell number (Figure 5.5, n = 12 decidual
samples). However, as no quantitative analysis was conducted, hCG-induced cell
proliferation cannot be conclusively stated. Furthermore, to ensure that the
population of cells undergoing apparent cellular proliferation is CD56Bnght uNK cells,
FACS analysis, determining cell surface expression of uNK cell-specific markers
must be undertaken.
hCG can propagate its hormonal signal to target cells through the LH/HCG receptor,
which was originally reported to be expressed on ovarian granulosa cells, theca
interna cells, and luteal cells (Acevedo 2002). Several lines of evidence have
demonstrated that the LH/hCG receptor is also expressed in the endothelium and
myometrium (Reshef, Lei et al. 1990; Lei, Reshef et al. 1992; Kornyei, Lei et al.
1993). A previous study reported that mRNA of the LH/HCG receptor was detected
in T lymphocytes derived from the peripheral blood of pregnant women (Lin, Lojun
et al. 1995). In addition, the LH/hCG receptor has been localised to macrophages
from term placenta and late secretory phase non-pregnant endometrium (Zhang, Rao
Ch et al. 2003). In the present study, uNK cells, isolated by MACS® separation from
1st trimester decidua, were shown to respond to hCG by releasing IL-10 protein
(Figure 5.7, Panel B, p<0.05, n = 8 decidual samples), and inhibiting IFNy protein
release (Figure 5.7, Panel C, p<0.01, n = 8 decidual samples). However, expression
of LH/hCG receptor mRNA was not detected in CD56Bnght uNK cells from 1st
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trimester decidua and late secretory non-pregnant endometrium by RT-PCR (Figure
5.4). As the uNK cells in this study were cultured alone, and any hCG-mediated
responses would be a result of direct interaction with the uNK cell, the findings
herein indicate a discrepancy between hCG-binding and LH/hCG receptor
distribution. This is in agreement with studies reporting no LH/hCG receptor
expression in PBNK cells (Sulke, Jones et al. 1985; van den Heuvel, Peralta et al.
2005) and PBMN cells, stimulated by exogenous hCG (Kosaka, Fujiwara et al.
2002),
Furthermore, a recent study has demonstrated that addition of mannose significantly
suppressed hCG-stimulated IL-8 production and interfered with the binding of hCG
to CD14-positive monocytes (Kosaka, Fujiwara et al. 2002). The authors proposed
that cell surface lectinsmay play a role in the hCG-signalling pathway; however they
failed to detect MMR mRNA in their cell preparation (Kosaka, Fujiwara et al. 2002).
Recently, pituitary hormones such as LH and TSH were reported to interact with
MMR (Fiete, Beranek et al. 1998; Simpson, Hitchen et al. 1999) and it was proposed
that immune cells are involved in the clearance of these hormones (Simpson, Hitchen
et al. 1999). This receptor recognises glycoconjugates terminating in mannose,
fucose, or N-acetylglucosamine in a Ca2+-dependent manner via C-type
carbohydrate-recognition domains (Taylor 2001). Therefore, we examined if the
MMR was present on uNK cells, both from non-pregnant endometrium and 1st
trimester decidua, and whether uNK cells treated with hCG would demonstrate hCG-
binding and if this would colocalise with MMR. MMR mRNA and protein was
detected in uNK cells isolated from 1st trimester decidua (Figure 5.8, samples 1-6 and
Figure 5.10) The protein distribution on the uNK cell surface appeared to be quite
clustered (Figure 5.10), although this may represent the constant recycling of the
MMR between the cell surface and the cytoplasm (East and Isacke 2002). MMR
mRNA expression in uNK cells isolated from a non-pregnant late secretory sample
was low in comparison to uNK cells derived from decidua, as analysed by RT-PCR.
This was further corroborated with quantitative analysis (Figure 5.9), however, such
comparisons should proceed with caution as these are very preliminary data and
further analysis of many more uNK samples isolated from non-pregnant
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endometrium is required. Moreover, both RT-PCR and Q-RT-PCR analysis
demonstrated markedly higher expression of MMR mRNA in decidua than in
isolated uNK cells, this may be explained by MMR expression on cells in decidua
other than the uNK cell, e.g. macrophages (Shepherd, Tarnowski et al. 1991; Taylor,
Gordon et al. 2005). FACS analysis demonstrated that not all uNK cells express
MMR on the cell surface, indeed only ~ 40 % of the uNK cells stain positive (Figure
5.11, Panel E, UL). Again, this may reflect shuttling of the receptor as opposed to
uNK cell distribution of MMR. However, this may indicate the presence of a sub-
population of uNK cells that express MMR in addition to the classic uNK cell
marker CD56Bnght. This distribution pattern was also observed with IHF studies in
which not every uNK cell stained positive for MMR (Figure 5.12, Panel A (I, II and
III)). Interestingly, after treatment with hCG, most antigenic sites positive for MMR
showed colocalisation with hCG (Figure 5.12, Panel A (IV, V and VI), Panel B).
Conversely, several antigenic sites positive for hCG did not exhibit colocalisation. In
the absence of an LH/hCG receptor, additional binding sites for hCG may exist and it
is notable that other C-type lectins have been identified on immune cells (Ebner,
Ehammer et al. 2004). For example proliferating antigen-presenting cells expressing
DC-SIGN (CD209) has been identified in the decidua of early human pregnancy
(Kammerer, Eggert et al. 2003).
A very recent study has demonstrated that glycosylation, terminal sialylation in
particular, differentially influences the lectin activities of MMR, allowing
oligomerisation of the receptor, resulting in multiple presentations of CR domains
(Su, Bakker et al. 2005). The authors also propose that this glycosylated-regulation
of MMR may facilitate binding of two sulfated hCG glycans, into two neighbouring
CR domain binding pockets (Su, Bakker et al. 2005), providing a potential
mechanism for the interaction between glycosylated hormones and MMR.
Additionally, Kovalevskaya et al (Kovalevskaya, Birken et al. 2002) reported that a
hyperglycosylated form of hCG arises very early in pregnancy and is rapidly replaced
by less glycosylated isoforms, showing that hCG glycoforms dynamically change as
pregnancy progresses. This finding has been suggested to provide a rationale for the
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proposed maternal recognition of the embryo during the earliest stages of pregnancy
in that the embryo may transmit the information about its presence to maternal
immune systems via highly glycosylated hCG, which mimics products produced in
bacterial infections (Kosaka, Fujiwara et al. 2002). Therefore, the physiological roles
of hCG not only in the endocrine system, but also in the immune system should be
investigated further with respect to aspects other than the so-called LH/HCG
receptor.
In conclusion, the present study demonstrated that uNK cells derived from 1st
trimester decidua are able to respond to hCG at concentrations < 1000 ng/ml by
enhancing their production of IL-10 and reducing their production of IFNy. This
study also demonstrated that a signalling pathway different from the LH/hCG
receptor system are responsible for this effect of hCG on uNK cells. In addition,
MMR was localised to uNK cells and IHF analysis showed areas of MMR and hCG
colocalisation, suggesting a potential mechanism by which hCG may bind to uNK
cells. These observations now require further functional studies to elucidate if a
potential LH/hCG - MMR interaction can facilitate downstream signalling and
induce proliferation and/or migration, providing an alternative mechanism for the
expansion of uNK cells observed during the late-secretory phase of the non-pregnant
menstrual cycle and the 1st trimester of pregnancy. These findings suggest that an
immune-endocrine network involving hCG and uNK cells exists and may play an
important role in regulation of the menstrual cycle and events of early pregnancy.




Decidualisation of the endometrial stromal compartment is essential for implantation
of the conceptus but, in the absence of pregnancy, loss of the decidual phenotype is
functionally linked to menstrual shedding of the endometrium (Bell 1990).
Decidualisation is governed by the steroid hormone progesterone acting via its
nuclear receptor (Huang, Tseng et al. 1987; Zhu, Huang et al. 1990; Tseng, Gao et al.
1992; Mizuno, Tanaka et al. 1998; Brosens, Hayashi et al. 1999), but at a paracrine
level may be regulated by a myriad of cytokines and growth factors, including
TGF(31 (Jones, Stoikos et al. 2006). The Wnt-signalling pathway antagonist,
Dickkopf (DKK) has also been implicated in the process of decidualisation as DKK
expression is localised to the stroma and increased in mid-secretory phase
endometrium (Tulac, Nayak et al. 2003; Giudice 2004). Additionally, DKK is
reported to be progesterone-dependent (Tulac, Overgaard et al. 2006). TGF(31 is
abundantly expressed in both endometrial epithelial and stromal cells and is thought
to play a critical role in cyclic tissue remodelling and inflammatory events associated
with menstruation (Bruner, Rodgers et al. 1995; Ulloa, Creemers et al. 2001). TGF(11
mediates its actions predominantly via the SMAD signalling pathway (Graff, Bansal
et al. 1996; Macias-Silva, Abdollah et al. 1996; Nakao, Imamura et al. 1997;
Massague and Wotton 2000; Shi and Massague 2003). However when the current
studies were initiated it remained to be determined whether TGF(31 affects either PR
or DKK to regulate the decidual process.
Decidualisation is also associated with a unique immune environment, characterised
by the presence of large numbers of uterine-specific natural killer cells (uNK)
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(Bulmer, Lunny et al. 1988). uNK cells increase in number in secretory phase
endometrial stroma, implying regulation by progesterone on their expansion in
number (King 2000). However, they lack the nuclear progesterone receptor
(Henderson, Saunders et al. 2003) and growth and differentiation may therefore
depend on interactions with endometrial stromal cells (ESCs) and regulation by other
cytokines (Trundley and Moffett 2004) or may involve other hormones such as
luteinising hormone (LH) and human chorionic gonadotrophin (hCG).
6.2 Findings of this thesis
These studies described in this thesis set out to investigate the role of TGFpl in
modulating the regulators of decidualisation and the resulting production of
decidualisation marker proteins, in an attempt to achieve better understanding of how
the process of decidualisation may be regulated in vivo. Additionally, the studies
herein have sought to characterise better the phenotypically unique uNK cell, whose
numbers expand in the mid to late secretory phase of the cycle in parallel with
decidualisation of the stroma.
In Chapter 3, studies focused on the impact of TGFpl on gene expression in non-
decidualised and decidualised stromal cells. The studies in this chapter were
performed using primary human ESCs, either non-differentiated or treated with 8-Br-
cAMP and MPA to induce a decidualised phenotype. Initially, studies were designed
to determine the effect of TGF(31 treatment on SMAa mRNA expression. The
studies presented herein demonstrate that TGF(31 treatment significantly augments
SMAa mRNA expression in both non-decidualised (Figure 3.7 and 6.13) and
decidualised ESCs (Figure 3.8 and 6.13). Previous papers have reported that human
stromal cells, which had been decidualised in vivo in the presence of a blastocyst,
expressed SMAa and displayed ultrastructural similarities with myofibroblasts
(Oliver, Montes et al. 1999). Oliver et al also reported that SMAa could be detected
by FACS analysis in decidual stromal cells, decidualised in vitro by treatment with
progesterone (Oliver, Montes et al. 1999). 1st trimester decidua sections were also
immunoprobed for aSMA, which was localised to the perivascular cells (Oliver,
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Montes et al. 1999). The stromal cells in the 1st trimester tissues used in the study by
Oliver et al would have been exposed to progesterone for at least 8 or 9 weeks and
should have been fully decidualised in vivo (Oliver, Montes et al. 1999). Previous
work in our laboratory has demonstrated a similar perivascular immunolocalisation
of SMAa in mid-secretory phase endometrium (Rodney Kelly and Sheila
MacPherson, unpublished observations). TGF(31, which has previously been
demonstrated to be an inducer of a myofibroblast phenotype (Desmouliere, Geinoz et
al. 1993; Jester, Barry-Lane et al. 1996; Serini, Bochaton-Piallat et al. 1998;
Grotendorst, Rahmanie et al. 2004; Lewis, Lygoe et al. 2004; Shephard, Martin et al.
2004), has also been shown to induce contractility of DSC (Kimatrai, Oliver et al.
2003). The studies described in Chapter 3 demonstrated that TGFfll upregulates
SMAa mRNA expression in both non-decidualised and decidualised ESC in
agreement with the previous studies. In the current study, treatment with TGF(31
induced a myofibroblast phenotype (induction of SMAa) in both non-decidualised
and decidualised ESCs (Figures 3.7 and 3.8). In contrast, Oliver et al have claimed
that SMAa is only present in DSCs when cultured with progesterone for 14 d
(Oliver, Montes et al. 1999). The stromal cells, in which TGFfTl induces a
myofibroblast phenotype in vitro, are the only endometrial cell type that retains their
PR throughout the menstrual cycle, including during decidualisation (Wang,
Critchley et al. 1998).
As progesterone is the hormone thought to be responsible for the process of
decidualisation (Brosens, Hayashi et al. 1999) and TGF(!1 has been detected in its
active form during the late-secretory and pre-menstrual phase of the cycle (Casslen,
Sandberg et al. 1998) further studies presented in this thesis concentrated on a
possible TGFpi-mediated regulation of PR expression. We report that TGF(31
induced a rapid upregulation of PR mRNA expression in both non-decidualised
(Figure 3.10) and decidualised (Figure 3.12) ESCs followed by a subsequent
downregulation (Figures 3.10 and 3.12), which was mirrored at a mature protein
level (Figures 3.11, 3.13, 3.14, and 6.3). However, Western blot analysis of the
reduction in PR protein (Figure 3.14) was not convincing and requires further
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experimentation with an increased number of samples and densometric analysis. This
inhibitory response was also observed in the PR positive breast cancer T47D cell line
(Figures 3.12 and 3.13). The initial TGFpi-induced upregulation of PR may be
mediated by the non-genomic PRs, however this was not analysed further. As no
functional role has been identified for the non-genomic receptors it is impossible to
identify downstream target genes which could be used to assess any impact of
TGF(31 on these putative membrane-bound receptors. The downregulation of PR in
both ESCs and T47D cells would suggest that the effect of TGFJ31 is perhaps not
stromal cell-specific but PR-specific. Furthermore, by transiently transfecting ESCs
with a PRE or an ERE linked to luciferase, as a reporter gene, we could demonstrate
that the TGF|31-induced downregulation of PR was not due to TGFpl-signalling
preventing ER-mediated PR gene transcription (Figure 3.15). This result suggested
that the observed TGFp l-induced downregulation of PR was without effect on gene
transcription, but could perhaps be attributed to TGF|31-induced alteration of RNA
stability, which may reduce the half-life of the mRNA and subsequently impact
mRNA expression and protein translation. Another possibility is that TGF(41 may be
acting on other sites of the PR promoter, e.g. SMAD binding sites, which in turn may
impact PR gene transcription via recruitment of co-activators or co-repressors, or
TGFp i may be interacting directly with co-regulators to impede PR binding to its
PRE, thus suppressing PR gene transcription. Further experimentation transfecting
ESCs with promoter-reporter constructs containing SMAD binding sites in addition
to a PRE or ERE may elucidate a mechanism by which TGFpl impacts PR
expression.
Previous studies have reported that Wnt family members are expressed in human
endometrium throughout the menstrual cycle (Tulac, Nayak et al. 2003). The authors
reported no significant menstrual cycle dependence of the Wnt ligands (except Wnt-
3), receptors, or downstream effectors (Tulac, Nayak et al. 2003). The authors
reported that Wnt-3 was significantly increased in proliferative compared with
secretory phase endometrium in accordance with data from Hou et al who report that
canonical Wnt signalling is critical to oestrogen-mediated uterine growth (Tulac,
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Nayak et al. 2003; Hou, Tan et al. 2004). Tulac et al also reported a significant up-
regulation of DKK in the secretory, compared with the proliferative phase, and that
expression was restricted to the stroma (Tulac, Nayak et al. 2003; Giudice 2004).
More recent findings have elucidated that DKK mRNA synthesis and protein
expression is upregulated in human ESCs, decidualised in vitro, and that the response
is progesterone specific and independent of cAMP and oestradiol (Tulac, Overgaard
et al. 2006). However, analysis of the DKK promoter region did not reveal
progesterone response element consensus sequences (Tulac, Overgaard et al. 2006).
The studies presented herein are in agreement with those of Tulac et al and
demonstrate induction of DKK protein release associated with decidualisation in
vitro (Figure 3.17, 3.19, 3.21, and 6.3). Additionally, to our knowledge we report for
the first time that TGF(51 suppresses DKKmRNA expression and protein release in a
TGFpi-specific manner and that this downregulation precedes that of PR mRNA
downregulation (Figure 3.16 - 3.19). If DKK is indeed involved in decidualisation
then perhaps this initial inhibition of DKK induces Wnt-signalling and heralds the
onset of TGFpi-induced abrogation of the decidualised phenotype in the ESC during
the normal menstrual cycle. As with ERE, TGF(31 treatment did not impact the
reporter gene activation of the PRE/ARE or GRE, which share an identical sequence
(Figure 3.15). However, as no PRE has as yet been identified on the DKK promoter,
any potential TGF|31-induced effect would be redundant with regards to DKK
mRNA transcription. To date, no evidence has been provided for the presence or
absence of an ARE or GRE on the DKK promoter. Interestingly, a recent publication
by Goldman et al has provided a possible mechanism for PRE-independent
progesterone mediated responses (Goldman and Shalev 2006). Goldman proposes
that in addition to the direct transcriptional activation through binding with its
cognate DNA response element, PR is capable of transcriptional activation
interacting with other classes of transcription factors on their cognate binding site,
e.g. CREB-binding protein and/or SP-1 (Goldman and Shalev 2006). The authors
suggest that in such cases where PR acts in a PRE-independent manner, that
progesterone acts as a co-activator or co-repressor (Goldman and Shalev 2006).
Although this proposed mechanism has not yet been conclusively proven, it does
suggest a potentially novel process by which progesterone regulates DKK.
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Although we report that TGFpi can induce SMAD phosphorylation consistent with
activation of its signalling pathway in the cells maintained in vitro in the studies
presented in this thesis (Figures 3.22 -3.23), no conclusive findings can be drawn on
whether the downregulation of PR and DKK are SMAD-regulated. Identification of
the pathways regulating the suppression of PR and DKK will be important for
evaluating the TGFpi-induced expression of PIAS y, which we have observed in
agreement with previous published data from Imoto et al (Imoto, Sugiyama et al.
2003). As PIAS y has been reported to inhibit SMAD transcriptional activity, this
TGFpl-induced expression of PIAS y (Figure 3.14) may provide a mechanism by
which TGFP1 inhibits the expression of PR and perhaps also DKK (summarised in
Figure 6.1).
Figure 6.1: Diagram depicting the hypothetical TGFP 1-mediated PIAS y inhibition
of SMAD transcriptional activity and therefore the potential target genes, PR and
DKK. TGFP 1 upregulates PIAS y, which inhibits SMAD transcriptional activity, and
in turn this may account for the TGFpl-mediated suppression of PR and DKK.
In Chapter 4, studies focused on the impact of TGFpi on gene expression of
decidualisation marker proteins. The studies in this chapter were conducted using
primary human ESCs, obtained from non-pregnant endometrium, treated with 8-Br-
cAMP and MPA to induce a decidualised phenotype, and DSCs obtained from 1st
TGFpi
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trimester decidua. As the studies in Chapter 3 had demonstrated that TGFfll was
capable of inhibiting the mediators of decidualisation, the initial focus of the studies
was to evaluate the effect of TGF(31 on the classical decidualisation marker proteins;
tissue factor (TF) (Lockwood, Krikun et al. 1994), IGFBP-1 (Irwin, Kirk et al. 1989)
and dPRL (Maslar and Riddick 1979). We report that TGF|31 significantly
downregulated mRNA expression of all three decidualisation markers (Figures 4.1,
4.3, and 4.5) and markedly suppressed mature protein release of both IGFBP-1
(Figure 4.2) and dPRL (Figure 4.4). These findings are in agreement with a number
of studies reporting a marked inhibitory effect of TGFpl on IGFBP-1 protein
secretion and basal and stimulated PRL secretion (Delidow, Billis et al. 1991;
Jikihara and Handwerger 1994; Kubota, Taguchi et al. 1997; Minami and Sarkar
1997; Coya, Alvarez et al. 1999; Mazella, Tang et al. 2004). However, it must be
noted that in the studies presented herein, the expected mRNA/protein kinetics were
not observed. This may be attributed to several possibilities; firstly, the small
reduction in IGFBP-1 and dPRL mRNA may be sufficient to result in a large change
in protein release, secondly, TGFpl may be acting at a transcript level to produce
greater levels of mRNA, whilst altering the RNA stability to prevent a rapid
downregualtion of the mRNA expression. Furthermore, TGF(31 may be altering
translation of the RNA code thereby impacting on the protein synthesis, or TGFjll
may be acting directly to impede the post-translational folding of the protein, thereby
impacting the export or transport of the protein into the supernatant.
It was previously suggested that the long-term effect of TGF(11 on inhibition of PRL
expression might be attributed to decreased cAMP levels (Tanaka, Miyazaki et al.
1993; Herrlich, Kuhn et al. 1996; Telgmann, Maronde et al. 1997) as the dPRL
promoter has previously been shown to contain a critical region located between -
332 bp and -270 bp relative to the start site that is activated by 8-Br-cAMP and PKA
(Telgmann, Maronde et al. 1997; Telgmann and Gellersen 1998). The data presented
herein has shown for the first time that TGF(31 abrogates the transactivation potential
of the dPRL promoter-reporter, by more than 50%, acting at the minimal PKA-
sensitive decidual PRL promoter construct (dPRL-332/Luc), in response to cAMP-
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treated endometrial stromal cells (Figure 4.16). This suggests that TGFpi acts upon
the region critical for successful transcription.
In contrast to the findings of the present studies, Celikkanat et al (Celikkanat, Atac et
al. 2000), have reported that TGFpi is without effect on the differentiation of human
ESC and on the production of dPRL, however their data are based on studies where
cells were not exposed to any decidualising stimuli. Interestingly, Kim et al (Kim,
Park et al. 2005), propose that TGF(11 potentiates the decidualisation process in ESC
and report that decidualisation is a progesterone-independent event, which is not only
in contrast to the studies presented in this thesis, but also with every other publication
studying decidualisation which have characterised it as a progesterone-dependent
process.
The cells in our study were obtained from non-pregnant endometrium and
decidualised in vitro and are therefore a model for the cells that decidualise in the
absence of a blastocyst during the normal cycle. Previous studies have sought to
identify an in vitro model better placed to study the effects and induction or
inhibition of decidualisation (Schatz and Lockwood 1993). For this purpose 1st
trimester decidual cells have been cultured and are reported to retain key
morphological features indicative of their decidualised in vivo state (Schatz, Papp et
al. 1994). In the current study, experiments to determine if stromal cells from 1st
trimester decidua de-differentiate demonstrated that although the cells are seen to de¬
differentiate morphologically (Figure 4.10) and release reduced concentrations of the
classic decidualisation marker, IGFBP-1, there is still a notable production of
IGFBP-1, even after prolonged culture in the absence of decidualising stimuli
(Figure 4.9). Furthermore, DSCs from gestations > 10 weeks release significantly
more IGFBP-1 and take longer to demonstrate reduced IGFBP-1 release (Figure 4.9,
panel B). Reduced recovery of IGFBP-1 from culture media may reflect a number of
changes during the culture period. For example, there may be a progenitor cell
present, which can proliferate and overgrow DSC in culture or alternatively in the
samples from > 10 week gestation, cells may be present that have returned to a
proliferative activity, even though they have been decidualised in vivo, and have
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become the confluent cell type in culture. Furthermore, the studies reported in this
thesis demonstrate that DSCs re-decidualised faster than ESC when treated in
parallel, and displayed an increased sensitivity to MPA (Figures 4.12 - 4.14),
implying the presence of a potential "decidualised phenotype memory" when cells
are decidualised in vivo. These findings would seem to be in agreement with those of
Oliver et al who used DSCs to analyse SMAa expression (Oliver, Montes et al.
1999), as these authors reported that the cells required exposure to progesterone in
vitro before the cells would present a decidualised phenotype (Oliver, Montes et al.
1999).
In addition, the present studies have demonstrated that TGFpi markedly inhibits the
expression of the classical decidualisation marker protein mRNAs in DSCs.
However, this downregulation was delayed by at least 24 h as compared to TGFfVl-
treated ESC (Figures 4.15, 4.17, 4.19), and was not reflected by a reduction in
mature protein secretion in DSC (Figures 4.16 and 4.19), implying that
decidualisation in vivo, confers some resistance to the actions of TGF(31. The
different response in DSCs as compared to ESCs is in contrast to findings by Jikihara
et al, who published that TGF(11-treatment significantly suppressed dPRL mRNA
and protein in term decidual fibroblasts (Jikihara and Handwerger 1994). This
discrepancy in TGFffl response in cells obtained from non-pregnant endometrium
and those which had been decidualised in the presence of a blastocyst and increasing
concentrations of hCG in the 1st trimester of pregnancy may contribute to an increase
in cellular protection against potential pathogenic cytokines and growth factors in
pregnant endometrium. Or, the role of TGF(11 in pregnant endometrium may differ
from that in non-pregnant, pre-menstrual endometrium, which would explain data
reporting high expression of TGFpl in 1st trimester decidua without any detrimental
effect to pregnancy (Lysiak, Hunt et al. 1995; Jokhi, King et al. 1997; Bennett,
Lagoo-Deenadayalan et al. 1999; Simpson, Robson et al. 2002).
These studies have demonstrated that TGFpl is an important growth factor capable
of modulating mediators of decidualisation resulting in suppression of the
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decidualisation marker proteins (Figure 6.3). The results obtained suggest that ESCs
isolated from non-pregnant endometrium are a better model than DSCs isolated from
1st trimester decidua for evaluating the events which occur in the premenstrual
endometrium and suggest that local TGFfU-signalling coordinates de-differentiation
of endometrial stromal compartment and tissue remodelling associated with
menstruation. It is likely that mass activation of TGF|31, in response to falling
progesterone levels, would elicit a rapid response as seen in the present in vitro
study, and possibly contribute to the cascade of events involved in menstruation.
Indeed, a previous study (Johannisson, Oberholzer et al. 1989) postulated that
progesterone withdrawal alone could not be responsible for the plethora of changes
observed within the endometrium during the late secretory and pre-menstrual phases
of the cycle. Therefore, the action of TGF|31 opposing progesterone-induced
responses, for example by the induction of DKK and reduced expression of
decidualisation marker proteins (Figure 6.3), serves to provide a rationale for the
efficacy of progesterone withdrawal.
TGF(11 is also responsible for stimulating expression of TIMPs and augmenting
synthesis of collagen and fibronectin, both matrix proteins (Huang, Wen et al. 1998).
Therefore, TGF(31 is proposed to act by limiting MMP activity and stabilising the
tissue, preventing aberrant breakdown of the endometrium during the secretory phase
of the menstrual cycle in accord with cyclical expression of TGFpl (Marshburn,
Arid et al. 1994) (Casslen, Sandberg et al. 1998). Overexpression and or
misregulation of TGFfU activation may be implicated in the aetiology of endometrial
disorders associated with menstruation, for example, aberrant menstrual blood loss
and further investigation into this possibility is warranted.
In Chapter 5, the studies focused on the phenotypically unique uNK cells that are
seen to increase in secretory phase endometrium and 1st trimester decidua of
pregnancy (King, Wellings et al. 1989; Loke and King 1997). At present the lineage,
origin and mechanism underlying the postovulatory expansion of uNK cells remains
to be established. The exact functions of these uNK cells in humans have yet to be
elucidated, but may involve a role in implantation and placentation (Loke and King
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1995; Loke and King 1997; King, Burrows et al. 1998; King 2000; Loke and King
2000; Loke and King 2000). A very recent study has reported that uNK cells, but not
peripheral blood-derived NK subsets, regulate trophoblast invasion both in vivo and
in vitro by production of IL-8 and EP-10 chemokines (Hanna, Goldman-Wohl et al.
2006). Furthermore, the authors also reported that uNK cells isolated from 1st
trimester decidua induced vascular growth in the decidua and interacted with the
decidual stroma (Hanna, Goldman-Wohl et al. 2006). The variation in uNK cell
number across the menstrual cycle suggests ovarian steroid regulation (King,
Burrows et al. 1998; Dunn, Kelly et al. 2003; Dosiou and Giudice 2005). uNK cell
expansion following the surge in pituitary-derived luteinising hormone (LH) across
the progesterone-dominated secretory phase, and the association of uNK cell demise
with falling levels of progesterone implicates progesterone as a central regulator of
their growth and this is supported by evidence that ovariectomised women lack uNK
cells (Loke and King 1995; Flynn, Byrne et al. 2000). However, search for evidence
for a direct hormonal effect on uNK cells, failed to identify either PR or ERa in
human uNK cells (King, Gardner et al. 1996; Stewart, Bulmer et al. 1998;
Henderson, Saunders et al. 2003). The focal expression of many inflammatory
mediators indicates that a more subtle mechanism, in addition to progesterone may
be involved in uNK cell expression. At the beginning of the present studies no data
had been compiled on the effect of LH or hCG on uNK cells. The data presented in
this thesis demonstrated that low does of hCG inhibited IFNy protein release by uNK
cells isolated from 1st trimester decidua (Figure 5.7 and 6.2), which may provide a
rationale for the regulation of trophoblast invasion, as limiting IFNy production, in
the very early stages of pregnancy may serve to explain the inability of uNK cells to
kill semiallogenic foetal cells (Trundley and Moffett 2004). This may also be
influenced by TGFfVl, which has recently been shown to suppress PBNK cell IFNy
(Laouar, Sutterwala et al. 2005; Meadows, Eriksson et al. 2006) and limit NK cell
activity (Meadows, Eriksson et al. 2006). Furthermore, uPA and PAI-1, which
regulate the activation of TGFpl, have been detected in the subpopulation of
extravillous cytotrophoblasts (Fisher and Damsky 1993). PAI-1 increases steadily
during pregnancy (Houlihan, Knuppel et al. 1996), whereas the production of uPA by
human trophoblasts is downregulated during the second trimester, paralleling the
Chapter 6 General Discussion 245
decline in the invasiveness of trophoblast cells with gestational age (Chou, Zhu et al.
2002), implying that levels of activated TGFpi will be highest during the 1st
trimester of pregnancy. This would be in agreement with several groups reporting
high levels of TGF(31 in 1st trimester decidua (Lysiak, Hunt et al. 1995; Jokhi, King
et al. 1997; Bennett, Lagoo-Deenadayalan et al. 1999; Simpson, Robson et al. 2002),
and may indicate that during the 1st trimester TGF(!1 may be acting to interact with
uNK cells to facilitate and regulate trophoblast invasion. Additionally, Kovalevskaya
et al (Kovalevskaya, Birken et al. 2002) reported that a hyperglycosylated form of
hCG arises very early in pregnancy and is rapidly replaced by less glycosylated
isoforms, showing that hCG glycoforms dynamically change as pregnancy
progresses. This finding, in concert with the regulation of IFNy, may provide a
mechanism by which the embryo may transmit the information about its presence to
maternal immune systems (Kosaka, Fujiwara et al. 2002).
hCG is considered to propagate its hormonal signal to target cells through the
LH/hCG receptor, which has been reported to be expressed on ovarian granulosa
cells, theca interna cells, luteal cells (Acevedo 2002) and macrophages from term
placenta and late secretory phase non-pregnant endometrium (Zhang, Rao Ch et al.
2003), however in these studies no expression of the LH/hCG receptor was detected
on the uNK cells (Figure 5.4). As the uNK cells in the current study were purified
prior to culture (Figure 5.1, 5.2 and 5.3), any hCG-mediated responses would be a
result of direct interaction with the uNK cell alone. We have demonstrated that hCG
binding occurs even though LH/hCG receptor is not present (Figures 5.10 and 5.12).
This finding is in agreement with studies analysing PB cells which failed to detect
LH/hCG receptor expression in either PBNK or PBMN cells (Sulke, Jones et al.
1985; Kosaka, Fujiwara et al. 2002; van den Heuvel, Peralta et al. 2005) but that
PBMN cells could be stimulated by exogenous hCG (Kosaka, Fujiwara et al. 2002).
A recent study has proposed that cell surface lectins, which can recognise
carbohydrate moieties in glycosylated proteins, may play a role in the hCG-signaling
pathway (Kosaka, Fujiwara et al. 2002). Recently, pituitary hormones such as LH
and TSH were reported to interact with the macrophage mannose receptor (MMR)
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(Fiete, Beranek et al. 1998; Simpson, Hitchen et al. 1999) and it was proposed that
immune cells are involved in the clearance of these hormones (Simpson, Hitchen et
al. 1999). Indeed recently, Laskarin et al have reported the presence of a functional
MMR on early decidual macrophages (Laskarin, Cupurdija et al. 2005) implicating
the receptor in maintaining homeostasis at the maternal-foetal interface (Laskarin,
Cupurdija et al. 2005). We report, for the first time that the MMR is present on uNK
cells, isolated from both non-pregnant endometrium and 1st trimester decidua (Figure
5.8 and 5.9). Further to this, we have found that cells treated with hCG show
colocalisation of hCG with the MMR (Figure 5.12). This binding may be facilitated
by terminal sialylation of the carbohydrates side chains on the MMR, which allows
oligomerisation of the MMR, resulting in multiple CR domains, providing a possible
binding site for the glycosylated hormones, such as LH and hCG (Su, Bakker et al.
2005).
The studies herein also provide non-quantitative evidence (photographic analysis,
Figure 5.15) that uNK cells proliferate in response to hCG-treatment. This is in
contrast with studies showing that culture with hCG did not induce CD56Br,ght cell
proliferation, in an in vitro culture system where the NK cells were co-cultured with
endometrial stromal cells (Inoue, Kanzaki et al. 1996). This putative LH/hCG-
mediated mechanism for regulation of uNK cell expansion and/or function in late-
secretory phase endometrium and 1st trimester pregnancy may be in concert with the
actions of progesterone acting on the ESC, which retains its PR throughout the cycle
(Wang, Critchley et al. 1998) (Figure 6.2). It is likely therefore that no one molecule
is responsible for the unique expression and actions of the uNK cells, but that
physiological endometrial changes mediated by paracrine hormonal-cellular
signalling may orchestrate the dynamic and complex milieu of the uterine
environment in which an immune-endocrine network involving hCG and uNK cells
exists.
6.3 Future studies
The studies presented in this thesis have shown that, in the culture system used,
TGFpi inhibits PR, DKK and the expression of decidualisation marker proteins;
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tissue factor, IGFBP-1 and prolactin. Although we showed that TGFfU is capable of
inducing SMAD phosphorylation, it remains to be identified whether downregulation
of the aforementioned genes is SMAD-dependent. Knockdown of SMAD 4
expression in primary ESCs was attempted but the non-targeting siRNA sequence
evoked a reduction in the mRNA expression of both PR and PRL, preventing any
conclusive evidence to determine the signalling pathway of TGFfll-mediated
suppression of PR and PRL. Further experiments utilising different non-targeting
siRNA sequences are required and should yield interesting results to conclusively
answer this question.
In the culture system using DSCs isolated from 1st trimester, whether reduced
expression of decidualising markers is due to de-differentiation or over proliferation
of a progenitor cell needs to be elucidated. A further possibility is that some of the
cells were not fully decidualised in vivo, prior to isolation, and may have proliferated
in vitro, overgrowing the fully decidualised non-proliferative cells. To answer these
possibilities, FACS analysis should be conducted to determine if a subset of cells are
present which may act as progenitor cells, e.g. CD34 positive. Additionally, IHC
may be performed; immunolocalising tissue factor antigens present on the cells to
determine if some remain non-decidualised.
uNK cells appeared to proliferate in response to hCG treatment, however, further
studies to quantify any increase in cell number should be performed. Studies using
Trypan blue™ exclusion staining and cell counts are necessary. Additionally,
incubation of cells with Bromodeoxyuridine (BrdU), which is an analogue of
thymidine and can be incorporated into the newly synthesised DNA of replicating
cells (S-phase cells), could be used to detect whether the cells were actively
replicating their DNA. Another potential effect of hCG treatment that was not
analysed was hCG-induced migration of uNK cells. Further work is required to
design a migration assay, either using a commercially available assay or using a slide
coated in an agarose-based medium to assess migration in response to hCG
treatment.
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Although colocalisation of hCG and the MMR on uNK cells was observed,
functionality of the MMR was not ascertained. Treatment with mannose, which will
compete for binding sites on MMRs, will elucidate if blocking potential hCG-
binding via the MMR prevents hCG binding to uNK cells. Furthermore, apart from
one sample, all uNK cell preparations were isolated form 1st trimester decidua and
had been exposed to hCG in vivo. Experiments using uNK cells isolated from non¬
pregnant late secretory phase endometrium would be necessary to deduce any
physiological response from hCG treatment, as cells which have been exposed to
hCG in vivo may have a limited response to the in vitro hCG treatment in the studies
presented herein.
Another area for investigation is the interaction between the ESC and the uNK cell.
Co-culture of the two cell types would be an ideal model for examining the effects of
cell to cell interactions. Additional treatment with progesterone and hCG, either
alone or in combination, would further advance the knowledge on uNK cell
expansion in late-secretory phase endometrium and decidua of early pregnancy. This
hypothesis is summarised in Figure 6.2.
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Figure 6.2: Diagram depicting the potential hCG-regulation of uNK expansion and
function. uNK cells express the MMR, which may bind LH and or hCG to facilitate
trophoblast invasion and cell expansion. Other functions may include interactions
with other cell types such as the ESC, which may release paracrine regulators e.g. IL-
15 in response to uNK derived IFNy.
6.4 Conclusion
These studies have shown for the first time that TGFpi may potentiate progesterone
withdrawal by acting as a progesterone receptor modulator, and may prevent the
process of decidualisation by both stimulating the Wnt-signalling pathway via
inhibition of DKK and suppressing the transactivation potential of the dPRL
promoter (Figure 6.3). Additionally, the studies herein have demonstrated that a
MMR receptor is present on uNK cells, and that this receptor may facilitate
FH/hCG-mediated actions on uNK cells (Figure 6.2). Future studies will focus on
firstly; the mechanism by which TGFpi mediates its actions to inhibit PR, DKK and
the expression of decidualisation marker proteins, secondly; the reason for the
suppression of IGFBP-1 protein release in DSCs isolated from 1st trimester decidua
and thirdly; the role of MMR in the uNK cell and if LH and or hCG plays a
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functional role in the expansion of uNK cells in the late secretory phase endometrium
and decidua of early pregnancy. These findings may represent important factors that
are critical in regulating both the progress of decidualisation and the withdrawal of
progesterone prior to menstruation. In addition, the phenotypically unique uNK cell
has been characterised further with regard to receptor expression and a possible
regulator of uNK cell function elucidated.
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A
Progesterone
Figure 6.3: Diagram depicting the process of decidualisation in vitro and the
response to treatment with TGFpi. Panel A depicts an ESC decidualised in vitro
with a "rounder" morphology and increased expression of DKK, the Wnt-signalling
antagonist, and the classical decidualisation markers; IGFBP-1, tissue factor and
dPRL. Panel B depicts the same cells treated with TGFpi, which suppresses
expression of PR and DKK in both non-decidualised and decidualised ESCs,
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8 Appendix
8.1 Patient information sheets and consent forms
LREC Number Title of Study
05/S1104/12 Origins of Uterine NK cells
1994/6/17 Local Mediators in Menstruation
2003/6/40
Studies of natural antimicrobial agents
from transformed uterine cells
1993/6/73 Study of the womb lining in both non¬
pregnant and pregnant women
Table 8.1: Patient information sheets and consent forms included in Appendix.
Study Number: LREC/05/S1104/12
Version 2: 4th April 2005
Patient information sheet - Group 1 (Hysterectomy)
Title of study - Origins of Uterine NK Cells
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please read the following information carefully and ask us if there is
anything that is not clear, or if you would like any further information.
Purpose of the study
There are white blood cells in the lining of the womb called uterine natural killer
cells (uNK). These cells are known to play an important role in key reproductive
processes eg implantation of a fertilised egg in early pregnancy and menstruation
(periods). However, the origins of these uNK cells is not known. It is possible that
these uNK cells may originate from the womb lining itself or from the blood supply
to the womb. To more fully investigate this we plan to study tissue samples from the
lining of the womb (endometrium) from a group of women who are not pregnant
(Groups 1 to 3) and those who are pregnant (Group 4). In addition, we also plan to
look at white blood cells from women who are voluntarily donating blood at the
Blood Transfusion Service (Group 5). This research will add to our knowledge and
understanding of the function of the lining of the womb in early pregnancy and
menstruation and may contribute to our understanding of the possible reasons for
early pregnancy failure and menstrual problems.
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What does the study involve ?
If you decide to take part in this study it would involve a short interview to enquire
about your recent health and to ensure that the entry criteria to the study have been
met. In addition, this study involves the collection of tissue samples from the lining
of the womb and a single 5ml blood sample (a teaspoon) to measure hormone levels.
Participation in this study is confined only to the day of your operation. The tissue
samples are obtained with agreement from a gynaecological pathologist.
Tissue samples would be obtained from the lining of the womb after the womb has
been removed. Therefore there would be no change to the planned surgical procedure
and subsequent recovery from the operation. Some of the cells from the tissue
sample of the lining of the womb may be cultured (grown), which is common
practice in a laboratory, and may be stored for up to one year.
The information and samples will be stored and may be used in related studies in the
future, addressing important and associated clinical research questions. At present
these future studies cannot be specified in detail but may involve collaboration with
laboratories working with Professor Hilary Critchley. The information and tissue
samples will be given a unique code to protect your anonymity.
It is up to you if you decide whether or not to take part. If you do decide to take part
you will be given this information sheet to keep and be asked to sign a consent form.
You are still free to withdraw at any time without giving a reason. A decision to
withdraw at any time or a decision not to take part will not affect the standard of care
you receive. This is non-therapeutic research from which you cannot expect to derive
any benefit.
The research proposed has been reviewed by the Local Research Ethics Committee.
If you are harmed from taking part in this study, there are no special compensation
arrangements. If you are harmed due to someone's negligence, then you may have
grounds for legal action but you may have to pay for it. Regardless of this, if you
wish to complain about any aspect of the way that you have been approached or
treated during the course of this study, the normal NHS complaints mechanisms may
be available to you.
If you require any further information from a doctor who is not involved in this study
you can contact Dr Christine West on 0131 242 2525.
Thank you for reading this information sheet.
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Study Number: LREC/05/S1104/12
Version 2: 4th April 2005
Patient information sheet - Group 2 (Diagnostic Laparoscopy & Lap-sterilisation)
What does the study involve ?
If you decide to take part in this study it would involve a short interview to enquire
about your recent health and to ensure that the entry criteria to the study have been
met. In addition, this study involves the collection of tissue samples from the lining
of the womb and a single 5ml blood sample (a teaspoon) to measure hormone levels.
Participation in this study is confined only to the day of your operation.
A sample of the lining of the womb is obtained using a fine plastic sampler (pipelle).
This is a routine procedure which involves passing the sampler through the neck of
the womb (cervix) into the womb cavity. This procedure would be carried out during
your planned surgery and whilst under general anaesthetic. We would not expect you
to experience any untoward effects from the collection of this tissue sample and
should not add to the discomfort that is normally expected following an operation.
In some cases, your doctor may have already explained that a tissue sample from the
lining of the womb is required as part of your routine clinical care. If your
gynaecologist decides that more tissue has been obtained than is required for clinical
needs then the surplus tissue, with your permission, could be used for research
purposes. Some of the cells from the tissue sample of the lining of the womb may be
cultured (grown), which is common practice in a laboratory, and may be stored for
up to one year.
Study Number: LREC/05/S1104/12
Version 2: 4th April 2005
Patient information sheet - Group 3 (Hysteroscopy)
What does the study involve ?
If you decide to take part in this study it would involve a short interview to enquire
about your recent health and to ensure that the entry criteria to the study have been
met. In addition, this study involves the collection of tissue samples from the lining
of the womb and a single 5ml blood sample (a teaspoon) to measure hormone levels.
Participation in this study is confined only to the day of your investigation.
Your gynaecologist has explained that a tissue sample from the lining of the womb is
required as part of your routine clinical care which will be obtained using a fine
plastic sampler (pipelle). This is a routine procedure which involves passing the
sampler through the neck of the womb (cervix) into the womb cavity. If your
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gynaecologist decides that more tissue has been obtained than is required for clinical
needs then the surplus tissue, with your permission, could be used for research
purposes. Some of the cells from the tissue sample of the lining of the womb may be
cultured (grown), which is common practice in a laboratory, and may be stored for
up to one year.
Study Number: LREC/05/S1104/12
Version 2: 4th April 2005
Patient information sheet - Group 4 (Termination of Pregnancy)
What does the study involve ?
If you decide to take part in this study it would involve a short interview to enquire
about your recent health and to ensure that the entry criteria to the study have been
met. In addition, this study involves the collection of tissue samples from the lining
of the womb. Participation in this study is confined only to the day of your operation.
If you decide to take part in this study it would involve the collection of a sample of
the pregnancy tissue which lines the womb. These tissue samples would have been
removed as a matter of routine during the normal operation procedure. Therefore,
your participation in this study would not change your planned operation or affect
your recovery from the operation. Some of the cells from the tissue sample of the
lining of the womb may be cultured (grown), which is common practice in a
laboratory, and may be stored for up to one year.
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Study Number: LREC/05/S1104/12
Patient Identification Number for
this trial:
8.1.1 Version 3 18th October
2005
Department of Obstetrics and
CONSENT FORM Gynaecology
Title of Project: Origins of Uterine NK Cells
Name of Researcher:
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2483
Or : 0131 242 6441
1. I confirm that I have read and understand the information sheet dated 4th April
2005(version 2) for Group of the above study and have had the opportunity to
ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at
any time, without giving any reason, and without my medical care or legal rights
being affected.
3. I agree to the provision of clinically significant information to my General
Practitioner.
4. I understand that my medical notes may be looked at by the researchers involved
in the study or from regulatory authorities where it is relevant to my taking part in
research. I give permission for these individuals to have access to my records.
5. I agree that the sample I have given and the information gathered from me may
be stored by Professor Hilary O D Critchley at the Centre for Reproductive Biology,
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University of Edinburgh for possible use in future projects, as described in the
attached information sheet. I understand that some of these projects may be carried
out by researchers other than Professor Critchley's laboratory who ran the first
project.
6. I understand that this is non-therapeutic research from which I cannot expect to
derive any benefit.
7. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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LREC/1994/6/17
Version 3: Amended - 16th October 2002
Patient information sheet
Local mediators in menstruation
Lay title: Study of the local uterine factors involved in menstruation
In order for us to better understand the problems of menstruation it is essential that
we have an opportunity to study womb-lining. Information gathered from this study
will hopefully enable us to design new methods of managing this very common
problem.
We would like your permission to collect a small sample (biopsy) from the lining of
the womb during the time of your planned procedure for which you are currently
attending the hospital.
The biopsy is collected with a slim plastic or metal instrument. The tissue collected
remains anonymous. It will be processed in the laboratory in several different ways
and will be used to investigate the function of the womb-lining. The tissue from the
lining of the uterus (womb) will be broken down into cells and these cells will be
used to examine the way in which menstruation (the monthly period) is controlled by
hormones. This research will allow a better understanding of why periods are
sometimes accompanied by distressing pain or a particularly large loss of blood. In
order to carry out several experiments on the cells we will treat them so that they will
grow in tissue culture. In addition we would like to collect a small sample of blood
for the measurement of hormone levels.
I understand that the sample I have given for the above research study and the
information gathered about me may be stored and consent to its inclusion in future
research projects addressing the processes involved in regulation of the womb lining
(endometrium). The information derived from such future studies will contribute to
the understanding of the event of menstruation and therefore contribute to furthering
knowledge when menstruation becomes problematic.
Involvement in this study will not involve any additional hospital attendance or an
extension of your planned management. No additional discomfort or inconvenience
will be experienced.
Your confidentiality will be strictly maintained throughout the study. If you
volunteer then you are under no obligation or commitment and may withdraw at any
time. Such a decision will not influence your treatment in any way.
Should you wish to contact an independent adviser concerning this study please feel
free to contact: -
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Dr C P West, Centre for Reproductive Health, Second Floor, Royal Infirmary of
Edinburgh at Little France
51 Little France Crescent, Edinburgh EH16 4SA
For further information about the study, please contact: -
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670 or 0131 242 6441
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Study Number: LREC/1994/6/17
Patient Identification Number for this trial:
CONSENT FORM
Department of Obstetrics and Gynaecology
Title of Project: Local mediators in menstruation
Study of the local uterine factors involved in menstruation
Name of Researcher:
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670
Or : 0131 242 6441
1. I confirm that I have read and understand the information sheet dated 16th
October 2002 (version 3) for the above study and have had the opportunity to ask
questions.
2. I understand that my participation is voluntary and that I am free to withdraw at
any time,without giving any reason, without my medical care or legal rights
being affected.
3. I understand that sections of any of my medical notes may be looked at by
responsible individuals or from regulatory authorities where it is relevant to my
taking part in research. I give permission for these individuals to have access to my
records.
4. I agree that the sample I have given and the information gathered from me may be
stored by Professor Hilary O D Critchley at the Centre for Reproductive Biology,
University of Edinburgh for possible use in future projects, as described in the
attached information sheet. I understand that some of these projects may be carried
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out by researchers other than Professor Critchley's laboratory who ran the first
project.
5.1 agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature




1 for researcher; 1 to be kept with hospital notes
Amended: 16th October 2002
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LREC/2003/6/40
Version 1: 21st October 2003
Patient information sheet
Study Title - Studies of natural antimicrobial agents from transformed
uterine cells
You are being invited to take part in a research study. Before you decide to take part
it is important for you to understand why the research is being done and what it will
involve. Please read the following information carefully and ask us if there is
anything that is not clear, or if you would like more information.
The purpose of this study is to understand more about the role of specific cells that
make up the lining of the womb (endometrium) that are associated with helping to
protect the reproductive tract from infection. The reproductive tract can be prone to
infection and sadly many of these infections can go undetected. Infections can cause
distressing conditions such as infertility and, in pregnancy, premature births.
Therefore, it is important to study the cells from the lining of the womb in women
who are pregnant and those who are not. This research will be beneficial by allowing
us to more fully understand how the reproductive tract attempts to protect itself from
infections.
To do these experiments it is essential to grow (culture) and treat these cells in the
laboratory in a particular way which prolongs the cells ability to exist for longer than
required for most cellular experiments. However, these cells will not be kept
indefinitely. Cells can lose their ability to be useful after repeated experiments as
over time the results obtained may become unreliable. Therefore the cells will be
destroyed before this happens.
It is up to you to decide whether or not to take part. If you do decide to take part you
will be given this information sheet to keep and be asked to sign a consent form. If
you decide to take part you are still free to withdraw at any time and without giving a
reason. A decision to withdraw at any time, or a decision not to take part, will not
affect the standard of care you receive.
If you decide to take part in this study it will involve obtaining a blood sample to
measure hormone levels and a tissue sample from the lining of the womb. The tissue
sample is obtained using a fine plastic sampler (pipelle). This is a procedure which is
carried out routinely in outpatient gynaecology clinics and theatres. This sample will
be obtained whilst you are asleep (anaesthetised) at the time of your planned surgery.
The information and tissue sample will be stored and may be used in related research
studies in the future. At present, these future studies cannot be specified in detail but
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may involve collaboration with laboratories working with Professor Critchley. It may
be possible that some of these laboratories will be in the UK and / or overseas.
Your confidentiality will be strictly maintained throughout the study. The
information and the tissue sample will be given a unique code to protect your
anonymity. Permission will be sought from your consultant regarding your inclusion
in the study and with your permission your GP will receive a letter informing him /
her of your participation. This study has been approved by the Local Research Ethics
Committee.
If you wish further information from a doctor who is not involved in this study in any
way you can contact Dr Christine West, Simpson Centre for Reproductive Health,
Royal infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4SA Tel
0131 242 2698
Thank you for reading this information sheet.
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Studies of natural antimicrobial agents from transformed uterine cells
Name of Researcher:
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670
Or : 0131 242 6441
1. I confirm that I have read and understand the information sheet dated 21st
October 2003 for the above study and have had the opportunity to ask questions.
3. I understand that my participation is voluntary and that I am free to withdraw at
any time,without giving any reason, and without my medical care or legal rights
being affected.
4. I agree to a letter being sent to my General Practioner about my participation in
this study.
4. I agree to the provision of any clinically significant information to my General
Practioner.
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5 I understand that my medical notes may be looked at by the researchers involved
in the study or from regulatory authorities where it is relevant to my taking part
in research. I give permission for these individuals to have access to my records.
6. I agree that the sample I have given and the information gathered from me may
be stored by Professor Hilary O D Critchley at the Centre for Reproductive Biology,
University of Edinburgh for possible use in future projects, as described in the
attached information sheet. I understand that some of these projects may be carried
out by researchers other than Professor Critchley's laboratory who ran the first
project.
7. I understand that this is non-therapeutic research from which I cannot expect to
derive any benefit.
8.1 agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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LREC/1993/6/73
Version 2: Amended - 16th October 2002
Patient information sheet
Lay title: Study of the womb lining in both non-pregnant and pregnant women
If you are being admitted to hospital for: Termination of Pregnancy
In order for us to better understand the problems of menstruation and repeated
pregnancy failure it is essential that we have an opportunity to study womb-lining in
healthy fertile women who do not report problems with menstruation and who have
conceived easily.
We would like your permission to collect a small sample (biopsy) from the lining of
the womb during the occasion of your termination. We are only interested in the
mother's womb lining; no fetal tissue will be collected.
The biopsy is collected with a slim plastic or metal instrument. The tissue collected
remains strictly anonymous. It will be processed in the laboratory in several
different ways and will be used to access a variety of aspects which influence the
function of the womb-lining. In addition we would like to collect a small sample of
blood, while you are asleep; for the measurement of hormone levels.
Involvement in this study will not involve any additional hospital attendance or an
extension of your planned management. No additional discomfort or inconvenience
will be experienced.
I understand that the sample I have given for the above research study and the
information gathered about me may be stored and consent to its inclusion in future
research projects addressing the processes involved in regulation of the womb lining
(endometrium). The information derived from such future studies will contribute to
the understanding of the event of menstruation and therefore contribute to furthering
knowledge when menstruation becomes problematic.
Your confidentiality will be strictly maintained throughout the study. If you
volunteer then you are under no obligation or commitment and may withdraw at any
time. Such a decision will not influence your treatment in any way.
Should you wish to contact an independent adviser concerning this study please feel
free to contact: -
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Dr C P West, Centre for Reproductive Health, Second Floor, Royal Infirmary of
Edinburgh at Little France
51 Little France Crescent, Edinburgh EH16 4SA
For further information about the study, please contact: -
Professor HOD Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670 or 0131 242 6441
LREC/1993/6/73
Version 3: Amended - 16th October 2002
Patient information sheet
Lay title: Study of the womb lining in both non-pregnant and pregnant women
If you are attending hospital for: - Planned Sterilisation Procedure
We would like your permission to collect a small sample (biopsy) from the lining of
the womb during the time of your planned sterilisation procedure for which you are
currently attending the hospital.
The biopsy is collected with a slim plastic or metal instrument. The tissue collected
remains strictly anonymous. It will be processed in the laboratory in several different
ways and will be used to investigate the function of the womb-lining. The tissue from
the lining of the uterus (womb) will be broken down into cells and these cells will be
used to examine the way in which menstruation (the monthly period) is controlled by
hormones. This research will allow a better understanding of why periods are
sometimes accompanied by distressing pain or a particularly large loss of blood. In
order to carry out several experiments on the cells we will treat them so that they will
grow in tissue culture. In addition we would like to collect a small sample of blood
for the measurement of hormone levels.
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Study Number: LREC/1993/6/73
Patient Identification Number for this trial:
CONSENT FORM Department of Obstetrics
and Gynaecology
Title of Project: Study of the womb lining in both non-pregnant and pregnant
women
Name of Researcher:
Professor El O D Critchley
New Royal Infirmary of Edinburgh
Simpson Centre for Reproductive Health
51 Little France Crescent
Edinburgh EH16 4SA
Tel: 0131 242 2670
Or : 0131 242 6441
1. I confirm that I have read and understand the information sheet dated 16th
October 2002 for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at
any time, without giving any reason, without my medical care or legal rights
being affected.
3. I understand that sections of any of my medical notes may be looked at by
responsible individuals or from regulatory authorities where it is relevant to my
taking part in research. I give permission for these individuals to have access to my
records.
4. I agree that the sample I have given and the information gathered from me may be
stored
Appendix 313
by Professor Hilary O D Critchley at the Centre for Reproductive Biology,
University of Edinburgh for possible use in future projects, as described in the
attached information sheet. I understand that some of these projects may be
carried out by researchers other than Professor Critchley's laboratory who ran the
first project.
5.1 agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
1 for patient; 1 for researcher; 1 to be kept with hospital notes
Amended: 16th October 2002
